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Abstract
Background
Stroke is the leading cause of long-term neurological disability in adults and the
third most common cause of death in Britain. It is well known that in addition
to the patient characteristics of age and severity, the treatment a stroke patient
receives in hospital significantly affects outcome. The effectiveness of complex
service interventions, how the benefits of these interventions are achieved and
the economic impact of different types of service delivery were explored.
Methods
The Stroke Unit Trialists’ Collaboration systematic review was updated and cur-
rently contains 31 clinical trials (6936 subjects). The aims were explored using
various basic frequentist and Bayesian meta-analysis techniques as well as more
complex meta-analysis ideas. These more complex ideas include: meta-regression
where covariate information is incorporated into the model; and network meta-
analysis where direct and indirect information is used in a mixed treatment com-
parisons model while also incorporating covariate information.
i
Results
Organised inpatient (stroke unit) care showed reductions in death, death or de-
pendency and death or institutional care compared to general medical wards.
Stroke unit care appears to reduce the risk of adverse outcomes through preven-
tion and treatment of complications. Acute, comprehensive and rehabilitation
stroke unit care appeared to be most effective and acute stroke unit care ap-
peared to be the most cost-effective. However, acute followed by rehabilitation
stroke unit care, if required, appears to be the most cost-effective pathway of care
compared to the other pathways analysed.
Discussion
Future research should focus on rehabilitation, acute and comprehensive systems
of inpatient care, and explore the best ways of preventing and managing spe-
cific complications. Effort should be made to make individual patient data and
information on the care pathway of a stroke patient available for meta-analysis.
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Summary
This thesis assesses the effectiveness of complex service interventions and the
impact of different types of service delivery. Chapter 1 introduces stroke, different
models of inpatient service delivery and current methods of assessing severity
in stroke patients. Additionally, meta-analysis and some basic meta-analysis
theory are described and finally the data sources used throughout this thesis are
summarised.
Chapters 2 and 3 investigate methods of measuring stroke severity and their
ability to predict outcome. Chapter 2 introduces a novel stroke severity scale
and its internal consistency, construct validity and predictive ability are assessed
with comparisons made to current methods of measuring severity. Chapter 3 in-
vestigates the amount of information retained when stroke severity is categorised
and assesses the equivalence of four stroke scale categorisations in current use.
Chapters 4 to 8 investigate the effectiveness of organised inpatient (stroke
unit) care by use of increasingly advanced meta-analysis techniques.
Chapter 4 uses standard frequentist meta-analysis to compare broadly “more”
organised care with “less” organised care to determine if organised inpatient
care is more beneficial than less organised care. Chapter 5 introduces a simple
xxii
Bayesian approach to meta-analysis to examine how organised inpatient care im-
proves patient outcomes by exploring the use of interventions to prevent compli-
cations. Chapter 6 expands the Bayesian meta-analysis model used in Chapter 5
by re-creating individual patient data from available grouped data and intro-
duces covariate effects into the model. This Chapter examines whether routine
automated monitoring for and treatment of physiological complications reduce
adverse outcomes in stroke patients.
Chapter 7 describes a complex network meta-analysis model with covariate
effects. The model allows the inclusion of studies with the joint distribution of
covariates, those with marginal data for one or more covariates as well as those
with no covariate information and provides an estimate of the covariate effects.
Treatment effects are estimated using direct and indirect comparisons giving a
more powerful comparison between different treatment types. This Chapter as-
sesses the possible bias in treatment effect estimation when covariates are not
accounted for in meta-analyses.
Chapter 8 applies the model described in Chapter 7 to determine whether any
one system of inpatient care is most effective in improving patient outcomes while
also estimating the effect of age and severity on patient outcome. Finally, Chap-
ter 9 implements a cost-utility analysis to determine which pathway of inpatient
care is most cost-effective.
The final Chapter discusses overall conclusions, alternative statistical and
economical analyses that could be performed and the possibilities for future work.
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Chapter 1
Introduction
1.1 Stroke
The World Health Organisation (WHO) defines stroke as ‘rapidly developed clin-
ical signs of focal or global disturbance of cerebral function lasting more than
24 hours or until death, with no apparent non-vascular cause’ (WHO MONICA
Project Principal Investigators, 1988). Essentially, stroke is the brain equivalent
of a heart attack: a disruption of the blood supply to the brain through a block-
age (ischaemic) or rupture (haemorrhagic) causing damage to the surrounding
tissues. Symptoms and signs include sudden numbness and tingling; weakness in
face, arm or leg especially on one side of the body; confusion; difficulty talking
or understanding speech; trouble seeing in one or both eyes; trouble walking,
dizziness, loss of balance or co-ordination; severe headaches without any known
cause.
Stroke is the leading cause of long-term neurological disability in adults (Wolfe,
2000), the second leading cause of death worldwide (Murray and Lopez, 1997)
1
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and the third most common cause of death in the Britain (Wolfe, 2000). Malm-
gren et al. (1989) have estimated that the total number of patients with first ever
stroke would increase by approximately 30% between 1983 and 2023, and Morris
et al. (2003) found that compared to the British mean in the British Regional
Heart Study (3.54 first events per 1000 person-years), Scottish towns had a higher
incidence of stroke (Ayr: 3.92; Dunfermline: 4.02; and Falkirk: 5.45)
Given these figures, the treatment of stroke is the focus of much clinical re-
search both globally and nationally in order to reduce deaths and the dependency
of survivors. Several systems of inpatient (stroke unit) care exist to treat patients
following stroke, however, it is not clear which system is most effective or how
the benefits of these systems of care are achieved. The aim of this thesis is to
explore how inpatient (stroke unit) services improve patient outcomes and which
inpatient service is most effective and most cost-effective.
1.2 Stroke services
One of the major problems in the treatment of stroke is that there is no powerfully
effective drug intervention available for all stroke patients. Good inpatient and
outpatient services are therefore required following stroke.
1.2.1 Inpatient services
Organised inpatient (stroke unit) care is the mainstay of stroke service. It is
a complex organisational intervention comprising nurses, doctors and therapists
who specialise in looking after stroke patients in hospital and work as a coordi-
nated team to provide a complex package of care to stroke patients (Stroke Unit
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Trialists’ Collaboration, 2007). There are several forms of stroke unit care, some
of which are subject to more specialised organisation than others. This leads to
a hierarchy of service organisation which in descending order of complexity are:
1. Stroke ward: a multidisciplinary team including specialist nursing staff
based in a discrete ward caring exclusively for stroke patients. This category
can be subdivided further:
a) acute stroke units which accept patients acutely but discharge early
(usually within seven days). These can be broadly subcategorised:
i) ‘intensive’ model of care with continuous monitoring, high nurse
staffing levels and the potential for life support;
ii) ‘semi-intensive’ model with continuous monitoring, high nurse staffing
levels but no life support facilities; and
iii) ‘non-intensive’ with none of the above.
b) comprehensive stroke units (a combination of acute and rehabilitation)
which accept patients acutely but also provide rehabilitation for several
weeks if necessary.
c) rehabilitation stroke units that accept patients after a delay, usually
of seven days or more, and focus on rehabilitation;
2. Mixed rehabilitation ward: a multidisciplinary team including specialist
nursing staff in a ward providing a generic rehabilitation service not exclu-
sively for stroke patients.
3. Mobile stroke team: a multidisciplinary team (excluding specialist nursing
staff) providing care in a variety of settings.
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4. General medical wards: care in an acute medical or neurology ward without
routine multidisciplinary input.
1.2.2 Discharge services
Following care in hospital, a range of different discharge services have been de-
veloped. The main aim of more organised discharge services compared to con-
ventional systems is to accelerate the return home of stroke patients who are
admitted to hospital. Early Supported Discharge Trialists (2008) describe a hi-
erarchy of discharge service approaches, which in descending order of level of
support are:
1. Early supported discharge (ESD) team co-ordination and delivery: a multi-
disciplinary team which co-ordinates discharge from hospital, post discharge
care and provides rehabilitation and patient care at home. The multidisci-
plinary team meets on a regular basis to plan patient care.
2. ESD team coordination: a multidisciplinary team plans and supervises the
discharge home and the immediate post-discharge care. However, care is
subsequently handed over to existing community-based agencies who pro-
vide continuing rehabilitation and support at home. Community-based
agencies do not usually provide co-ordinated multidisciplinary team care
(that is, no input from a multidisciplinary team which would meet on a
regular basis to plan patient care).
3. No ESD: patients have access to multidisciplinary team care in hospital
but this ends at hospital discharge. Their subsequent care is provided by a
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range of community stroke services which are not planned or provided by
a co-ordinated team or are provided by trained healthcare volunteers.
1.3 Stroke scales
Stroke is a complex condition which can affect many aspects of body function.
Measuring the impact of stroke may therefore be problematic. Stroke scales are
assessment tools designed to quantify different aspects of the effect of stroke, re-
covery and impairment following stroke. There does not exist a gold standard
scale which incorporates all criteria of an ideal stroke scale (Lyden and Hanston,
1998). Therefore, several separate scales are generally recorded for each patient,
all of which fall into one of four broad categories: pathology; impairment; dis-
ability (activity); or handicap (participation).
Pathology describes the diagnosis of stroke, therefore pathological scales are
usually measured using imaging or histology to categorise patients broadly. Im-
pairments are usually described as the symptoms and signs of stroke so impair-
ment scales numerically record specific findings of detailed neurological exami-
nation. This type of scale is particularly important in assessing patients almost
immediately after stroke onset. Disability, or activity, refers to the personally
meaningful functions or activities the patient can achieve, such as bathing and
dressing. These scales measure functional outcome and are used to assess stroke-
related disability and performance in occupational functions. Finally, handicap,
or participation, is the change in social position following stroke. These scales
are the most difficult to measure (Wolfe, 2000).
All stroke scales have their advantages and disadvantages as discussed in
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Kasner (2006) and Lyden and Hanston (1998). Below follows a more detailed
description of some of the more commonly used stroke scales.
1.3.1 Oxfordshire Community Stroke Project
The Oxfordshire Community Stroke Project (OCSP) classification is a pathologi-
cal scale which attempts to classify patients by site and size of lesion. Presenting
neurological symptoms and signs are used to distribute patients into one of four
groups: lacunar stroke (LACS); total anterior circulation stroke (TACS); partial
anterior circulation stroke (PACS); and posterior circulation stroke (POCS). The
fourth letter at the end of each acronym may denote the type of stroke: syndrome
(S) with indeterminate pathogenesis, prior to imaging; or infarct (I). Table 1.1
describes the definition of each group of the OCSP (Bamford et al., 1991).
The OCSP is useful in stratifying patients in clinical trials, especially in the
acute phase since patients can be classified quickly and reliably so that appropri-
ate treatments and therapies may be administered (Lindley et al., 1993). How-
ever, in the very acute stage classifications may change over time due to the
Table 1.1: The Oxfordshire Community Stroke Project classification.
Group Description
LACS Pure motor stroke, pure sensory stroke, sensori-motor stroke,
or ataxic hemiparesis
TACS Present with a triad of hemiparesis, dysphasia and homony-
mous hemianopia
PACS Present with two of the features of TACS, or isolated dyspha-
sia or parietal lobe signs
POCS Brain stem or cerebellar signs, and/or isolated homonymous
hemianopia
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occurrence or resolution of neurological signs (Mead et al., 2000).
1.3.2 National Institutes of Health Stroke Scale
The National Institutes of Health Stroke Scale (NIHSS) was specifically designed
to be used by non-neurologists. It is a 15 item neurological impairment scale
with a maximum deficit of 42 points, originally devised by Brott et al. (1989).
The NIHSS has been modified to give the version in current use (Lyden et al.,
1999) which is described in Table 1.2. The scale measures key components of a
standard neurological examination including eye movement, motor and sensory
involvement and level of consciousness.
A simpler, modified version, the mNIHSS, has been proposed (Lyden et al.,
2001) where the items consciousness, facial palsy, ataxia and dysarthia have been
dropped. However, this has not been widely adopted.
A drawback of the NIHSS is that patients with identical scores could have
quite distinct clinical diagnoses. However, the NIHSS is simple, valid, reliable
and well established in the stroke community, with video training available to
teach new carers how to apply it (Lyden et al., 2005).
1.3.3 Scandinavian Stroke Scale
The Scandinavian Stroke Scale (SSS) is an impairment scale designed as both an
initial prognostic and long-term functional score for use by non-neurologists. The
initial prognostic score includes consciousness, eye movement and motor power,
while the long-term functional score incorporates items of functional significance
to the patient such as speech and facial palsy (Scandinavian Stroke Study Group,
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Table 1.2: Current form of the National Institutes of Health Stroke Scale.
Item Name Response Item Name Response
1a Level of 0 = Alert 6a Left motor 0 = Normal
consciousness 1 = Not alert, arousable leg 1 = Drift before 5 seconds
2 = Not alert, obtunded 2 = Falls before 5 seconds
3 = Unresponsive 3 = No effort against gravity
4 = No movement
1b Questions 0 = Answer both correctly
1 = Answers one correctly 6b Right motor 0 = Normal
2 = Answers neither correctly leg 1 = Drift before 5 seconds
2 = Falls before 5 seconds
1c Commands 0 = Performs both tasks correctly 3 = No effort against gravity
1 = Performs one task correctly 4 = No movement
2 = Performs neither task
7 Ataxia 0 = Absent
2 Gaze 0 = Normal 1 = One limb
1 = Partial gaze palsy 2 = Two limbs
2 = Total gaze palsy
8 Sensory 0 = Normal
3 Visual fields 0 = No visual loss 1 = Mild loss
1 = Partial hemianopsia 2 = Severe loss
2 = Complete hemianopsia
3 = Bilateral hemianopsia 9 Language 0 = Normal
1 = Mild aphasia
4 Facial palsy 0 = No drift 2 = Severe aphasia
1 = Minor paralysis 3 = Mute or global aphasia
2 = Partial paralysis
3 = Complete paralysis 10 Dysarthria 0 = Normal
1 = Mild
5a Left motor 0 = Normal 2 = Severe
arm 1 = Drift before 10 seconds
2 = Falls before 10 seconds 11 Extinction/ 0 = Normal
3 = No effort against gravity inattention 1 = Mild
4 = No movement 2 = Severe
5b Right motor 0 = Normal
arm 1 = Drift before 10 seconds
2 = Falls before 10 seconds Total 42
3 = No effort against gravity
4 = No movement
1985). All items of the SSS can also be used so that the impairment of a patient
can be measured as numerical value between 0 and 58, where lower scores indicate
greater impairment. Shortened versions of the SSS, often labelled prognostic and
long-term scores, can also be used and have total scores of 22 and 48, respectively.
The full, prognostic and long-term scores are described in Table 1.3.
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Table 1.3: Full, initial prognostic and long-term functional scores of the Scan-
dinavian Stroke Scale.
Function Response Prognostic Long-term
Score Score
Consciousness 6 = Fully conscious X
4 = Somnolent, can be awakened to full consciousness
2 = Reacts to verbal command, but is not fully conscious
Eye movement 4 = No gaze palsy X
2 = Gaze palsy present
0 = Conjugate eye deviation
Arm, motor power∗ 6 = Raises arm with normal strength X X
5 = Raises arm with reduced strength
4 = Raises arm with flexion in elbow
2 = Can move, but not against gravity
0 = Paralysis
Hand, motor power∗ 6 = Normal strength X
4 = Reduced strength in full range
2 = Some movement, fingertips do not reach palm
0 = Paralysis
Leg, motor power∗ 6 = Normal strength X X
5 = Raises straight leg with reduced strength
4 = Raises leg with flexion of knee
2 = Can move, but not against gravity
0 = Paralysis
Orientation 6 = Correct for time, place and person X
4 = Two of these
2 = One of these
0 = Completely disoriented
Speech 10 = No aphasia X
6 = Limited vocabulary or incoherent speech
3 = More than yes/no, but not longer sentences
0 = Only yes/no or less
Facial palsy 2 = None/dubious X
0 = Present
Gait 12 = Walks 5m without aids X
9 = Walks with aids
6 = Walks with help of another person
3 = Sits without support
0 = Bedridden/wheelchair
Total 58 22 48
∗ Motor power is assessed only on the affected side
Although the SSS is intended for use in conscious patients only, it has good
interobserver agreement and the initial long-term scores correlate well with out-
come at threes months (Scandinavian Stroke Study Group, 1987).
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1.3.4 Barthel Index
The Barthel Index (BI) (Mahoney and Barthel, 1965), given in Table 1.4 is a
measure of activities of daily living (ADL) competence. It is a 10 item disability,
or activity, scale ranging from 0 to 100, where lower scores indicate greater de-
pendency. Occasionally, this score may be re-scaled from 0 to 20, with each item
weighting divided by five.
The main advantage of this scale is that patients can be evaluated by direct
observation or by telephone interviews or reports of nurses and staff (Lyden and
Hanston, 1998). One of the major disadvantages of the BI is that a “ceiling
effect” can occur, where a patient with a maximal score may still be disabled in
a such a way that they are unable to live independently (Dromerick et al., 2003).
1.3.5 Modified Rankin Scale
Originally, the Rankin Scale was argued to be a measure of handicap, or partic-
ipation. However, the Rankin Scale is now generally considered to be a global
or mixed assessment scale which groups patients into five categories based on
their ability to perform previous activities and their requirements for assistance
(Rankin, 1957). The modified Rankin Scale (mRS), described in Table 1.5, is a
seven point scale that combines the five points of the Rankin Scale with additional
levels for no dependence and death (van Swieten et al., 1988).
The mRS allows easy and rapid assessment of the effect of stroke, with a one-
point shift in the scale often considered to be clinically important. However, the
use of broad categories may reduce sensitivity to change and scoring is determined
by the overall impression of the functional ability of a patient by the examiner
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Table 1.4: The Barthel Index.
Item Response
Bowels 0 = Incontinent (or need to be given enema)
5 = Occasional accident (once per week)
10 = Continent
Bladder 0 = Incontinent, or catheterised and unable to manage
5 = Occasional accident (max once per 24 hours)
10 = Continent (for more than 7 days)
Grooming 0 = Needs help with personal care
5 = Independent face/hair/teeth/shaving
Toilet use 0 = Dependent
5 = Needs some help, but can do something alone
10 = Independent (on and off, dressing, wiping)
Feeding 0 = Unable
5 = Needs help cutting, spreading butter, etc
10 = Independent (food provided in reach)
Transfer 0 = Unable, no sitting balance
5 = Major help (one or two people, physical), can sit
10 = Minor help (verbal or physical)
15 = Independent
Mobility 0 = Immobile
5 = Wheelchair independent, including corners, etc
10 = Walks with help of one person (verba or physical)
15 = Independent (but may use any aid, e.g. stick)
Dressing 0 = Dependent
5 = Needs help, but can do about half unaided
10 = Independent (including buttons, zips, laces, etc)
Stairs 0 = Unable
5 = Needs help (verbal, physical, carrying aid)
10 = Independent up and down
Total 100
(Dromerick et al., 2003). More precise algorithms have been developed to improve
the reliability of rating the Rankin Scale (Wilson et al., 2002).
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Table 1.5: The modified Rankin Scale.
Level
0 = No symptoms
1 = No significant disability, despite symptoms
Able to perform all usual duties and activities
2 = Slight disability
Unable to perform all previous activities but able to look after
own affairs without assistance
3 = Moderate disability
Requires some help, but able to walk without assistance
4 = Moderately severe disability
Unable to walk without assistance and unable to attend to own
bodily needs without assistance
5 = Severe disability
Bedridden, incontinent, and requires constant nursing care and
attention
6 = Dead
1.4 Meta-analysis
In medical research, information on the efficacy of a treatment may be available
from a number of clinical studies with similar treatment protocols. However,
when the studies are considered separately they may be either too small or too
limited in scope to come to a general conclusion about the effect of the treatment
(DerSimonian and Laird, 1986). Meta-analysis, defined as the statistical analysis
of a large collection of analytic results for the purpose of integrating the find-
ings (Dickersin and Berlin, 1992), attempts to combine the findings across such
studies in order to gain statistical power, strengthen the evidence about possible
treatment effects and, in adequately powered studies, to find out more about
subgroups and possible interactions.
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‘Systematic review’ is a phrase that is often used to describe the whole process
of collecting and analysing data. One of the first stages of a systematic review
is the search for appropriate trials. However, since not all relevant trials may be
published, the search must also include unpublished and ongoing trials. Therefore
the search for appropriate studies to include in the analysis must be as thorough
as possible.
Once appropriate trials have been found, the quality of the trial must also
considered. Important aspects to consider are randomisation, allocation con-
cealment, completeness of follow-up, presence of intention-to-treat analysis and
blinded assessment. Trials that do not have adequate levels of any of these may
still be included in the meta-analysis, but a sensitivity analysis excluding such
trials should also be performed to identify possible bias in the results.
Meta-analysis using individual patient data (IPD) is widely regarded as the
gold-standard approach to meta-analysis. If covariates are of interest the use of
IPD typically has greater power than meta-regression incorporating study level
covariates, which represent the average covariate response of each study. However,
there is great effort involved to obtain IPD. Issues of ownership and access to data
need to be addressed as well as the time and effort involved in the collection of
data. It is often unclear whether benefits gained in using IPD outweigh the extra
cost involved (Sutton and Higgins, 2008).
Meta-analysis has become increasingly popular not only in medical research
but also statistical research. Several approaches to meta-analysis have been devel-
oped, each with its advantages and disadvantages. Methodology includes fixed-
effects or random-effects models and frequentist or Bayesian approaches.
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In a fixed-effects model the result from each study included in the analy-
sis is assumed to estimate the same quantity with any deviations due to ran-
dom sampling variability. Although this may sound reasonable it does not take
into account the possible heterogeneity between trials such as slightly different
types of patients, or slightly different treatment regimes. Therefore it may be
unreasonable to assume that any differences between trials are due to random
variation alone. A random-effects model on the other hand relaxes this assump-
tion. Instead the model allows the treatment effects to differ from each other
but assumes they are drawn from a common distribution of effect sizes. This
distribution is usually assumed to be the Normal distribution, with a variance
determined by the data. Accounting for between-study heterogeneity often leads
to similar pooled-estimates to those obtained by a fixed-effects method, however,
confidence intervals are wider and so the estimates are more conservative (Sutton
et al., 2001).
There are two possible approaches for deciding between fixed- and random-
effects models. Firstly, model choice could be informed by a test for heterogeneity,
such as the Q or I2 statistics (Higgins and Thompson, 2002). That is, if the
test is non-significant then a fixed-effects model may be appropriate, whereas if
the test is significant, a random-effects model should be used. However, these
heterogeneity tests often have low power, implying that heterogeneity may exist
when the test produces a non-significant result (Boissel et al., 1989). The other
approach is always to use a random-effects model since the degree of variation
between studies will determine the width of the confidence interval. Therefore,
when between study variation is low, the inflation in the confidence interval may
be negligible, producing a result similar to the fixed-effects method (Sutton et
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al., 2001).
Frequentist approaches to meta-analysis generally calculate a weighted av-
erage of results obtained from individual studies. Bayesian methods, however,
consider both the data and the model parameters to be random quantities about
which there is uncertainty, instead of constant values which, in the case of param-
eters, are unknown. The likely values of these parameters are described through
a probability distribution that quantifies this uncertainty (Schmid, 2001). Using
this approach allows all parameter uncertainty to be automatically accounted for
in the analysis. Also, in the meta-analysis context, individual trials can “bor-
row strength” from other trials, meaning that with every iteration the updated
estimates take into account the results from all other trials in the analysis, giv-
ing a better estimate for the individual trial effects. Interpretation of Bayesian
credible intervals is simpler than that of the frequentist confidence intervals since
direct probability statements can be made regarding the model parameters, the
quantities of interest. Additionally, prior knowledge of possible effects may be
incorporated into the analysis. However, use of different prior distributions can
change the conclusions and so a sensitivity analysis is always required. Further
drawbacks of using a Bayesian approach include the possible computational com-
plexity of such models. Also, there is no direct measure of statistical significance
analogous to the p-value in frequentist inference (Sutton and Abrams, 2001).
The theoretical basis of commonly used fixed- and random-effects models
using frequentist and Bayesian approaches is discussed below. Note that the
models given are for the odds ratio measure of treatment effect but they can
be modified to obtain other measures, for example risk difference or risk ratio.
Models are illustrated for the outcome of death but translate directly to other
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outcomes as required.
1.4.1 Peto meta-analysis
Yusuf et al. (1985) describe a frequentist fixed-effect approach to meta-analysis,
the Peto method, similar to that proposed by Mantel and Haenszel (1959) for
“2× 2” tables.
Suppose there is a trial i with Ni patients, ni of whom were treated and di of
whom died. The observed number of patients who died in the treated group, Oi,
are compared with the corresponding expected number Ei, where Ei = nidi/Ni.
If there was no treatment effect then Oi−Ei would only differ randomly from
zero, whereas if treatment were beneficial then Oi−Ei would tend to be negative,
with variance Vi, where
Vi =
Ei
(
1− ni
Ni
)
(Ni − di)
(Ni − 1) ,
and hence with standard error
√
Vi.
Now suppose there are m independent trials, the grand total (GT ) would be
given by
GT =
m∑
i=1
Oi − Ei. (1.1)
If there was no treatment effect then this would also only differ randomly from
zero, with variance equal to the sum of the individual variances (SIV )
SIV =
m∑
i=1
Vi.
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Equation 1.1 assumes that all data from all randomised trials are available, with-
out bias due to unavailability of unpromising results or to patient withdrawal.
It does not assume patients across different trials can be compared directly, nor
does it implicitly assume homogeneity of treatment effects in different trials. If,
however, treatment effects are approximately similar then an estimate of the odds
ratio (OR) for death among treated patients versus controls is given by
OR = exp
(
GT
SIV
)
,
with approximate 95% confidence interval (CI)
exp
(
GT
SIV
± 1.96√
SIV
)
.
1.4.2 DerSimonian and Laird meta-analysis
DerSimonian and Laird (1986) describe a frequentist random-effects method of
meta-analysis based on the inverse-variance method where the weight given to
each trial is chosen to be the inverse of the variance of the effect estimate.
As in the Peto method suppose there are m independent trials denoted i =
1, ...,m. Consider data from each trial consisting of the number of patients in the
treatment (nTi) and control (nCi) groups, and the number of patients with some
event in each of the groups, rTi and rCi. Therefore, for a particular trial, i, the
log odds ratio of the treatment effect estimate is given by
δi = ln
(
qTi(1− qCi)
qCi(1− qTi)
)
,
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where qTi = rTi/nTi and qCi = rCi/nCi are the proportions of events in treatment
and control groups, respectively.
In the random-effects model, the individual trial treatment effect estimate, δi,
can be defined as
δi = θi + εi,
where εi ∼ Normal(0, σ2i ) represents the sampling error of the ith study, and θi
is the true treatment effect in the ith study given by
θi = d+ υi.
It is assumed that υi ∼ Normal(0, τ 2) is the deviation of the ith study’s treatment
effect from the mean log odds ratio of treatment, d, where τ 2 is a measure of the
heterogeneity between studies. It is also assumed that εi and υi are independent.
Therefore, δi is also normally distributed with mean d and variance υi + εi.
The weighted estimator of the overall treatment effect form independent trials
is calculated as
dˆ =
∑m
i=1wiδi∑m
i=1wi
,
where wi is the inverse of the sampling variance of the ith trial.
Taking the exponent gives an estimate of the overall odds ratio of death among
treated patients to that among controls, namely
OR = exp (dˆ),
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with approximate 95% confidence interval, as given in Sidik and Jonkman (2002),
exp
(
dˆ± 1.96√∑m
i=1wi
)
.
1.4.3 Bayesian random-effect meta-analysis
Sutton et al. (2008) describe a model for Bayesian random-effects meta-analysis,
combining individual patient data and aggregate data (grouped data) for individ-
ually allocated and cluster allocated studies. Part 3 of this model (individually
allocated aggregate data studies) will be described in detail in this section.
As with the DerSimonian and Laird model described in Section 1.4.2 suppose
there are m trials with data of the form nCi, nTi, rCi and rTi. It is assumed that
rCi ∼ Binomial(pCi, nCi),
rTi ∼ Binomial(pTi, nTi),
where pCi and pTi are the associated probabilities of event in the control and
treatment groups, respectively.
The associated probabilities of event for the control group are modelled as
logit(pCi) = µi, (1.2)
where µi are the control group event rates for each study expressed on the logit
scale. The control group event rates are each given vague prior distributions,
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given here as a diffuse Normal distribution with mean 0 and variance 106,
µi ∼ Normal(0, 106).
The vague prior distributions may use different values to those quoted in this
Chapter. However, all must have reasonably large values for the variance. For
example, a variance of 103 is used in Chapters 7 and 8. There are no specific
guidelines on which values can be considered reasonably diffuse.
For the treatment group the model for the associated probabilities of event is
given by
logit(pTi) = µi + δi, (1.3)
where δi are the treatment effects for each trial on the log-odds ratio scale and
are assumed to be interchangeable across all studies. The treatment effects are
Normally distributed with mean d and variance τ 2,
δi ∼ Normal(d, τ 2).
The parameter d is given a vague prior distribution,
d ∼ Normal(0, 106),
and a sensitivity analysis is performed on the prior required for τ 2. Based on
previous research (Lambert et al., 2005), three different priors are considered.
The Inverse-Gamma distribution is the most commonly used prior distribution
for variance parameters. It has an approximately uniform distribution but with
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a ‘spike’ of probability mass close to zero
1
τ 2
∼ Gamma(0.001, 0.001).
The Uniform prior distribution on the standard deviation is recommended by
Spiegelhalter et al. (2004),
τ ∼ Uniform(0, 100).
Lastly, the Half-Normal prior distribution, truncated at zero, placed on the stan-
dard deviation has been used in previous meta-analysis applications
τ ∼ Normal(0, 100) for τ > 0.
The overall odds ratio for treatment effect is estimated by taking the exponent
of the mean of the treatment effects
OR = exp (d),
with 95% credible interval dictated by the posterior standard deviation of d.
1.5 Data sources and software
Several sets of data from different sources were obtained to answer the research
questions. Four main sets of data were used, which will briefly be described here
along with the software used for the analyses.
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1.5.1 Glasgow Royal Infirmary cohorts
Data were obtained from two cohort studies. The first cohort (Barber et al., 2004)
consisted of 873 consecutive patients admitted to the Glasgow Royal Infirmary
over a two year period (2000-2002). In addition to baseline assessments of stroke
characteristics and stroke severity, early neurological deterioration was assessed
at day three and functional outcomes (death, dependency and requirement for
institutional care) at 1 month following stroke.
The second (Sellars et al., 2007) was a prospective cohort of consecutive ad-
missions to the Glasgow Royal Infirmary during a 17 month period from June
2004 to November 2005. Patients included were those with first or recurrent is-
chemic or haemorrhagic stroke within 7 days of admission to hospital. In total
412 patients were recruited into the study and were followed up at three months
after stroke. As with the first cohort, in addition to baseline characteristics,
the OCSP clinical classification, modified Rankin Scale and Barthel Activities of
Daily Living Index were also recorded.
These datasets are used in Chapter 3 to investigate how much information
is lost by categorising severity and whether the currently used categories are
equivalent across different stroke scales.
1.5.2 Intravenous Magnesium Efficacy in Stroke trial
The Intravenous Magnesium Efficacy in Stroke (IMAGES) trial was an interna-
tional, multicentre, double-blind, placebo-controlled, parallel group study which
enrolled and randomised patients between October 1997 and April 2003 (In-
travenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators, 2004).
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Randomised participants received either intravenous magnesium sulphate (1188
participants) or matching placebo (1198 participants). Outcomes included death
and disability at 90 days (defined as Barthel score less than 95 or modified Rankin
scale greater than 1). Baseline characteristics and OCSP classifications were also
recorded during this trial.
This dataset is used in Chapter 2 to evaluate the internal consistency and
validity of the IMAGES stroke scale.
1.5.3 Acute Stroke Unit of the Western Infirmary
The Acute Stroke Unit (ASU) of the Western Infirmary in Glasgow serves a catch-
ment population of 220,000. Unselected patients who present within 72 hours of
onset of acute neurological deficit with no known alternative to a vascular cause
are admitted irrespective of age or severity of the neurological deficit. Approxi-
mately 800 patients are admitted each year. Patients have their stroke subtype
categorised using the OCSP clinical classification, and brain imaging using ei-
ther CT or MRI is performed promptly after admission (in most cases within 24
hours) on all patients with a clinical diagnosis of stroke. Clinical, radiological and
biochemical data from each patient are reviewed and verified by a neurologist,
radiologist and stroke physicians before being recorded prospectively on a com-
puter database. Data extracted from this database included NIHSS assessments
(including individual NIHSS items), database entries corresponding to the com-
ponents of the IMAGES Stroke Scale, ISS, (described in more detail in Chapter
2), clinical classification (incorporating lateralisation, OCSP classification and fi-
nal diagnosis), CT findings (to differentiate between ischaemic and haemorrhagic
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stroke), age, and sex of each patient. Routine prospective recording of NIHSS as-
sessment was available from 1998 until 2003. Hence NIHSS scores were available
for a subset of ASU database patients.
This dataset is used in Chapter 2 to evaluate the internal consistency and
validity of the IMAGES stroke scale.
1.5.4 Stroke Unit Trialists’ Collaboration database
The Stroke Unit Trialists’ Collaboration (SUTC) database consists of 31 prospec-
tive trials (Stroke Unit Trialists’ Collaboration, 2007). Each used some form of
random allocation of stroke patients to an organised system of inpatient (stroke
unit) care or an alternative form of inpatient care, generally contemporary con-
ventional care, but also including an alternative model of organised inpatient
care. Trials were included if treatment allocation was carried out on a strictly
random basis or with a quasi-random procedure such as bed availability or date
of admission.
Eligibility and methodological quality of published trials were initially as-
sessed by two review authors. Characteristics of unpublished trials were estab-
lished through discussion with the trial co-ordinator. Descriptive information
about the service characteristics of the treatment groups were obtained through
a structured interview or correspondence with the trial co-ordinators. Trials were
then allocated the service subgroups described in Section 1.2.1. Trialists were
asked to provide information on the number of patients who were dead, requiring
institutional care, dependent and missing at the end of scheduled follow up. The
following subgroup information was also requested:
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1. age: up to 75 years or greater than 75 years;
2. sex: male or female;
3. stroke severity: dependency at the time of randomisation (usually within 1
week of stroke):
a) mild stroke: equivalent to a Barthel Index of between 10 and 20 during
the first week;
b) moderate stroke: equivalent to a Barthel Index from 3 to 9 during the
first week;
c) severe stroke: equivalent to a Barthel Index from 0 to 2 during the
first week.
A more detailed description of the trials included in this database will be
provided in Chapter 4.
This database is used in Chapters 4, 5, 6 and 8 to investigate which types of
stroke unit are most effective and possible reasons why stroke units are effective.
Additionally, in Chapters 6 and 8, data from the Gateshead acute monitoring
trial (Davis et al., 2000) was used alongside the SUTC database. The Gateshead
trial randomised a total of 258 patients to receive “augmented care” (72 hours of
continuous physiological monitoring) or “standard care” (routine 4 hourly obser-
vations) to test if intense monitoring could improve the detection of physiological
complications which exacerbate neuronal injury thereby improving outcome. This
trial is currently unpublished.
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1.5.5 Software
Analyses were performed in Windows XP Professional using various statistical
packages including: the SAS system 8.2 (SAS, Cary, NC); SPSS 15.0 for Windows
(SPSS Inc, Chicago, IL); S-Plus 7.0 for Windows (Insightful Corporation, Seattle,
WA); WinBUGS version 1.4.1 (Lunn et al., 2000); Review Manager (RevMan)
4.2 for Windows (Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2003); and Minitab 15 (Minitab Incorporation, State College, PA).
Chapter 2
Consistency and validity of the
IMAGES Stroke Scale
This Chapter introduces and assesses a novel stroke severity scale, the IMAGES
Stroke Scale (ISS). Comparisons are made between this scale and current mea-
sures of stroke severity to determine whether the ISS offers a suitable alternative
of measuring severity that requires no specific training and can be easily derived
from routinely collected data. If ISS is found to be interchangeable with current
stroke severity scales, this would allow patient severity to be measured using the
same scale so that all patient severities are comparable across trials.
2.1 Background
Neurological impairment scales numerically grade deficits on neurological exam-
ination (Lyden and Lau, 1991) and have prognostic value in determining death
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or dependency of acute stroke patients. Most widely used is the National Insti-
tutes of Health stroke scale (NIHSS), a 15-item scale measuring key components
of a standard neurological examination (Brott et al., 1989) as described in Sec-
tion 1.3.2. However, the NIHSS is recognised to be complex and to contain items
with poor inter-observer reliability. Simpler modifications have been proposed
(Lyden et al., 2001) but not widely adopted. Retrospective estimation of NIHSS
from documentation of neurological deficits is possible but requires detailed med-
ical records to be available (Kasner, 2006). Alternatively, the Oxfordshire Com-
munity Stroke Project classification (OCSP) assigns patients one of four clinical
subtypes according to presenting neurological symptoms and signs (Bamford et
al., 1991) and is also prognostically valuable, although not developed for this
purpose.
The Intravenous Magnesium Efficacy in Stroke (IMAGES) trial was an in-
ternational, multi-centre, double-blind, placebo-controlled, parallel group study
investigating whether intravenous magnesium sulphate, given within 12 hours
of stroke onset, reduced death or disability at 90 days (Intravenous Magnesium
Efficacy in Stroke (IMAGES) Study Investigators, 2004). A secondary analysis
formulated the IMAGES Stroke Scale (ISS), which incorporates elements used to
derive OCSP classification (Bamford et al., 1991), and the Glasgow Coma Scale
(GCS) (Jennett and Teasdale, 1977).
In this Chapter the novel IMAGES Stroke Scale is investigated. The internal
consistency of the ISS and NIHSS and the construct validity of the ISS in predict-
ing NIHSS are assessed. The ability of the ISS to predict death or dependency 90
days after stroke is investigated along with whether it provides additional prog-
nostic information to a simple clinical classification such as the OCSP and how
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its predictive accuracy compares to that of the NIHSS.
2.2 Methods
The ISS is created by combining components of the OCSP, as described in Sec-
tion 1.3.1, and the Glasgow Coma Scale (Jennett and Teasdale, 1977). The Glas-
gow Coma Scale (Table 2.1) is an impairment scale which measures impairment
after head trauma, for example, head injuries or non-traumatic conditions such
as stroke. The scale assesses eye movement, motor and verbal response where
high and low numbers represent normal and impaired responses, respectively.
The total score, the EMV Score, is the sum of the individual responses giving a
maximum value of 15 (normal) and minimum value of 3 (maximum impairment).
Table 2.1: The Glasgow Coma (or Responsiveness) Scale.
Observation Response
Eye 4 = Spontaneous
opening (E) 3 = To speech
2 = To pain
1 = Nil
Best motor 6 = Obeys
response (M) 5 = Localises
4 = Withdraws
3 = Abnormal flexion
2 = Extends
1 = Nil
Verbal 5 = Orientated
response (V) 4 = Confused conversation
3 = Inappropriate words
2 = Incomprehensible sounds
1 = Nil
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Table 2.2: The IMAGES Stroke Scale.
Item Score
Unilateral weakness of:
face 1 point
arm 2 points
leg 2 points
Sensory loss 1 point
Dysphasia 2 points
Neglect 1 point
Hemianopia 3 points
Brainstem signs 1 point
Any abnormality in the
GSC components of:
eye 1 point
motor 1 point
verbal 1 point
Total 16 points
The ISS (Table 2.2) consists of the presence or absence of: unilateral face
weakness (1 point), unilateral arm weakness (2 points), unilateral leg weakness (2
points), unilateral sensory loss (1 point), dysphasia (2 points), neglect (1 point),
hemianopia (3 points), brainstem signs (1 point), any abnormality in the GCS
eye component (1 point), motor component (1 point) and verbal component (1
point), yielding a maximum deficit of 16 points. The score assigned to each item
was loosely based on its weighting in the NIHSS stroke scale (Table 1.2).
To evaluate the internal consistency and construct validity of the ISS and
whether the ISS and NIHSS were interchangeable measures of impairment, data
from an Acute Stroke Unit (ASU), described in Section 1.5.3, were used. The
ASU admits patients within 72 hours of stroke onset irrespective of age or severity.
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Prospectively documented brain imaging findings and OCSP classification were
available for all patients, while NIHSS score was available for a subset of patients
and the ISS score was derived retrospectively from the database. Since NIHSS
was only available for a subset of patients, the dependence of recording of NIHSS
on patient characteristics of age and severity (measured using ISS) was examined.
The internal consistency of the ISS and NIHSS was measured using Cronbach’s
alpha correlation coefficient (Armitage and Colton, 1998), which tests whether
the items within the scale measure a single construct. Subjective guidelines for
interpretation of Cronbach’s alpha are: < 0.60 unacceptable, 0.61−0.65 undesir-
able, 0.66− 0.70 minimally acceptable, 0.71− 0.80 respectable, 0.81− 0.90 very
good, and > 0.90 some items possibly redundant (Armitage and Colton, 1998).
Construct validity, which refers to the extent to which ISS can be related to other
constructs, was measured by analysing the ISS relationship with NIHSS using the
Spearman correlation coefficient. Bland-Altman plots (Bland and Altman, 1999)
were created to assess whether the ISS and NIHSS are interchangeable methods
of assessing stroke. ISS and NIHSS were scaled as a percentage of the maximum
deficits since the ranges of the scales are different. This limits interpretation of
systematic bias. However, the variability in differences in percentages will give
some information about whether the scales are interchangeable.
Internal consistency, construct validity and Bland-Altman plots were analysed
for all data available in the ASU, as well as within the OCSP clinical subgroups:
total anterior, partial anterior and posterior circulation syndromes (TACS, PACS
and POCS), and lacunar syndrome (LACS). Additionally, internal consistency of
NIHSS was measured when its items were dichotomised as present or absent to
determine if the dichotomisation of scale components leads to poorer internal
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consistency.
The prognostic value of the ISS was analysed using the 1198 patients ran-
domised to the control group in the original IMAGES trial described in Sec-
tion 1.5.2. The primary outcome was the combined outcome of death or depen-
dency defined as Barthel Index (BI) less than 95 and the secondary outcome of
death or dependency defined as modified Rankin Score greater than or equal to
2. Outcomes were analysed using logistic regression and effect sizes expressed
in terms of odds ratios. Although this contrasts with Chapters 3 and 4 where
dependency is defined as mRS greater than 2, cut-offs are subjective and may be
defined differently depending on the context. Significance of effects was tested us-
ing generalised likelihood ratio tests. ROC curves (Armitage and Colton, 1998)
were used to assess the usefulness of ISS in predicting outcome of stroke and
compared to previous ROC curves calculated for NIHSS (Muir et al., 1996).
2.3 Results
2.3.1 Internal consistency and construct validity
The 8284 patients admitted between 1990 and 2005 in the ASU database of the
Western Infirmary in Glasgow had ISS recorded retrospectively. Of these, 2111
(25.5%) had both ISS and NIHSS recorded, 6851 (82.7%) had both ISS and OCSP
classification recorded, and 1777 (21.5%) patients had all three stroke scales (ISS,
NIHSS and OCSP) recorded. Figure 2.1 shows that the recording of NIHSS did
not depend on the patient characteristics of age and severity.
The standardised Cronbach’s alpha for ISS, based on 8284 patients, was 0.48,
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Figure 2.1: Boxplots showing distribution of (a) age and (b) ISS total for
those patients with and without NIHSS recorded.
indicating ‘unacceptable’ internal consistency. This is compared with the stan-
dardised Cronbach’s alpha for NIHSS, based on 2111 patients, of 0.85, indicating
‘very good’ internal consistency. Internal consistency for ISS based on the NIHSS
subset was similar (0.49). Table 2.3 gives the standardised internal consistencies
Table 2.3: Internal consistency and Spearman rank correlation of ISS and
NIHSS by OCSP classification.
OCSP
ISS Cronbach’s NIHSS Cronbach’s Spearman rank
observations Alpha observations Alpha correlation
(%) ISS (%) NIHSS (95% CI)
LACS 2223 (32%) 0.41 627 (35%) 0.76 0.38 (0.31, 0.45)
PACS 2377 (35%) 0.46 600 (34%) 0.78 0.50 (0.44, 0.56)
POCS 735 (11%) 0.46 179 (10%) 0.88 0.40 (0.27, 0.51)
TACS 1516 (22%) 0.24 371 (21%) 0.67 0.21 (0.11, 0.31)
Total 6851 0.49 1777 0.85 0.63 (0.60, 0.65)∗
∗Total correlation calculated using 1777 patients who had ISS, NIHSS and OCSP classifications
recorded. Total correlation for patients with only ISS and NIHSS recorded is given as 0.61 (0.59,
0.64).
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Table 2.4: Internal consistency NIHSS by OCSP classification when the
NIHSS items are dichotomised.
OCSP
Observations Cronbach’s
(%) Alpha
LACS 627 (35.3) 0.67
PACS 600 (34.8) 0.74
POCS 179 (10.1) 0.80
TACS 371 (20.9) 0.59
Total 1777 0.80∗
∗Cronbach’s alpha based on 1777 patients
who had ISS, NIHSS and OCSP classifi-
cations recorded. Cronbach’s alpha for all
patient with NIHSS recorded is 0.80
within each OCSP category which were ‘unacceptable’ for ISS and at least ‘min-
imally acceptable’ for NIHSS. The standardised internal consistency of NIHSS
appears to reduce when the items are dichotomised, as shown in Table 2.4
The Spearman correlation between ISS and NIHSS, based on 2111 patients,
showed a modest and significantly positive correlation (0.61; 95% CI: 0.59, 0.64)
between ISS and NIHSS (Figure 2.2). Table 2.3 shows significant but weaker
positive correlations between ISS and NIHSS within each OCSP subgroup. Fig-
ure 2.2 shows for a given value of ISS, there is large variability in the equivalent
value of NIHSS.
The Bland-Altman plot for the complete data, Figure 2.3(a), shows that the
difference between the scaled measures for small averaged measures (0-20) in-
creases as the average increases. The same pattern emerges within the OCSP
classifications of PACS, POCS and LACS patients. This non-uniform propor-
tional difference in the Bland-Altman plot could be due to a flooring effect of
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Figure 2.2: Scatterplot of ISS and NIHSS.
the scales. The majority of patients have small averaged scores but patients can-
not score less than zero, meaning that the difference between scaled measures can
take a wider range of values as the averaged score increases. This makes interpre-
tation difficult as the underlying assumptions for interpretation are uniform bias
and variability about the mean. However, for TACS patients, whose strokes are
generally more severe (and therefore the measures obtained for ISS and NIHSS
are larger), Figure 2.3(b) shows that the points are randomly scattered within
the plot, making underlying assumptions valid.
2.3.2 Prediction of functional outcome
Of the 1198 patients randomised into the control group, 787 (66%) were recorded
as having a Barthel Index of less than 95 at 90 days following stroke and 858
(72%) had a modified Rankin Scale greater than or equal to 2. Table 2.5 shows
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Figure 2.3: Bland-Altman plot of ISS and NIHSS for (a) all patients and
(b) TACS patients. ISS and NIHSS are scaled as a percentage
of maximum due to different ranges of each scales. Re-scaling
allows comparability of the scales on the Bland-Altman plot.
the proportions of patients with good (BI ≥ 95 or mRS < 2) and poor outcome
(BI < 95 or mRS ≥ 2) in each of the OCSP classifications.
Figure 2.4 shows that those with poor outcomes have slightly larger ISS scores
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Table 2.5: Percentage of patients with good (BI ≥ 95 or mRS < 2) and poor
(BI < 95 or mRS ≥ 2) outcome in each OCSP classification.
OCSP
Barthel Index mRankin Scale
Total
BI ≥ 95 BI < 95 mRS < 2 mRS ≥ 2
LACS 178 (47%) 204 (53%) 153 (40%) 229 (60%) 382
PACS 175 (40%) 266 (60%) 141 (32%) 300 (68%) 441
POCS 11 (42%) 15 (58%) 8 (31%) 18 (69%) 26
TACS 47 (13%) 302 (87%) 38 (11%) 311 (89%) 349
Total 411 (34%) 787 (66%) 340 (28%) 858 (72%) 1198
than those with good outcomes. Median ISS scores for TACS patients with poor
outcomes appears to be greater than the median scores for other levels of OCSP,
with LACS patients having the lowest ISS score.
Table 2.6 describes the models fitted for each outcome. OCSP and ISS were
each independently and significantly associated with both outcomes (model 1:
p < 0.001; and model 2: p < 0.001). When ISS alone is included in the model,
for each point increment of ISS the odds of BI < 95 increased by a factor of 1.31
(95% CI 1.25, 1.37) and the odds of mRS ≥ 2 by 1.31 (95% CI 1.25, 1.38). ISS
added significant prognostic information when added to OCSP for both outcomes
(model 3: p < 0.001). However, if ISS (which is constructed from OCSP inter
alia) is known, OCSP does not add any significant prognostic information (model
4: BI: p = 0.20; mRS: p = 0.57).
For both functional outcomes, the area under the ROC curve for ISS (Fig-
ure 2.5) was 0.71 (95% CI: 0.67, 0.74). Patients scoring 8 or greater could be
predicted as being dead or dependent at 90 days since this cut-point best max-
imises sensitivity and specificity. The sensitivity and specificity at the cut-point
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Figure 2.4: Boxplot of IMAGES Stroke Scale by OCSP for outcomes (a)
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circles represent possible outliers, while +’s represent means.
of 8 for BI < 95 were 0.58 (0.54, 0.61) and 0.75 (0.71, 0.79), respectively, indicat-
ing that approximately 58% of events (poor outcomes) were classified correctly
and 75% of non-events (good outcomes) were classified correctly. For mRS ≥ 2
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Table 2.6: Summary of models fitted for each outcome and p-values for the
effects of each term.
Model
BI< 95 mRS≥ 2
p-value p-value
1. OCSP <0.001 <0.001
2. ISS <0.001 <0.001
3. ISS (given OCSP) <0.001 <0.001
4. OCSP (given ISS) 0.20 0.57
the sensitivity and specificity at the cut-point of 8 were 0.56 (0.52, 0.59) and
0.77 (0.72, 0.81), respectively. In a previous analysis of ROC curves for NIHSS
(Muir et al., 1996), which subjectively used an NIHSS of 7 as the best possible
cut-point for maximising sensitivity and specificity, the sensitivity and specificity
were approximately 0.85 and 0.70, respectively.
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Figure 2.5: ROC curves for (a) Barthel Index < 95 and (b) modified Rankin
Scale ≥ 2.
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2.4 Discussion
The IMAGES stroke scale can be derived from data documented routinely in
most stroke patients. In contrast, retrospective estimation of NIHSS requires de-
tailed neurological examination findings to be recorded (Kasner, 2006). However,
according to established guidelines for the interpretation of internal consistency
(Armitage and Colton, 1998), the performance of ISS was found to be ‘unac-
ceptable’ while that of NIHSS was ‘very good’. The binary coding of the ISS
components (present or absent), compared with the more finely graded NIHSS
items, may partially explain the low internal consistency of ISS. The internal
consistency of NIHSS was reduced when the items of NIHSS were dichotomised,
but were still not as low as the ISS score. Additionally, the ISS measures a
range of aspects of stroke severity, clinical symptoms and signs, and measures of
consciousness giving a further explanation for the low internal consistency and
also an explanation for the modest correlation between ISS and NIHSS, shown
in Figure 2.2.
Reliability (inter-observer, intraobserver, or test-retest agreement) was not
assessable based on the data available. Criterion validity was not assessed as
there is no ‘gold-standard’ scale to measure dependence after stroke (Kasner,
2006). Additionally, content validity was not assessed as this is based on expert
opinion and is not a quantitative measure.
The large variability in the equivalent value of NIHSS for a given value of
ISS (Figure 2.2) shows that the scales may not be interchangeable, which is also
reflected in the Bland-Altman plots. The large variability in the proportional
difference between ISS and NIHSS in the Bland-Altman plots suggests that the
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scales may not be interchangeable since, for a given scaled value of NIHSS, the
corresponding scaled ISS value could proportionally score between 18% lower and
up to 59% higher than the scaled NIHSS. This lack of interchangeability may be
explained by ISS and NIHSS measuring different constructs.
Both OCSP and ISS have significant association with the outcome of stroke
(BI < 95 and mRS ≥ 2). If ISS is known, OCSP does not add any significant
additional prognostic information, but if OCSP is known then ISS adds signif-
icant additional prognostic information. Finally, by analysing the ROC curves
and comparing this to previous work (Muir et al., 1996) it is shown that when
identifying the cut-point on each of ISS and NIHSS that maximises sensitivity
and specificity, the NIHSS allows a better prediction of outcome than ISS.
A large data set from a broad case mix of patients was used to analyse the
consistency and validity of the ISS. This has an advantage over highly selected
trial patients as conclusions are not restricted to a specific subset of stroke pa-
tients. However, not all patients had OCSP and NIHSS recorded in addition
to ISS, reducing the sample size available for analysis. Although this limitation
could be a possible source of bias, an examination of the data showed that the
recording of NIHSS appeared to be independent of patient characteristics.
The original IMAGES trial data were rigorously collected meaning that there
were few missing data, allowing the calculation of the prognostic value of ISS com-
pared to the OCSP. The most obvious limitation to the study of the prognostic
value of ISS and NIHSS is that there is not a direct comparison of functional dis-
ability outcome for both of these scales. ROC curves from previously published
work were used to estimate the sensitivity and specificity of NIHSS.
Its wide familiarity and standardised video training make the NIHSS the
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preferred acute stroke scale. However, in large simple trials, especially those
conducted in countries where there are language barriers and with limited access
to training material, the ISS offers an alternative since it is easily derived from
routinely available data without the need for specific training. However, further
development to improve its internal consistency and prognostic value would be
required to make it useful in practice.
Chapter 3
Categorising stroke severity
using different stroke scales
In the previous Chapter, it was shown that the IMAGES Stroke Scale was not
interchangeable with NIHSS and the NIHSS allows a better prediction of out-
come compared to ISS. Therefore, since ISS cannot be used as a general method
of measuring severity in stroke patients, it would beneficial to examine whether
current methods of measuring stroke severity are equivalent in predicting out-
comes of patients. Additionally, the categorisation of stroke severity is common
in meta-analysis (see Chapters 6, 7 and 8) and it is of further interest to examine
how much information is retained when stroke scales are categorised, and if these
categorisations are also equivalent.
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3.1 Background
Stroke is a very heterogeneous condition where patients can present with a range
of severities, from those that resolve within a few hours, to those which are
rapidly fatal. When measuring severity using scales such as those described in
Section 1.3, further variation is introduced by the use of different scales, or the
redundancy of items within a standard scale which masks the true severity of an
individual patient.
Meta-analysis often tries to compare the efficacy of an intervention between
stroke patients with different severities. However, the use of different methods
of measuring stroke severity may complicate analyses. Furthermore, although
individual patient data is considered the gold standard for meta-analyses, the
collection of individual patient data in meta-analysis is difficult, time-consuming
and sometimes not feasible. Therefore, severity data is often stratified into a
small number of categories, making the collection of aggregate data over the
small number of strata easier and meta-analyses simpler.
There is uncertainty as to whether the categorisations used for different stroke
scales are equivalent. While discrepancies between severity classifications in the
different stroke scales do not influence the treatment effect, they may influence
the effect of interactions between severity and treatment. Therefore, the amount
of information retained by categorising severity, and whether the currently used
cut-offs are equivalent across different stroke scales, was investigated.
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3.2 Methods
3.2.1 Data
In order to investigate severity and its categorisations, data from the Glasgow
Royal Infirmary cohorts, as described in Section 1.5.1, were used. The first cohort
(Barber et al., 2004) contains measurements of the Scandinavian stroke scale
(SSS), modified Rankin Scale (mRS) and the Barthel Index (BI) as described in
Sections 1.3.3, 1.3.5 and 1.3.4, respectively. In addition to the modified Rankin
Scale and Barthel Index, the second cohort (Sellars et al., 2007) also recorded
measurements of the National Institutes of Health stroke scale (NIHSS) described
in Section 1.3.2. Table 3.1 shows how each of these stroke scales are used to
categorise patients into mild, moderate and severe. For both cohorts the outcomes
of death, dependency and institutional care were recorded at the end of follow
up (one month in Barber et al. (2004) and three months in Sellars et al. (2007)),
with dependency defined as mRS > 2.
Table 3.1: Mild, moderate and severe categories using baseline levels for four
established stroke scales.
Scale Mild Moderate Severe
Barthel Index 10 - 20 3 - 9 0 - 2
modified Rankin Scale 0 - 3 4 5
Scandinavian Stroke Scale 43 - 58 26 - 42 0 - 25
NIH Stroke Scale 0 - 5 6 - 14 15 - 42
Barthel Index, Scandinavian Stroke Scale and modified Rankin
Scale recorded on day 3, National Institutes of Health Stroke Scale
recorded on day 1-5.
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3.2.2 Statistical methods
Several methods have been developed in order to choose the optimal cut-points
and number of groupings for continuous variables. Taylor and Yu (2002) sum-
marise the work of a number of authors in this area. Cox (1957) discusses methods
of grouping variates so that the intervals retain as much information as possible.
Connor (1972) considered the choice of optimal cut-points for a continuous vari-
able and found relatively little loss in efficacy with as few as three or four optimal
intervals. Altman et al. (1994) describe a data-dependent approach to defining
“low” and “high” risk groups using a minimum p-value approach. Cut-points
are varied systematically when categorising a continuous variable and a p-value
is computed for each cut-point. The cut-points are then chosen to correspond to
the most significant relationship with outcome. The authors warn that naive use
of this approach is associated with considerable inflation of false-positive error
rates due to multiple testing. While a correction of the minimal p-value allows
for multiple testing in large sample sizes, they also warn that the effect of the
covariate may still be considerably overestimated. The authors recommend con-
structing three or more prespecified groups, and basing the choice of cut-point
on simplicity, biological reasoning and knowledge of measurement techniques.
Stroke severity has generally been stratified into three categories: mild, mod-
erate and severe. The categories have been chosen in a similar, though less for-
mal, fashion to the minimum p-value approach described by Altman et al. (1994).
Three categories were chosen for several reasons. Suppose a small trial was con-
ducted which stratified its randomisation by severity plus another variable, for
example, age. This would lead to at least six strata in total which, in a small
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trial, may lead to strata containing few patients and hence randomised blocks
that are incomplete. This may lead to an imbalance of randomised treatments
across stratification variables, undermining the very aim of stratification. There-
fore, it would not be feasible to stratify severity by more than three categories.
However, dichotomising severity may lead to too few categories and possibly to
the loss of too much information.
Receiver operating characteristic (ROC) curves were used to assess the useful-
ness of each stroke scale in predicting outcome of stroke. In addition to assessing
the area under the ROC curve (AUC) of each scale, the AUC for each full scale
was compared to that of the categorised scale to determine how much infor-
mation is retained after categorising severity as mild, moderate or severe. The
differences in AUC were calculated using an algorithm developed by SAS Insti-
tute Inc. (2007). Subjective guidelines for interpretation of the AUC, based on
suggestions by Swets (1988) and Greiner et al. (2000) are: 0.50 non-informative;
0.51−0.70 low accuracy; 0.71−0.90 moderate accuracy; 0.91−0.99 high accuracy;
and 1.00 perfect accuracy.
The agreement between the categorisations of different scales was assessed.
In ordinal measures such as severity, certain disagreements are more serious than
others. For example, a severe patient classified as mild is a more serious disagree-
ment than a moderate patient classified as mild. Therefore, a weighted kappa
analysis (Cohen, 1968) was performed to account for the ordering of the cate-
gories using the Cicchetti-Allison kappa coefficient (Cicchetti and Allison, 1971)
where exact agreement is given the maximum weight of 1 and disagreements
in adjacent and disparate categories weighted as 0.5 and 0, respectively. Sub-
jective guidelines for the interpretation of the kappa statistic are: < 0.00 poor
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agreement; 0.0 − 0.20 slight agreement; 0.21 − 0.40 fair agreement; 0.41 − 0.60
moderate agreement; 0.61 − 0.80 substantial agreement; and 0.81 − 1.00 almost
perfect agreement (Landis and Koch, 1977).
3.3 Results
Of the 733 acute stroke patients in the Barber et al. (2004) Glasgow Royal In-
firmary cohort, 665 (91%) had modified Rankin Score, Barthel Index and Scan-
dinavian Stroke scale recorded within three days of admission. The outcomes
of death and death or dependency were available for all patients and death or
institutional care was available for 572 patients (78%). Outcomes were recorded
at one month following stroke.
In the Sellars et al. (2007) cohort, of the 412 acute stroke patients, 405 (98%)
had modified Rankin Score, Barthel Index and NIH stroke scale recorded within
three days of admission. Again the outcomes of death and death or dependency
Table 3.2: Percentage of patients in mild, moderate and severe categories for
each stroke scale in each cohort.
Study/scale Mild Moderate Severe Total
Barber et al. (2004)
SSS 409 (56%) 170 (23%) 147 (20%) 726
mRS 357 (54%) 193 (29%) 115 (17%) 665
BI 416 (57%) 157 (22%) 151 (21%) 724
Sellars et al. (2007)
NIHSS 221 (54%) 125 (31%) 63 (15%) 409
mRS 222 (54%) 109 (26%) 81 (20%) 412
BI 232 (57%) 93 (23%) 83 (20%) 408
SSS represents Scandinavian Stroke Scale; mRS - modified Rankin
Scale; NIHSS represents National Institutes of Health Stroke Scale;
and BI - Barthel Index.
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were available for all patients while death or institutional care was available for
406 patients (99%). Outcomes were recorded at three months following stroke.
Table 3.2 shows, for the Barber et al. (2004) and Sellars et al. (2007) co-
horts, the number and percentage of patients in the mild, moderate and severe
categories, as defined in Table 3.1. Table 3.2 shows that the percentages are ap-
proximately the same across each scale within cohorts as well as between cohorts.
3.3.1 Comparison of full and categorised stroke scales
The accuracy of predicting outcome can be determined by examining the area
under the ROC curve. Tables 3.3 and 3.4 show the estimated areas with 95%
confidence limits for the full scales, categorised scales and the differences between
these for the Barber et al. (2004) and Sellars et al. (2007) cohorts, respectively.
P -values are also given for the test of statistical significance of the differences.
All areas under the ROC curves for the Barber et al. (2004) cohort (Table 3.3)
show moderate or high accuracy in predicting outcome for both the full and cat-
egorised scales. Although the p-values show statistically significant differences
between the AUCs of the full and categorised scales (differences which appear to
be larger for the death or dependency and death or institutional care outcomes),
the difference estimates are small with narrow confidence intervals. The compar-
ison of the full and categorised scales can be seen more clearly in the ROC curves
in Figure 3.1, which demonstrate little difference between the full and categorised
scales for the outcome of death while there is slightly lower predictive accuracy
of the categorised scales for the outcomes of death or dependency and death or
institutional care. Note also that the predictive accuracy for the full scales is also
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Table 3.3: Estimates and 95% confidence limits for the area under the ROC
curve of each stroke scale for the full scale, categorised scale and
the difference between them (full−categorised) for the Barber et
al. (2004) cohort.
Outcome SSS mRS BI
Death
Full 0.93 (0.90, 0.96) 0.92 (0.89, 0.95) 0.92 (0.90, 0.95)
Category 0.88 (0.85, 0.92) 0.92 (0.89, 0.95) 0.90 (0.88, 0.93)
Difference 0.044 (0.028, 0.059) 0.0004 (-0.001, 0.001) 0.019 (0.008, 0.029)
p < 0.001 p = 0.357 p < 0.001
Death or dependency
Full 0.86 (0.84, 0.89) 0.88 (0.86, 0.91) 0.89 (0.87, 0.91)
Category 0.79 (0.76, 0.82) 0.83 (0.81, 0.86) 0.81 (0.79, 0.84)
Difference 0.075 (0.059, 0.092) 0.049 (0.034, 0.065) 0.081 (0.063, 0.098)
p < 0.001 p < 0.001 p < 0.001
Death or institutional care
Full 0.92 (0.90, 0.94) 0.92 (0.90, 0.94) 0.93 (0.91, 0.95)
Category 0.86 (0.83, 0.89) 0.88 (0.85, 0.90) 0.86 (0.83, 0.89)
Difference 0.062 (0.045, 0.079) 0.042 (0.028, 0.057) 0.067 (0.049, 0.086)
p = 0.002 p < 0.001 p < 0.001
Note: positive values indicate the area under the ROC curve is greater for the full scale, while
negative values indicate the area under the ROC curve is greater for the categorised scale. SSS
represents Scandinavian Stroke Scale; mRS - modified Rankin Scale; and BI - Barthel Index.
lower for these outcomes.
The areas under the curve for the Sellars et al. (2007) cohort (Table 3.4)
also show moderate to high accuracy in predicting outcome. Again the p-values
show statistically significant differences between the full and categorised scales
although, as before, the estimates of the differences are small with narrow con-
fidence intervals. Figure 3.2 shows the comparisons for the Sellars et al. (2007)
cohort.
Notice also that the area under the ROC curves for mRS and BI in the Barber
et al. (2004) cohort, where outcomes were recorded at one month, are larger than
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Figure 3.1: ROC curves of (a) Scandinavian Stroke Scale (SSS), (b) modified
Rankin Scale (mRS) and (c) Barthel Index (BI) in the Barber et
al. (2004) cohort for the outcomes of death, death or dependency
and death or institutional care, where the blue line represents
the full scale and the red line represents the categorised scale.
Sensitivity and specificity are calculated at each level: less than
or equal to the level for SSS and BI, and greater than or equal
to the level for mRS. The dotted line represents the line of ‘no
information’.
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Table 3.4: Estimates and 95% confidence limits for the area under the ROC
curve of each stroke scale for the full scale, categorised scale and
the difference between them (full−categorised) for the Sellars et
al. (2007) cohort.
Outcome NIHSS mRS BI
Death
Full 0.84 (0.78, 0.89) 0.84 (0.79, 0.88) 0.87 (0.83, 0.92)
Category 0.81 (0.75, 0.86) 0.82 (0.77, 0.88) 0.84 (0.79, 0.89)
Difference 0.026 (0.006, 0.046) 0.015 (0.001, 0.029) 0.032 (0.014, 0.051)
p = 0.011 p = 0.031 p < 0.001
Death or dependency
Full 0.77 (0.73, 0.82) 0.80 (0.76, 0.84) 0.80 (0.75, 0.84)
Category 0.73 (0.68, 0.77) 0.75 (0.70, 0.79) 0.73 (0.69, 0.77)
Difference 0.044 (0.021, 0.067) 0.057 (0.042, 0.092) 0.067 (0.036, 0.078)
p < 0.001 p < 0.001 p < 0.001
Death or institutional care
Full 0.84 (0.80, 0.89) 0.87 (0.83, 0.90) 0.90 (0.86, 0.93)
Category 0.81 (0.76, 0.85) 0.84 (0.80, 0.89) 0.86 (0.82, 0.90)
Difference 0.034 (0.015, 0.052) 0.022 (0.008, 0.036) 0.034 (0.017, 0.052)
p = 0.002 p < 0.001 p < 0.001
Note: positive values indicate the area under the ROC curve is greater for the full scale, while
negative values indicate the area under the ROC curve is greater for the categorised scale.
NIHSS represents National Institutes of Health Stroke Scale; mRS - modified Rankin Scale;
and BI - Barthel Index.
the areas under the curves in the Sellars et al. (2007) cohort. This is to be
expected as in the latter cohort, outcome is predicted over a longer time period
(3 months versus 1 month) during which events unrelated to initial stroke severity
are more likely to occur and influence outcome.
3.3.2 Comparison of stroke scales
The estimates, 95% confidence limits and p-values for the differences in area under
the ROC curve between each scale for the Barber et al. (2004) and Sellars et al.
(2007) cohort are given in Tables 3.5 and 3.6, respectively. Both tables give the
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Figure 3.2: ROC curves of (a) National Institutes of Health Stroke Scale
(NIHSS), (b) modified Rankin Scale (mRS) and (c) Barthel Index
(BI) in the Sellars et al. (2007) cohort for the outcomes of death,
death or dependency and death or institutional care, where the
blue line represents the full scale and the red line represents the
categorised scale. Sensitivity and specificity are calculated at
each level: less than or equal to the level for BI and greater
than or equal to the level for NIHSS and mRS. The dotted line
represents the line of ‘no information’.
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Table 3.5: Estimates and 95% confidence limits for the differences in areas
under the ROC curves between each stroke scale for the full and
categorised versions in the Barber et al. (2004) cohort.
Outcome SSS - mRS SSS - BI mRS - BI
Death
Full 0.007 (-0.014, 0.028) 0.006 (-0.009, 0.021) -0.001 (-0.015, 0.013)
p = 0.512 p = 0.423 p = 0.908
Category -0.036 (-0.062, -0.011) -0.019 (-0.040, 0.002) 0.017 (0.003, 0.032)
p = 0.006 p = 0.079 p = 0.020
Death or dependency
Full -0.017 (-0.030, -0.003) -0.027 (-0.041, -0.013) -0.010 (-0.021, 0.0002)
p = 0.014 p < 0.001 p = 0.055
Category -0.043 (-0.062, -0.024) -0.022 (-0.041, -0.003) 0.021 (0.007, 0.035)
p < 0.001 p = 0.023 p = 0.003
Death or institutional care
Full -0.005 (-0.009, -0.020) -0.009 (-0.023, -0.004) -0.015 (-0.026, -0.003)
p = 0.470 p = 0.181 p = 0.011
Category -0.014 (-0.038, 0.010) -0.004 (-0.026, 0.019) 0.010 (-0.006, 0.027)
p = 0.250 p = 0.752 p = 0.217
Note: positive values indicate the area under the ROC curve is greater for the first scale, while
negative values indicate the area under the ROC curve is greater for the second scale. SSS represents
Scandinavian Stroke Scale; mRS - modified Rankin Scale; and BI - Barthel Index.
difference in area between scales for the full and categorised versions.
For the Barber et al. (2004) cohort (Table 3.5) the majority of the significant
differences in areas lie within the death or dependency outcome. For both the
full and categorised scales, mRS has a larger area under the curve than SSS and
BI, while BI has a larger area than SSS, suggesting mRS has the best predic-
tive accuracy for one month following stroke. However, as before, even though
the differences are statistically significant, their estimates are small with narrow
confidence intervals.
In the Sellars et al. (2007) cohort (Table 3.6) any differences in predictive
accuracy between stroke scales are less apparent three months after stroke. There
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Table 3.6: Estimates and 95% confidence limits for the differences in areas
under the ROC curves between each stroke scale for the full and
categorised versions in the Sellars et al. (2007) cohort.
Outcome NIHSS - mRS NIHSS - BI mRS - BI
Death
Full -0.002 (-0.039, 0.035) -0.035 (-0.068, -0.002) -0.033 (-0.057, -0.008)
p = 0.900 p = 0.037 p = 0.009
Category -0.013 (-0.053, 0.026) -0.029 (-0.064, 0.006) -0.015 (-0.044, 0.013)
p = 0.511 p = 0.109 p = 0.291
Death or dependency
Full -0.031 (-0.063, 0.002) -0.026 (-0.063, 0.011) 0.004 (-0.022, 0.031)
p = 0.063 p = 0.164 p = 0.752
Category -0.018 (-0.051, 0.015) -0.004 (-0.040, 0.032) 0.014 (-0.015, 0.044)
p = 0.291 p = 0.845 p = 0.341
Death or institutional care
Full -0.027 (-0.057, 0.003) -0.055 (-0.083, -0.028) -0.029 (-0.052, -0.005)
p = 0.082 p < 0.001 p = 0.018
Category -0.038 (-0.072, -0.005) -0.054 (-0.086, -0.023) -0.016 (-0.046, 0.013)
p = 0.025 p < 0.001 p = 0.284
Note: positive values indicate the area under the ROC curve is greater for the first scale, while
negative values indicate the area under the ROC curve is greater for the second scale. NIHSS
represents the National Institutes of Health Stroke Scale; mRS - modified Rankin Scale; and BI -
Barthel Index.
are no significant differences in the death or dependency outcome. For the death
or institutional care outcome, categorised mRS and BI have significantly larger
areas under the ROC curves than categorised NIHSS, but as for the Barber et al.
(2004) cohort, the confidence intervals are narrow and the estimated differences
are small.
Weighted kappa analysis between categorised scales within each cohort was
performed to test the agreement between scales (Table 3.7). The lower triangular
entries (values in blue) show the results obtained in the Barber et al. (2004)
cohort, while the upper triangular entries (values in red) show the results for the
Sellars et al. (2007) cohort. Subjective guidelines, given in Section 3.2, suggest
CHAPTER 3. CATEGORISING STROKE SEVERITY 56
Table 3.7: Weighted kappa estimates and 95% confidence intervals between
categorised stroke scales for both cohorts.
SSS mRS BI
NIHSS - 0.66 (0.60, 0.71) 0.66 (0.60, 0.71)
mRS 0.77 (0.74, 0.81) - 0.77 (0.72, 0.82)
BI 0.80 (0.76, 0.83) 0.85 (0.82, 0.89) -
Note: values in blue in the lower triangular represent the Barber et al. (2004)
cohort, while values in red in the upper triangular represent the Sellars et al.
(2007) cohort. Values represent the agreement in categorising stroke patients
into mild, moderate and severe categories. SSS represents Scandinavian Stroke
Scale; NIHSS - National Institutes of Health Stroke Scale; mRS - modified
Rankin Scale; and BI - Barthel Index.
BI, mRS and SSS all have excellent agreement with each other when categorised
into mild, moderate and severe, while NIHSS has substantial agreement with
mRS and BI. Lastly, notice that the agreement measures between mRS and BI
for the two cohorts are quite different.
3.4 Discussion
This study shows that the Scandinavian Stroke Scale, the modified Rankin Scale,
the Barthel Index and the National Institutes of Health Stroke Scale all have
moderate to high predictive accuracy. This is particularly true for the outcome
of death and only slightly less so for the composite outcomes of death or depen-
dency and death or institutional care. When the scales are categorised into mild,
moderate and severe the reduction in the area under the ROC curve, although sta-
tistically significant, is small and may not be clinically important. This suggests
that there is little predictive information lost when these scales are categorised.
A secondary finding was that the predictive accuracy of the full and categorised
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scales was slightly greater in the Barber et al. (2004) cohort compared to the
Sellars et al. (2007) cohort, most likely due to the longer follow-up times in the
Sellars et al. (2007) cohort.
When comparing the area under the ROC curves between stroke scales it was
found that at one month follow-up (Barber et al. (2004) cohort) the mRS pre-
dicted death or dependency better than both the SSS and the BI. Dependency
was measured using the mRS, therefore it would be expected that baseline mRS
would be better at predicting one month mRS. At three months follow-up (Sel-
lars et al. (2007) cohort) the mRS and BI predicted death or institutional care
better than NIHSS. Although these comparisons were statistically significant,
estimates for the difference between scales either when full or categorised were
small, suggesting they may not be clinically important. Lastly, the weighted
kappa analyses for the categorised scales showed that there was substantial to
almost perfect agreement amongst all scales.
These analyses used data from two different cohorts, both of which contained
several hundred patients from unselected hospital admissions with a broad range
of case mix. Within each cohort there were few missing data, limiting the possi-
bility of a bias in the collection of data possibly due to the recording of severity
being dependent on patient characteristics. Each cohort had several measure-
ments of severity allowing four different stroke scales to be tested for equivalence
between the full and categorised versions. The scales used in this analysis are
recorded in the vast majority of stroke trials. Additionally, the follow-up times
for the Barber et al. (2004) and Sellars et al. (2007) cohorts were different (one
month and three months, respectively) showing that the results obtained do not
simply apply to one stroke scale or to a specific length of follow-up.
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One obvious limitation to these analyses is that data were not available to
directly compare SSS with NIHSS, or with any of the other stroke scales currently
used in practice. Also, data were not available to allow a direct comparison of
predictive ability at different follow-up lengths via longitudinal measurements of
outcome within a cohort.
Future research should focus on comparing the stroke scales used here with
other scales used in practice such as the Glasgow Coma Scale (Jennett and Teas-
dale, 1977), the Canadian Neurological Scale (Coˆte´ et al., 1989) or the Edinburgh
Stroke Predictor (Weir et al., 2003). Follow-up lengths in meta-analyses are often
longer than those for which data were available, for example, six or twelve months.
Therefore, since predictive accuracy is lower for longer follow-up times, it may
be of interest to perform comparisons of AUC for stroke scales at later follow-up
times to assess if the equivalence of full and categorised scales is maintained.
This study shows that the categorisation of stroke scales into mild, moderate
and severe does not substantially reduce the predictive ability of the scale. Stroke
scales stratified in this way appear to be equivalent to each other and although
the prognostic accuracy for longer follow-up is reduced, it is not further reduced
by categorisation of the stroke scales. These findings emphasise that stratification
of randomisation in acute stroke clinical trials according to severity classified as
mild, moderate or severe is a pragmatic approach which retains much of the
prognostic information contained in the corresponding full assessment scale.
Chapter 4
Organised inpatient (stroke unit)
care for stroke
In this Chapter frequentist meta-analysis approaches are used in order to address
the question of whether organised inpatient (stroke unit) care improves the sur-
vival and independence of stroke patients and their ability to return home. Sev-
eral comparisons of “more” organised with “less” organised care are conducted
allowing more specific service comparisons to be viewed. This analysis includes
outcome data from recent trials and there is interest in whether the conclusions
reached differ from the previous version of this review.
4.1 Background
During the acute phase of stroke, patients are frequently admitted to hospital
where they can receive care in a variety of different ways or settings. Previously,
the care of patients with stroke was provided within general medical or neurology
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wards alongside a range of other patient groups where they would be managed by
non-specialist staff without routine multidisciplinary input. Organised inpatient
(stroke unit) care is a term used to describe the focusing of care for patients
with stroke in hospital under a multidisciplinary team who specialise in stroke
management (Stroke Unit Trialists’ Collaboration, 2007).
There is uncertainty whether the perceived effort and cost in focusing the
care of stroke patients in hospital within specially organised units would improve
the survival and recovery of patients receiving that care (Stroke Unit Trialists’
Collaboration, 2007). In this study, the questions addressed are whether improv-
ing the organisation of inpatient stroke services can bring about improvements in
important patient outcomes and whether the conclusions reached following the
inclusion of outcome data from recent trials are altered from the previous version
of this review (Stroke Unit Trialists’ Collaboration, 2006).
4.2 Methods
4.2.1 Trial identification
The Stroke Unit Trialists’ Collaboration searched the Cochrane Stroke Group
Trials Register (last searched April 2006) to identify appropriate trials for inclu-
sion (full details of search strategy given in Sandercock et al. (2008)). In order
to identify additional trials, reference lists of relevant articles were studied, col-
leagues and researchers were contacted and preliminary findings were publicised
at stroke conferences in the UK, Scandinavia, Germany, Netherlands, Switzer-
land, Spain, Canada, South America, Australia, Belgium, USA and Hong Kong.
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The search was not restricted by date, language or any other criteria.
The study included all prospective clinical trials that used some form of ran-
dom allocation of stroke patients to an organised system of inpatient (stroke unit)
care or an alternative form of inpatient care. The definition of stroke unit care
used was very broad (defined as a multidisciplinary team specialising in stroke
care) and included services based in a discrete ward or provided by a mobile
stroke team. Contemporary conventional care was defined as being provided in a
general medical ward or less organised form of stroke care. Section 1.2.1 provides
a detailed description of the types of intervention considered in this study. A
clinical definition of stroke (focal neurological deficit due to cerebrovascular dis-
ease, excluding subarachnoid haemorrhage and subdural haematoma) was used
and any patients admitted to hospital following stroke were eligible.
Published trials were scrutinised by two review authors who assessed their
eligibility and methodological quality. Characteristics of unpublished trials were
established through discussion with the trial co-ordinator. Trials were included
if treatment allocation was carried out in a strictly random basis or with a quasi-
random procedure, such as bed availability or date of admission. A formal scoring
system for methodological quality was not used but method of allocation conceal-
ment, completeness of follow-up, presence of intention to treat analysis and the
presence of blinded assessment to follow-up were recorded.
4.2.2 Data extraction
Descriptive information about the service characteristics of the organised inpa-
tient (stroke unit) care and conventional care settings were obtained through a
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structured interview or correspondence with the trial co-ordinators. Trials were
then allocated to six service subgroups (acute semi-intensive stroke unit; compre-
hensive stroke unit; rehabilitation stroke unit; mixed rehabilitation ward; mobile
stroke team; and general medical ward) as defined in Section 1.2.1.
The primary outcomes were death, and the combined outcomes of death or
dependency and death or the requirement for institutional care at the end of
scheduled follow-up of the original trial. Dependency was defined as requiring
physical assistance for one or more of the following criteria: transfers, mobility,
dressing, feeding or toileting. These criteria were approximately equivalent to
modified Rankin Scale > 2, Barthel Index < 19, or an Activity Index (AI) > 83
as described by Hamrin (1982). The requirement for institutional care was taken
to be care in a residential home, nursing home or hospital at the end of scheduled
follow-up. Trial co-ordinators were asked to provide the number of patients who
were dead, dependent, requiring institutional care and missing at the end of
scheduled follow-up. Outcome data from published sources were confirmed and
supplemented with unpublished information provided by the trial co-ordinators.
A secondary outcome was duration of stay in hospital, institution or both. Patient
quality of life and patient and carer satisfaction were also assessed as secondary
outcomes but are not analysed in this review update.
The following subgroup information was sought primarily for the outcome of
death or requiring institutional care:
1. age: up to 75 years or greater than 75 years;
2. sex: male or female;
3. stroke severity: mild, moderate or severe, as defined by the Barthel Index
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in Table 3.1.
Unpublished aggregate data were obtained for the majority of trials but insuffi-
cient amounts of individual patient data were available to allow a comprehensive
IPD analysis.
4.2.3 Description of studies
A total of 48 trials were identified. Of these, 13 were excluded, two are awaiting
assessment and two are ongoing. The remaining 31 trials contained outcome
information on a total of 6936 participants (Ronning and Guldvog, 1998; Vemmos
et al., 2001; Ma et al., 2004; Peacock et al., 1972; Patel, 2000; Stevens et al., 1984;
Garraway et al., 1980; Svensson et al., 1993; Fagerberg et al., 2000; Sulter et al.,
2003; Kaste et al., 1995; Gordon and Kohn, 1966; Cabral et al., 2003; Sivenius
et al., 1985; Dey et al., 2005; Wood-Dauphinee et al., 1984; Feldman et al., 1962;
Aitken et al., 1993; Juby et al., 1996; Kalra et al., 1993; Kalra and Eade, 1995;
Kalra et al., 2000; Yagura et al., 2005; Cavallini et al., 2003; Hankey et al., 1997;
von Arbin et al., 1980; Laursen et al., 1995; Ilmavirta, 1994; Indredavik et al.,
1991; Strand et al., 1985; Hamrin, 1982).
The principal review author conducted a structured interview with the trial
co-ordinators for 23 trials to determine the service characteristics. For four trials,
access to detailed unpublished information was available, while for the remaining
four there was access to published information only. Service comparisons within
these 31 trials are summarised in Figure 4.1. The most common comparison was
between comprehensive stroke ward (service 2) and general medical ward (service
6) with eleven trials looking at this comparison.
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Figure 4.1: Summary of number of service comparisons within included trials
(denoted by red numbers). Numbers within nodes denote treat-
ments: 1 is acute stroke ward; 2 is comprehensive stroke ward; 3
is rehabilitation stroke ward; 4 is mixed rehabilitation ward; 5 is
mobile stroke team; and 6 is general medical ward. Treatments 1,
2 and 3 are subcategories of stroke unit. Since three of the trials
each had three treatment arms, the total number of comparisons
is greater than the number of trials.
Of the 31 trials where data were available, 16 used a formal randomisation
procedure such as random numbers, sequentially numbered sealed envelopes or
central randomisation. Eight trials used an unclear method of randomisation and
the remaining seven used an informal randomisation based on bed availability
(Yagura et al., 2005; Cavallini et al., 2003; von Arbin et al., 1980; Strand et al.,
1985), strict admission rota (Patel, 2000; Hamrin, 1982) or patient date of birth
(Ronning and Guldvog, 1998). Sensitivity analysis was performed removing these
seven trials from the analysis to exclude possible bias in the conclusions. Only
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ten trials used a blinded assessment of outcome for all patients.
For trials with missing outcome data it was assumed these patients were
alive and living at home, which may have introduced a small bias in favour of
the control group in the scenario where patient outcomes are better for those
admitted to a stroke unit.
A more detailed description of the trials included in this study can be found
in Stroke Unit Trialists’ Collaboration (2007).
4.2.4 Statistical methods
Data were analysed using the Cochrane Collaborations statistical software, Revman
(Cochrane Collaboration, 2003), where primary outcomes (death, death or de-
pendency, death or institutional care) were calculated as the odds ratios with
95% confidence intervals of an adverse outcome in more organised versus con-
temporary conventional care. Unless there was significant heterogeneity, a fixed-
effect approach (Peto method, Section 1.4.1) was used. However, in the case
of heterogeneity, a random-effects approach (DerSimonian and Laird method,
Section 1.4.2) was used instead.
The Q-statistic is used to measure heterogeneity and is calculated as:
Q =
k∑
i=1
wi(θi − θˆ)2,
where θˆ is the estimated pooled treatment effect, θi are the individual trial treat-
ment effect estimates and wi = 1/var(θi). This is compared to a χ
2 distribution
with k−1 degrees of freedom, where k is the number of trials, to obtain a p-value
indicating the extent of between-study variability (Higgins and Thompson, 2002).
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Length of stay in a hospital or institution was analysed using standardised
mean difference (SMD) with random-effects (Cochrane Collaboration, 2005). The
SMD for each trial, i, including adjustment for small sample bias, is given by:
SMDi =
(
m1i −m2i
si
)(
1− 3
4Ni − 9
)
,
where m1i and m2i are the means in each treatment arm and
si =
√
(n1i − 1)τ 21i + (n2i − 1)τ 22i
Ni − 2 ,
are the pooled standard deviation of the two groups. Ni is the total number of
subjects in trial i, n1i and n2i are the total number of subjects in each treatment
arm of trial i, and τ1i and τ2i are the standard deviations in each treatment arm
of trial i. The overall pooled SMD is given by:
SMD =
∑m
i=1wiSMDi∑m
i=1wi
,
where wi = 1/var(SMDi).
4.3 Results
Due to the different service comparisons within this study, the results are pre-
sented in three sections: Section 4.3.1 compares organised inpatient (stroke unit)
care with an alternative service; Section 4.3.2 describes the most common com-
parison of organised inpatient (stroke unit) care against general medical ward;
and finally Section 4.3.3 compares different forms of organised inpatient (stroke
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unit) care.
4.3.1 Organised inpatient (stroke unit) care vs. alterna-
tive service
This section examines the impact of increased levels of organisation of stroke care
on patient outcomes. If both services satisfy the definition of stroke unit then
the less organised system of care was taken as the comparator service. Figure 4.2
summarises the comparison between organised (stroke unit) care with an alter-
native (less organised) form of care. Comparisons are: (a) stroke ward (including
rehabilitation ward, comprehensive ward and acute ward) versus general medi-
cal ward; (b) mixed rehabilitation ward versus general medical ward; (c) mobile
stroke team versus general medical ward; (d) stroke ward versus mixed rehabili-
tation ward; (e) stroke ward versus mobile stroke team; and (f) more organised
stroke ward versus less organised stroke ward.
These analyses were not complicated by significant heterogeneity between
trials (death: p=0.28; death or institutional care: p=0.16; death or dependency:
p=0.06), therefore, the Peto meta-analysis method was used in the analyses.
Conclusions remained unchanged when trials with short or variable follow-up were
excluded, or when trials with informal randomisation procedures were excluded.
Additionally, for the death or dependency outcome, when analysis was restricted
to trials with unequivocal blinded final assessment for all patients, the conclusions
also remained unchanged.
The odds of death were significantly lower in stroke ward compared to general
medical ward (odds ratio 0.83, 95% confidence interval 0.71 to 0.96; p = 0.01)
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Figure 4.2: Comparing organised stroke unit care with alternative (less or-
ganised) service for the outcomes of death, death or institutional
care and death or dependency. Comparisons are: (a) stroke ward
vs general medical ward; (b) mixed rehabilitation ward vs general
medical ward; (c) mobile stroke team vs general medical ward;
(d) stroke ward vs mixed rehabilitation ward; (e) stroke ward vs
mobile stroke team; and (f) more organised stroke ward versus
less organised stroke ward. The total is the overall pooled esti-
mate from the six comparisons. Odds ratios, obtained using the
Peto meta-analysis method, are represented by the shaded dia-
mond with corresponding 95% confidence intervals represented
by the line. Odds ratios are plotted on the natural log-scale.
and mobile stroke team (0.35, 0.19 to 0.65; p < 0.001). The overall estimate
showed a significant reduction in odds of death for more organised care (0.82,
0.73 to 0.92; p = 0.001).
For death or requirement for institutional care there was also a reduction in
the odds of poor outcome in stroke ward compared to general medical ward (0.80,
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0.70 to 0.90; p < 0.001) and mobile stroke team (0.40, 0.23 to 0.68; p < 0.001),
also with a significant reduction in overall odds of poor outcome in the more
organised care group (0.81, 0.74 to 0.90; p < 0.001).
For death or dependency there was a significant reduction in odds of poor
outcome in stroke ward (0.83, 0.72 to 0.96; p = 0.01) and mixed rehabilitation
ward (0.65, 0.47 to 0.90; p = 0.01) compared to general medical ward, and a
significant reduction in more organised stroke ward compared to less organised
stroke ward (0.29, 0.18 to 0.46; p < 0.001). There was a significant reduction in
overall odds of death or dependency in the more organised care group (0.79, 0.71
to 0.88; p < 0.001).
Three trials (Vemmos et al., 2001; Juby et al., 1996; Indredavik et al., 1991)
extended follow up of patients for a further five years post stroke and two trials
for a further ten years (Juby et al., 1996; Indredavik et al., 1991). The summary
of results for these trials are given in Figure 4.3. The odds of death and death
or institutional care continue to be reduced in stroke unit care five (death: 0.74,
0.59 to 0.94; death or institutional care: 0.62, 0.43 to 0.89) and ten years post
stroke (death: 0.53, 0.36 to 0.80; death or institutional care: 0.57, 0.37 to 0.88),
while the reduction in odds of death or dependency is still significant after five
years (0.59, 0.38 to 0.92) but not after ten years (0.77, 0.45 to 1.31).
For the length of stay outcome, a random-effects model on the standardised
mean difference (SMD) showed a modest reduction in length of stay in compre-
hensive stroke ward compared to general medical ward (SMD -0.19, 95% CI -0.31
to -0.06), which is approximately equivalent to 2.5 days (0.5 to 4.5 days). How-
ever, these summary estimates are complicated by significant heterogeneity and
there are major methodological limitations to consider. Trials included in this
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Figure 4.3: Comparing organised stroke unit care with alternative service for
the outcomes of (a) death, (b) death or institutional care and (c)
death or dependency at 5- and 10-year follow-up. Odds ratios
presented as in Figure 4.2.
study recorded length of stay differently (mean or median) and in some cases
standard deviations had to be inferred from p-values or from results of similar
trials. Trials also calculated length of stay in different ways, such as acute stay
or total stay in hospital or institution. These limitations prevent more general
conclusions to be formed from this analysis.
4.3.2 Organised inpatient (stroke unit care) care vs. gen-
eral medical ward
The results described in this section are for the most common comparison of or-
ganised stroke unit care versus general medical ward. Figure 4.4 gives a summary
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Figure 4.4: Comparing organised stroke unit care with general medical wards
for the outcomes of death, death or institutional care and death
or dependency. Comparisons are: (a) comprehensive stroke ward;
(b) rehabilitation stroke ward; (c) mobile stroke team; and (d)
mixed rehabilitation ward. The total is the overall pooled es-
timate from the four comparisons. Odds ratios presented as in
Figure 4.2.
of the comparisons between organised care and general medical wards for the out-
comes of death, death or institutional care and death or dependency. Comparison
(a) is comprehensive stroke ward; (b) rehabilitation stroke ward; (c) mobile stroke
team; and (d) mixed rehabilitation ward.
As in Section 4.3.1, there was no significant heterogeneity between trials
(death: p=0.81; death or institutional care: p=0.29; death or dependency: p=0.55)
enabling the use of the Peto meta-analysis method.
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Table 4.1: Odds ratios and confidence intervals for the comparisons of com-
prehensive stroke wards and mixed rehabilitations wards with gen-
eral medical wards for the outcomes of death or institutional care
and death or dependency.
Outcome Odds ratio (95% CI) P -value
Comprehensive stroke ward
Death or institutional care 0.80 (0.70 to 0.92) 0.002
Death or dependency 0.83 (0.71 to 0.97) 0.02
Mixed rehabilitation ward
Death or institutional care 0.71 (0.51 to 0.99) 0.04
Death or dependency 0.65 (0.47 to 0.90) 0.01
Compared to general medical wards, the odds of death are significantly re-
duced in comprehensive stroke wards (0.85, 0.72 to 0.99; p = 0.03) and non-
significantly reduced in rehabilitation wards (0.69, 0.46 to 1.05; p = 0.08) with
an overall reduction in odds of death (0.86, 0.76 to 0.98; p = 0.02). For the
outcomes of death or institutional care and death or dependency there were sig-
nificant reductions in odds of poor outcome for comprehensive stroke wards and
mixed rehabilitation wards, given in Table 4.1, with identical overall reductions
in odds of poor outcome in stroke wards (0.82, 0.73 to 0.92, p < 0.001).
4.3.3 Comparisons of different forms of organised inpa-
tient (stroke unit) care
This section determines whether the benefits of stroke unit care are only achieved
through specialised stroke wards or if the benefits can also be achieved by mo-
bile stroke team care or a generic disability service. Therefore, the results are
presented for direct comparisons of different forms of organised care. Figure 4.5
summarises the comparisons of (a) acute stroke ward versus comprehensive stroke
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Figure 4.5: Comparing different systems of organised care for the outcomes
of death, death or institutional care and death or dependency.
Comparisons are: (a) acute stroke ward vs comprehensive stroke
ward; (b) acute stroke ward vs mixed rehabilitation ward; (c)
comprehensive stroke ward vs mobile stroke team; and (d) reha-
bilitation stroke ward vs mixed rehabilitation ward. Odds ratios
presented as in Figure 4.2.
ward; (b) acute stroke ward vs mixed rehabilitation ward; (c) comprehensive
stroke ward vs mobile stroke team; and (d) rehabilitation stroke ward vs mixed
rehabilitation ward for the outcomes of death, death or institutional care and
death or dependency.
The Peto meta-analysis method was used to analyse the outcomes of death
and death or institutional care since there was no significant heterogeneity be-
tween trials (Table 4.2). However, there was significant heterogeneity observed
for the outcome of death or dependency when comparing acute stroke ward and
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Table 4.2: P -values for test for heterogeneity in the comparisons of different
forms of stroke unit care.
Outcome P -value
Acute stroke ward∗
Death 0.06
Death or institutional care 0.25
Death or dependency < 0.01
Rehabilitation stroke ward∗
Death 0.95
Death or institutional care 0.92
Death or dependency 0.72
∗Versus alternative service.
alternative service. Therefore, for this comparison, the DerSimonian and Laird
meta-analysis method was used. For the comparison of comprehensive stroke
ward and mobile stroke team, the test for heterogeneity was not applicable as
only one trial analysed this comparison.
For the outcomes of death and death or institutional care there tended to be
reductions in odds of poor outcome in comprehensive stroke wards compared to
mobile stroke teams (death: 0.35, 0.19 to 0.65; death or institutional care: 0.40,
0.23 to 0.68) and stroke rehabilitation wards compared with mixed rehabilitation
wards (death: 0.51, 0.29 to 0.90; death or institutional care: 0.74, 0.52 to 1.07).
However, there were few trials available for these comparisons and the numbers
within trials were small, preventing any formal conclusions from being drawn.
There was a significant reduction in odds of death or dependency in acute
stroke wards compared to comprehensive stroke wards (0.27, 0.16 to 0.45), how-
ever, there were also significant heterogeneity in the results. After applying a
random-effects model, there was no significant difference between services.
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4.4 Discussion
This study addresses the question of whether more organised inpatient care could
improve patient outcomes in comparison to less organised care and allows more
specific service comparisons to be viewed. Section 4.3.1 confirms the conclusions
described in previous versions of this review (Stroke Unit Trialists’ Collaboration,
2006): patients receiving organised (stroke unit) care are more likely to survive,
return home and regain independence than those receiving a less organised ser-
vice, with a suggestion that the benefit may last for five or even ten years post
stroke. Organised inpatient care is typically provided within a discrete ward
which offers a substantial period of rehabilitation if required.
There were substantial amounts of new data available for this updated re-
view. A total of eight new trials (for one of which individual patient data were
available) were included in addition to the 23 trials in the previous version of the
review. Therefore, the main strength of this study is the large number of trials
available for analysis. The large amount of new information collected allowed
the comparison between several different types of stroke unit care and the use
of combined outcomes, such as death or dependency and death or institutional
care, are particularly important when event numbers within trials are small.
While this information allows the comparison between different types of stroke
unit, for some comparisons there are few or no trials available, particularly for
comparison of different forms of stroke unit care. This illustrates the need for an
indirect comparisons approach to estimate the differences between service types.
Dependency is an important measure of patient outcome but can be affected
by observer bias if final assessment was not carried out in a blinded fashion.
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The sensitivity analysis performed in the study, where only trials that used un-
equivocal blinded assessment were included, suggested that the results were not
influenced by this bias. The requirement for institutional care is a good substi-
tute for dependency. However, it may be affected by national health care systems
or cultural factors.
The results obtained from the length of stay analysis in this study may be
affected by the different methods of recording and calculating the length of stay in
each trial, possibly causing the significant heterogeneity. It seems most reasonable
to conclude that there was very little, if any, difference in length of stay between
more and less organised care.
Finally, one last limitation of this study is that although the majority of trials
are recent, some of the trials included are relatively old and standards of care
may have changed in recent years. However, these trials are also randomised and
so should have reasonable internal validity and not have a confounding effect on
the final conclusions.
This study does not explain why stroke unit care improves patient outcomes.
Some suggestions are the prevention of complications or more intense monitoring
of acute patients. Future research should focus on which components of stroke
unit care provide benefit to stroke patients, as examined in Chapters 5 and 6.
Direct comparisons of different models of stroke unit care could also be examined;
however, since this may not be achievable, Chapter 8 examines possible differences
using an indirect comparisons method. Collaboration between stroke trialists
should be pre-planned to ensure similar variables and outcomes are measured
within trials in order to lessen the problems that occur in retrospective systematic
reviews.
Chapter 5
Prevention of complications in
organised inpatient (stroke unit)
care
In Chapter 4 it was shown that patients receiving more organised inpatient (stroke
unit) care are more likely to survive regain independence and return home than
those receiving a less organised service. However, the analysis did not explain
how these benefits were achieved. Using simple Bayesian random-effects models,
this Chapter explores whether the use of interventions to prevent complications
explains the benefit of organised inpatient (stroke unit) care.
5.1 Background
It has been known for many years that organised inpatient (stroke unit) care re-
duces the risk of death after stroke (Stroke Unit Trialists’ Collaboration, 1997a),
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but it is not clear how this benefit is achieved. The Stroke Unit Trialists Collab-
oration carried out an analysis 10 years ago which suggested that Stroke Units
may reduce deaths through preventing complications (Stroke Unit Trialists’ Col-
laboration, 1997b). However, this analysis had limited statistical power and its
conclusions were speculative.
In the most recent update of the stroke unit systematic review (Stroke Unit
Trialists’ Collaboration, 2007), data were available from a larger number of con-
trolled clinical trials. This allowed the question “does the prevention of compli-
cations explain the survival benefit of stroke unit care?” to be revisited. If this is
the case then one would expect the following observations to be associated with
stroke unit care:
a) the more frequent use of interventions designed to prevent complications,
b) a smaller number of recorded serious complications, and
c) fewer deaths attributed to complications.
This Chapter describes a further analysis of the stroke unit review which
addresses these questions.
5.2 Methods
5.2.1 Data
This is a further analysis of a collaborative systematic review carried out by the
Stroke Unit Trialists Collaboration (Stroke Unit Trialists’ Collaboration, 2007)
as described in Section 1.5.4 and Chapter 4. In summary, this database includes
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31 prospective trials using some form of random allocation of stroke patients
to an organised system of inpatient (stroke unit) care or an alternative form of
inpatient care. In addition to the main outcomes (death, dependency and need
for institutional care) and subgroup data (age and severity) already available,
information was sought on the following outcomes:
1. specific interventions directed at reducing complications,
2. complications recorded during early hospital care (first 4 weeks), and
3. certified cause of death during follow-up.
The exact criteria used were those defined in the individual trials.
The specific interventions directed at reducing complications included antibi-
otic therapy, measures to prevent aspiration (systematic assessment of swallowing
and modification of dietary intake), intravenous fluids, insulin, oxygen, paraceta-
mol, tube feeding and urinary catheterisation.
Complications were classified into four categories to reflect previous epidemi-
ological work linking complications to cause of death (Bamford et al., 1990):
a) neurological (cerebral oedema, stroke recurrence, stroke progression, seizures,
anxiety, depression),
b) cardiovascular complications (myocardial infarction, arrhythmia, congestive
cardiac failure),
c) complications of immobility (chest infection, urinary tract infection, other
infections, dehydration, venous thromboembolism, falls, pressure sores, pain),
and
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d) other complications (for example cancer, gastro-intestinal haemorrhage, sui-
cide).
In addition, common ‘physiological complications’, defined as physiological
abnormalities which did not fulfil a conventional medical diagnosis, were recorded.
These included hypertension, hyperglycaemia, hypoxia, hypotension and pyrexia.
The specific definitions of these complications were as reported within the original
trials.
Cause of death was recorded at the end of scheduled follow up for the majority
of trials with this information. However, there were three trials which recorded
at discharge (Gordon and Kohn, 1966; Yagura et al., 2005; Cavallini et al., 2003),
three trials which recorded at an earlier fixed time point (Vemmos et al., 2001;
Kalra et al., 2000; Hamrin, 1982) and one trial with incomplete data (Aitken et
al., 1993). The median time for recorded cause of death was six months with an
inter-quartile range of three to twelve months.
5.2.2 Statistical methods
Data were analysed using hierarchical Bayesian models in WinBUGS. A direct
random-effects model was used to calculate odds ratios and 95% credible inter-
vals (CrI). The model used is described in Section 1.4.3 with an Inverse-Gamma
distribution for the treatment effect variance. The WinBUGS code for this model
is given in Appendix A.
Absolute risk differences for cause of death were also calculated using hierar-
chical models in WinBUGS. This model is described by Warn et al. (2002). As
with the log-odds ratio model described in Section 1.4.3, suppose, for trial i, nCi
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and nTi are the number of patients in the control and treatment groups, respec-
tively, and rCi and rTi are the number of events in the control and treatment
groups, respectively, where
rCi ∼ Binomial(pCi, nCi),
rTi ∼ Binomial(pTi, nTi).
In Equations 1.2 and 1.3, the logits of the control and treatment group risks
(pCi and pTi) are replaced by the risks themselves, giving
pCi = µi,
pTi = µi + δi,
where δi is now the absolute risk difference. However, since pCi and pTi are
probabilities, they must be constrained to lie between 0 and 1. Therefore µi ∼
Uniform(0, 1) and δi is constrained to the interval [−pCi, 1−pCi] so that the model
is now
pCi = µi,
pTi = µi +min(max(δi,−pCi), 1− pCi).
As with the log-odds ratio model, δi ∼ Normal(d, τ 2) where d ∼ Normal(0, 106)
and 1/τ 2 ∼ Gamma(0.001, 0.001).
The WinBUGS code for this model is given in Appendix B.
Model fit was checked using residual deviance (Spiegelhalter et al., 1998)
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calculated as
D¯res =
∑
i,j
2
(
rij log
(
rij
rˆij
)
+ (nij − rij) log
(
nij − rij
nij − rˆij
))
,
where nij is the total number of subjects in trial i treatment j, rij is the observed
number of events and rˆij is the expected number of events from the model, cal-
culated as rˆij = pˆijnij.
Deviance measures the fit of the model to the datapoints using the likelihood
function. To calculate residual deviance, the deviance of the saturated model is
subtracted from the fitted model and, under the null hypothesis of an adequate
fit, one would expect the residual deviance to have a mean equal to the number
of datapoints (Spiegelhalter et al., 2002).
5.3 Results
A subset of trials within the updated systematic review (Stroke Unit Trialists’
Collaboration, 2007) were able to provide much more detailed data for these
additional analyses of complications as outlined below. Further details of the
included trials are summarised in Chapter 4. For all outcomes the fit of the model
was adequate, as given by residual deviance. Sensitivity analysis was carried out
since Bayesian analyses can be sensitive to the choice of priors and initial values.
The conclusions were unaffected by choice of prior distribution and initial values.
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5.3.1 Interventions to prevent complications
Up to seven trials (1652 patients) recorded the number of patients receiving one or
more intervention to prevent complications (Ronning and Guldvog, 1998; Patel,
2000; Sulter et al., 2003; Wood-Dauphinee et al., 1984; Kalra et al., 1993, 2000;
Indredavik et al., 1991). The results of this analysis are shown in Table 5.1. The
use of the following interventions was associated with stroke unit care: measures
to prevent aspiration (odds ratio 2.42, 95% credible interval 1.36 to 4.36); oxygen
therapy (2.39, 1.36 to 4.66); paracetamol (2.80, 1.14 to 4.83); and possibly re-
duced use of urinary catheterisation (0.58, 0.27 to 1.11). The credible interval for
tube feeding in incredibly wide indicating that there is large uncertainty for the
effect of tube feeding. This could be due to heterogeneity or the credible interval
being driven by the use of diffuse priors due to lack of data.
Table 5.1: Frequency and comparison of intervention use in stroke units ver-
sus conventional care.
Intervention
Number of events Odds ratio
Stroke unit (%) Control (%) (95% CrI)
Antibiotics 109 (36.6) 75 (24.5) 1.76 (0.25, 18.77)
Aspiration prevention 44 (28.9) 22 (14.5) 2.42 (1.36, 4.36)
Intravenous fluids 473 (76.5) 319 (48.4) 2.59 (1.20, 33.02)
Insulin 46 (8.6) 34 (6.3) 1.42 (0.72, 3.03)
Oxygen 185 (52.3) 120 (33.9) 2.39 (1.36, 4.66)
Paracetamol 212 (37.9) 106 (18.7) 2.80 (1.14, 4.83)
Tube feeding 58 (26.7) 27 (12.4) 2.36 (0.02, 100>)
Urinary catheter 72 (21.1) 99 (29.3) 0.58 (0.27, 1.11)
Results are presented as median (posterior) odds ratios with 95% credible intervals of
intervention use in stroke units versus conventional care.
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5.3.2 Complications during acute hospital stay
Up to eight trials (1824 patients) recorded the number of patients having one or
more complication (Ma et al., 2004; Sulter et al., 2003; Wood-Dauphinee et al.,
1984; Kalra et al., 1993, 2000; Cavallini et al., 2003; Ilmavirta, 1994; Indredavik et
al., 1991). The main findings are summarised in Table 5.2. Statistically significant
reductions in stroke progression or recurrence, chest infection, other infections,
falls and pressure sores were seen in stroke units. There were no significant
differences in odds of physiological complications.
5.3.3 Certified cause of death
Seventeen trials (3327 participants) had information on certified cause of death
available (Vemmos et al., 2001; Stevens et al., 1984; Garraway et al., 1980; Sul-
ter et al., 2003; Gordon and Kohn, 1966; Sivenius et al., 1985; Dey et al., 2005;
Wood-Dauphinee et al., 1984; Feldman et al., 1962; Aitken et al., 1993; Kalra
et al., 2000; Yagura et al., 2005; Cavallini et al., 2003; Hankey et al., 1997; Il-
mavirta, 1994; Indredavik et al., 1991; Hamrin, 1982). Within this group of trials
organised (stroke unit) care resulted in reduced all-cause case fatality (0.75, 0.59
to 0.92). The results for certified cause of death are summarised in Table 5.3 and
indicate that significant reductions in deaths were observed for complications of
immobility (0.59, 0.41 to 0.86), but not for any other categories. When these are
analysed as absolute risk difference notice that there is a reduction in deaths at-
tributed to complications of immobility of approximately 3 deaths per 100 stroke
patients.
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Table 5.2: Frequency and comparison of occurrence of complications in stroke
units versus conventional care.
Complication
Number of events Odds ratio
Stroke unit (%) Control (%) (95% CrI)
Neurological
Anxiety or depression 112 (16.7) 132 (19.7) 0.74 (0.27, 1.97)
Seizures 15 ( 2.7) 17 ( 3.1) 0.86 (0.37, 1.95)
Stroke progression/recurrence∗ 85 (9.4) 121 (13.5) 0.66 (0.46, 0.95)
Cardiovascular
Cardiovascular† 83 (14.2) 66 (11.0) 1.52 (0.58, 4.54)
Complications of immobility
Chest infection 87 (12.0) 134 (18.6) 0.60 (0.42, 0.87)
Dehydration 21 ( 5.1) 43 (10.1) 0.81 (0.31, 2.53)
Venous thromboembolism‡ 30 ( 4.4) 35 ( 5.0) 0.85 (0.49, 1.49)
Falls 28 (18.4) 43 (28.3) 0.57 (0.33, 0.97)
Other infections§ 122 (13.5) 201 (21.9) 0.56 (0.40, 0.84)
Pain 70 (12.1) 71 (12.3) 0.73 (0.14, 2.60)
Pressure sores 21 ( 4.7) 43 ( 9.6) 0.44 (0.22, 0.85)
Other complications
Other 22 ( 2.9) 24 ( 3.1) 0.95 (0.46, 2.10)
Physiological complications
High blood pressure 21 (13.0) 9 ( 5.6) 1.95 (<0.01, 100>)
Hyperglycaemia 55 (14.3) 71 (17.8) 0.78 (0.43, 1.49)
Hypoxia 33 (10.5) 28 ( 8.9) 2.33 (0.04, 100>)
Low blood pressure 60 (22.1) 68 (25.1) 1.85 (0.04, 100>)
Pyrexia 102 (19.6) 112 (20.9) 0.88 (0.39, 1.86)
Results are presented as median odds ratios with 95% credible intervals of occurrence of complications
in stroke units versus conventional care.
∗Stroke progression and early recurrence were often not distinguished in the original trials.
†Individual cardiovascular complications (for example ischemic heart disease, arrythmia) were usually
grouped together.
‡Includes deep vein thrombosis and pulmonary embolism
§Predominately urinary tract infection
5.4 Discussion
It has been recognised over the last decade that patients who are managed in
an organised inpatient (stroke unit) setting are more likely to survive, return
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Table 5.3: Comparison of certified cause of death in stroke unit versus con-
ventional care.
Cause of death
Stroke unit Control Absolute risk Odds ratio
(%) (%) difference (95% CrI) (95% CrI)
Neurological 8.1 7.8 0.20 (-2.66, 2.90) 1.07 (0.81, 1.44)
Cardiovascular 3.6 4.9 -1.20 (-4.27, 1.24) 0.71 (0.45, 1.10)
Immobility-related 4.4 7.0 -2.84 (-5.81, -0.10) 0.59 (0.41, 0.86)
Other 2.4 3.2 -1.42 (-4.16, 0.90) 0.74 (0.47, 1.17)
Overall 18.5 23.0 -4.77 (-8.81, -0.83) 0.75 (0.59, 0.92)
Percentages (%) are the percentage of total patients in each group that died from a particular cause
of death. Absolute risk difference is given as the number of deaths per 100 patients with stroke with
corresponding 95% credible interval. Odds ratios are median with 95% credible intervals
home, and regain independence, than those managed in conventional care set-
tings (Stroke Unit Trialists’ Collaboration, 1997a). However, there has been
considerable uncertainty as to why this benefit may occur and how stroke unit
care could influence outcomes. In a previous analysis from Stroke Unit Trialists’
Collaboration (1997b), it was suggested that some of the survival benefit of stroke
unit care may be explained by a reduction in complications. However, there was
limited statistical power to carry out this analysis. In the current update, con-
siderably larger amounts of data were available, which indicated that stroke unit
care appeared to reduce complications of immobility (in particular, infections),
although there were also reductions in stroke recurrence or progression. The
current analysis suggests that some of these reductions could be explained by
a more comprehensive implementation of measures to prevent complications: in
particular, measures to prevent aspiration, oxygen treatment, and treatment for
pyrexia.
Although this analysis has a number of strengths, in particular using a much
larger dataset than previously available, a number of limitations must also be
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acknowledged. Firstly, although a pooled analysis of a number of trials was
carried out there is still limited information around some complications (par-
ticularly physiological complications) and credible intervals are correspondingly
broad. Secondly, the recording of some complications in the included trials were
often not done in a blinded fashion and varying definitions of complications may
have been used. For example, it was often difficult to distinguish between the
complications of very early stroke recurrence and progression of the original stroke
symptoms. Therefore, the current analysis may have been subject to observer
bias. Similarly, the information on certified cause of death is frequently not
confirmed by post-mortem examination and so could also be subject to bias.
Thirdly, the analysis of complications may be difficult to interpret. In theory,
careful monitoring could identify and treat more problems than those identified
in a less careful model of care. Fourthly, early mobilisation and training was re-
ported as an objective of care in most of the included trials. However, no standard
definition of measuring mobilisation was used, meaning this potentially impor-
tant aspect of care could not be analysed. Likewise, other components of stroke
unit care (for example, prompt use of antithrombotic drugs, improved monitor-
ing) could not individually be analysed. Finally, the analysis demonstrates an
association between stroke unit care and reduction in certain complications, but
does not explain how this effect was achieved. Individual patient data analysis
would enable a more direct analysis of association between the increase in use of
interventions and the decrease of recorded complications. That is, determining
whether those patients who received interventions are also the ones who avoided
complications.
Although this analysis suggests that stroke unit care may have helped prevent
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complications, the picture is likely to be complex and there are other possibilities.
It is plausible that early stroke unit care could have resulted in patients having
less disabling symptoms and hence were less prone to suffer complications. It is
also plausible that if patients in stroke units are less likely to die through other
(identified) mechanisms, they would also be less likely to suffer complications as-
sociated with the last stages of life. The analysis cannot conclusively discriminate
between these competing possibilities.
Despite these remaining uncertainties, the findings emphasise the potential
importance of complications as a treatable factor in stroke outcome. Future
research should explore the best ways of preventing and managing specific com-
plications, particularly those that seem to carry a high risk of causing harm.
Chapter 6
Routine automated physiological
monitoring in acute stroke
Similarly to Chapter 5, this Chapter examines how the benefits of organised inpa-
tient (stroke unit) care are achieved. By expanding the aggregated data obtained
from trials to form individual patient data, covariate effects are introduced to the
Bayesian random-effects models used in Chapter 5 to examine whether routine
automated monitoring for, and treatment of physiological complications reduce
adverse outcomes in stroke patients.
6.1 Background
Although organised inpatient (stroke unit) care is well established in acute stroke
management there remain considerable uncertainties about the value of individual
components of stroke unit care (Langhorne and Dennis, 2004). One topical and
controversial area concerns the lengths to which clinical staff should go to identify
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and treat common physiological abnormalities (such as pyrexia, hypoxia, blood
pressure abnormalities, fast or slow heart rate and hyperglycaemia). Although
a small number of clinical trials have addressed this question, the findings have
been inconclusive.
A collaborative systematic review and meta-analysis was conducted compar-
ing a conventional stroke unit approach with conventional stroke unit care plus
continuous monitoring in the acute phase, and addresses whether routine auto-
mated monitoring for and treatment of physiological abnormalities (compared
with conventional intermittent monitoring) will:
1. result in more physiological abnormalities being detected and treated,
2. reduce the risk of stroke progression,
3. reduce the risk of long term dependency or death, and
4. be most effective in “high risk” patients (those who are older with co-
morbidity and more severe stroke).
6.2 Methods
6.2.1 Data
A search was conducted for trials which compared routine automated monitoring
in a stroke unit versus conventional stroke unit care as source data for meta-
analysis and meta-regression. In addition to data from the Stroke Unit Trial-
ists Collaboration systematic review (Stroke Unit Trialists’ Collaboration, 2007)
(where the Cochrane Stroke Group Trials Register was last searched for trials in
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April 2006, full details of search strategy given in Sandercock et al. (2008)), ref-
erence lists of related articles were scanned, and colleagues and researchers were
contacted in an effort to identify published, unpublished and ongoing trials. In
addition to existing grouped data, individual patient data was requested. How-
ever, if these could not be obtained, the most detailed published and unpublished
data available were used.
The search identified four completed clinical trials with a total of 785 patients
(Davis et al., 2000; Sulter et al., 2003; Cavallini et al., 2003; Ilmavirta, 1994),
as summarised in Table 6.1, which compared routine automated monitoring in a
stroke unit versus conventional stroke unit care. Three of the trials (517 patients)
were randomised (Davis et al., 2000; Sulter et al., 2003; Ilmavirta, 1994). Indi-
vidual patient data were obtained from two trials (Davis et al., 2000; Sulter et
al., 2003) and two provided published and unpublished grouped data (Cavallini
et al., 2003; Ilmavirta, 1994).
Physiological complications recorded by trials included increased or decreased
glucose, blood and heart rate abnormalities, pyrexia and hypoxia. The main
outcomes of interest were stroke progression (SP), death, death or dependency,
death or need for institutional care, and length of stay. Subgroups were defined
Table 6.1: Summary of trials included in analysis.
Trial Type∗ N Status Data†
Davis et al. (2000) RCT 258 Unpublished IPD
Sulter et al. (2003) RCT 54 Published 2003 IPD
Cavallini et al. (2003) CCT 268 Published 2003 AD
Ilmavirta (1994) RCT 213 Published 1993 AD
∗Type: RCT = randomised control trial; CCT = controlled clinical trial
†Data: IPD = individual patient data; AD = aggregate (grouped) data
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by severity, age, risk group and comorbidities (atrial fibrillation, diabetes, and
heart failure).
For two studies (Davis et al., 2000; Sulter et al., 2003), SP was defined as
any deterioration in power of arm, leg, speech, consciousness level, or death
between admission and day three. Deterioration was defined as a rise in National
Institutes of Health Stroke Scale (NIHSS) by at least 1 point, or at least a 2 point
fall in Scandinavian Stroke Scale (SSS). One study (Cavallini et al., 2003) used a
local definition while in another (Ilmavirta, 1994), data were limited and SP was
defined as becoming unconscious between admission and the worst point of the
first week of hospital stay.
Death, dependency and institutional care were recorded at three months after
stroke for three of the trials (Davis et al., 2000; Sulter et al., 2003; Ilmavirta, 1994)
while outcomes were recorded at discharge in another trial (Cavallini et al., 2003).
The criteria for independence were equivalent to a modified Rankin score of 0 -
2, or a Barthel Index of 19 - 20. Those with these scores missing who were in
institutional care were assumed to be dependent.
In the four trials, age was classified as those under 70 versus those aged 70 or
more. Table 6.2 shows how severity was defined in each of the trials. Chapter 3
Table 6.2: Definition of severity in each included trial.
Severity Mild Moderate Severe
Sulter et al. (2003) (NIHSS) 0 - 5 6 - 13 >13
Davis et al. (2000) (SSS) >42 25 - 42 <25
Cavallini et al. (2003) (Barthel) 10 - 20 3 - 9 0 - 2
Ilmavirta (1994) (patient
Mobile
Not mobile/ Reduced
functionality) conscious consciousness
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Table 6.3: Definition of risk groups using age and OCSP classification.
LACS/POCS TACS/PACS
Age < 70 low medium
Age ≥ 70 medium high
shows the equivalence of several methods of categorising severity, therefore, it is
assumed the severity categorisations used in this analysis were also equivalent.
In the current analysis, severity was dichotomised by combining the moderate
group with the severe group and comparing this to the mild group.
Risk group is based on a combination of the Oxfordshire Community Stroke
Project (OCSP) classification and age (Table 6.3). Older patients also tend to
have more severe strokes and Bamford et al. (1991) show that patients with
an OCSP classification of partial anterior circulation syndrome (PACS) or total
anterior circulation syndrome (TACS) generally have more severe strokes than
those with lacunar syndrome (LACS) or posterior circulation syndrome (POCS).
Risk group was therefore calculated for two of the trials (Davis et al., 2000; Sulter
et al., 2003) and in the current analysis risk group was dichotomised by combining
the medium and high risk groups and comparing this to the low risk group.
6.2.2 Statistical methods
Complications and main outcomes data were analysed using hierarchical Bayesian
models in WinBUGS. For the complications data, absolute risk difference was
analysed using the same model as described in Section 5.2.2, whereas the main
outcomes were analysed as both odds ratios (using the model described in Sec-
tion 1.4.3) and absolute risk differences, each with 95% credible intervals (CrI).
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Both models used an Inverse-Gamma distribution for the treatment effect vari-
ance. In addition, length of hospital stay was compared between conventional
acute stroke unit care and routine monitoring using the weighted mean difference
calculated by the Cochrane Collaboration statistical software, Revman (Cochrane
Collaboration, 2003).
In order to analyse subgroups, the aggregated data can be expanded to form
individual patient data. For example, if the number of subjects who died within
each severity subgroup of each treatment is known then this information could
be used to extrapolate to the individual patient data. The data are stacked with
an extra variable denoting the treatment of each patient allowing the data to
be modelled more easily. Therefore, a slightly different modelling approach, as
described by Sutton et al. (2008), is adopted.
Let Yij denote the outcome of subject j in trial i, which is modelled directly
as
Yij ∼ Bernoulli(pij),
where pij is the probability of an event, which is then modelled as
logit(pij) = µi + δitij + β
0
jxij + βxijtij. (6.1)
As with previous models, let the prior for the baseline event rates be µi ∼
Normal(0, 106), and let δi ∼ Normal(d, τ 2) be the random treatment effects in
trial i where d ∼ Normal(0, 106) is the prior for the mean treatment effects and
the prior for the between-trial treatment variance is
1
τ 2
∼ Gamma(0.001, 0.001).
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The additional terms in equation (6.1) represent the inclusion of the subgroup
effects. The first term, β0jxij, denotes the main (random) effect of the covariate
xij with coefficient β
0
j ∼ Normal(b, τ 2b ), where b ∼ Normal(0, 106) gives the prior
for the mean covariate effect on the outcome, and the variance is distributed as
an Inverse-Gamma
1
τ 2b
∼ Gamma(0.001, 0.001).
Finally, the second additional term, βxijtij, denotes the interaction between
the covariate xij and treatment tij. The coefficient of this (fixed-effect) term,
with prior β ∼ Normal(0, 106), determines how the covariate changes the effect
of treatment.
The WinBUGS code for this model is given Appendix C.
6.3 Results
All trials recorded physiological complications of interest and were able to provide
information on the main outcomes. Three studies (Davis et al., 2000; Sulter et
al., 2003; Ilmavirta, 1994) provided data on age of patient for the outcomes of
death and death or institutional care and two of these (Davis et al., 2000; Sulter
et al., 2003) provided additional data on age of patient for outcomes of death or
dependency and SP. All four trials provided data on severity for the outcomes of
death, death or dependency and death or institutional care and two (Davis et al.,
2000; Sulter et al., 2003) also provided data on SP. Risk group data were obtained
from two studies (Davis et al., 2000; Sulter et al., 2003) which also provided data
on atrial fibrillation, diabetes and heart failure for all main outcomes.
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6.3.1 Identified complications
Data were available on recorded physiological complications in the monitoring
and conventional care groups, given as number and percentage of complications
recorded in each group. Table 6.4 shows there were no significant differences
in absolute risk of physiological complications recorded between monitoring and
conventional care groups.
Table 6.4: Frequency and comparison of recorded physiological complications
in monitoring units versus conventional care.
Complication
Number of events Absolute risk
Monitoring (%) Control (%) difference (95% CrI)
Pyrexia 89 (22.7) 87 (21.8) 0.02 (-0.17, 0.21)
Hypoxia 19 (4.9) 13 (3.3) 0.02 (-0.52, 0.56)
Glucose∗ 36 (9.2) 48 (12.0) -0.02 (-0.11, 0.09)
Blood pressure∗ 81 (20.7) 51 (12.8) 0.12 (-0.20, 0.49)
Heart rate∗ 84 (21.5) 70 (17.5) 0.05 (-0.11, 0.23)
Results are presented as median posterior absolute risk difference with 95% credible
interval of complications in monitoring units versus conventional care.
∗Either increased or decreased.
6.3.2 Main outcomes
The results for main outcomes are summarised in Figure 6.1. There were no
significant differences in odds of death (odds ratio 0.85; 95% credible interval 0.27
to 1.67), death or dependency (0.61; 0.17 to 1.98), or death or institutional care
(0.92; 0.61 to 1.33) between conventional stroke units and the monitoring units.
There was a non-significant tendency towards a reduction in SP in the monitoring
groups (0.70; 0.43 to 1.16) compared with conventional care. However, there
were no significant absolute differences between the two treatment groups for
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Figure 6.1: Comparison of main outcomes in acute monitoring units versus
conventional care. Results are presented in odds ratio (I.) and
absolute risk difference (II.). Main outcomes are: (a) death;
(b) death or dependency; (c) death or institutional care; (d)
stroke progression. Results are presented as median ORs or
ARDs (shaded diamond) in stroke units versus conventional care,
with corresponding 95% credible intervals represented by the line.
Odds ratios are plotted on the natural log-scale.
these outcomes. There was a small reduction in length of stay in the monitoring
group (weighted mean difference: 4.5 days; CI: 0.08 to 8.93), however, there was
heterogeneity between trials (p = 0.02).
6.3.3 Subgroups: age, stroke severity and risk group
There were no significant differences in the odds of outcome between monitoring
and conventional care groups for each subgroup of patients. However, Figure 6.2
shows there was a significantly greater reduction in odds of SP in the monitoring
group for those who had mild strokes compared to those who had moderate
or severe strokes (mild: 0.12, 0.01 to 1.46; moderate or severe: 0.90, 0.10 to
8.65; ratio: 7.29, 1.46 to 62.05). There was also a tendency towards a greater
reduction in odds of death or dependency in the monitoring group for those
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Figure 6.2: Comparison of main outcomes in monitoring units versus con-
ventional care for each covariate subgroup (I.) and interaction
between severity and treatment group (II.) where comparisons
are: age < 70 vs ≥ 70; severity moderate or severe vs mild; risk
group medium or high vs. low. Main outcomes are: (a) death;
(b) death or dependency; (c) death or institutional care; and (d)
stroke progression. Odds ratios presented as in Figure 6.1.
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classed as low risk compared to those classed as medium or high risk (low: 0.25,
0.002 to 8.64; medium or high: 0.99, 0.01 to 29.46; ratio: 3.82, 0.72 to 24.7). The
credible intervals are extremely wide due to lack of data, resulting in considerable
imprecision in the results.
6.3.4 Subgroups: comorbidities
Figure 6.3 shows there were no significant differences between monitoring and
conventional care groups in each comorbidity subgroup. However, there was a
significantly greater reduction in the odds of death in the monitoring group for
those who did not suffer heart failure compared to those who did suffer heart
failure (ratio - heart failure/no heart failure: 9.38, 1.68 to 66.69).
6.4 Discussion
This review analysed the added impact of routine automated monitoring on a
background of organised stroke unit care. There were no significant increases
in the number of recorded physiological complications in the monitoring unit.
However, routine monitoring may reduce the risk of stroke progression and there
was also a slight reduction in length of hospital stay in the monitoring group.
From these analyses, it was also found that: the reduction in risk of stroke
progression in the monitoring group was greater in mild stroke patients than
in moderate or severe patients; the reduction in death or dependency in the
monitoring group was greatest in those patients classed as low risk; and the
reduction in death was greatest in those who did not suffer heart failure. However,
caution is needed when interpreting these conclusions since there was little data
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Figure 6.3: Comparison of main outcomes in monitoring units versus conven-
tional care for each covariate subgroup (I.) and interaction be-
tween severity and treatment group (II.) where comparisons were
comorbidity vs. no comorbidity. Main outcomes are: (a) death;
(b) death or dependency; (c) death or institutional care; and (d)
stroke progression. Odds ratios presented as in Figure 6.1.
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resulting in wide credible intervals.
All trials included in this study were randomised controlled trials or controlled
clinical trials. Individual patient data was obtained for two of the trials and
detailed grouped data, published and unpublished, were available for the others
allowing the estimation of possible subgroup effects.
Given that there are a small number of trials used in this analysis and a
small number of events within each trial, especially when analysing subgroups,
the type of model chosen to analyse this data has several benefits. Outcomes
were modelled directly as the Bernoulli distribution, which is advantageous here
since pooling individual trial effects sizes as odds ratios can often require the
assumption of normality that may not always be valid. Additionally, the direct
model allows zero events to be modelled without the need for continuity correc-
tion. Lastly, a random-effects model allows the trial specific effects to be different
from each other but assumes that they are from a common distribution, in this
case the Normal distribution. In other words, it assumes that all trials are similar
but not identical. In contrast, a fixed-effects model would assume that all trials
are estimating exactly the same treatment effect.
However, given these strengths a number of weaknesses must also be acknowl-
edged. Firstly, there are only four trials in total in these analyses, and for some
analyses, data were only available from two trials. This means that there may
not be enough data to estimate accurately treatment or subgroup effects. This
is reflected in the relatively large credible intervals and large heterogeneity be-
tween trials. Additionally, individual patient data could not be obtained for all
studies, thus limiting the analysis to two trials when analysing co-morbidities.
Secondly, not all trials used the same definitions of outcome, in particular, stroke
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progression. Thirdly, the findings did not reflect all the initial beliefs as it would
appear from this analysis that patients with mild strokes appear to benefit more
from routine monitoring than moderate or severe patients. However, a possible
explanation may be that, since mild patients are likely to have a better prognosis
than moderate or severe patients, this advantage may increase in a monitoring
setting since any complications they suffer may be reduced, and may therefore
also reduce the risk of stroke progression. Finally, there was significant hetero-
geneity in length of stay among trials and one trial (Cavallini et al., 2003) was
methodologically weaker than the other trials. However, the lack of data for some
outcomes also meant the lack of potential for sensitivity analysis and so the trial
with methodological limitations (Cavallini et al., 2003) was not excluded from
any analyses.
Despite the uncertainties in this study, the findings highlight the potential
importance of routine automated monitoring in reducing risk of stroke progression
and reducing length of hospital stay. Since the magnitude of benefits of routine
automated physiological monitoring may be small, a large multi-centred trial may
be required to clarify the uncertainties found in this meta-analysis and identify
if the added costs and efforts of such a policy are justified by better patient
recovery. The trial should be sufficiently large in order to examine appropriately
which subgroups of patients and subgroups by co-morbidity may benefit most
from routine automated monitoring.
Chapter 7
Collapsed and overlapping
covariate categories
This Chapter introduces a network meta-analysis model with covariate effects,
allowing the inclusion of all trials either with or without covariate data. This
model allows direct and indirect information to be used to give a more powerful
estimate of differences between treatment services while also accounting for co-
variates. This analysis assesses the possible bias in treatment effect estimation
(aggregation, or ecological bias) when covariates are not accounted for in the
model. Given the results from Chapter 3, this Chapter assumes that the cat-
egorisation of severity from different measures of stroke severity are equivalent
and that most of the prognostic information from the full scales is retained.
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7.1 Background
Meta-analysis, defined as the statistical analysis of a large collection of analytic
results for the purpose of integrating the findings (Dickersin and Berlin, 1992),
attempts to combine results across studies in order to gain statistical power and
to strengthen the evidence about possible treatment effects, and in adequately
powered studies to find out more about subgroups and possible interactions.
Several meta-analysis techniques have been designed to incorporate most, if not
all, of the information available for analysis. This includes accommodating more
than one active treatment of interest, for example indirect comparisons (Lu and
Ades, 2006), or combining individual patient data (IPD), covariate data, and
aggregated data (Sutton et al., 2008).
Often covariate data are also available, which can be taken into account.
Generally, covariate data which are most likely to be available in a meta-analysis
context will be in categorical form, for instance sex, or old age versus young.
Some trials may provide information on treatment effects within each cell of the
covariate classification, while in other trials only marginal data (that is, infor-
mation on one covariate aggregated over the another) for one or more of the
covariates may be available, or no covariate breakdown data at all. Previously,
this covariate data has often been ignored or analysed in such a way that does not
permit estimation of how these covariates are related to outcome, for example in
a stratified analysis where each stratum is treated as a separate trial.
Meta-analysis of randomised trials based on aggregated data is, however, vul-
nerable to forms of aggregation, or ecological bias (Rothman and Greenland,
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1998). Rothman and Greenland (1998) define ecological bias as ‘the failure of ex-
pected ecological effect estimates to reflect the biological effect at the individual
level’. The conditions for a covariate to be a confounder are different in individual
and aggregated data. For a covariate to be a confounder at the individual level,
the outcome and covariate must be associated. Covariates which influence the
outcome can give rise to ecological bias even though, due to the randomisation,
they are not associated with the treatment. This type of bias will occur in only
non-linear models (Rothman and Greenland, 1998). However, non-linear models,
for example logistic regression models, are by far the most commonly used in
meta-analysis of binary outcome data. This ecological bias can be shown using
simple calculations.
It is assumed that the treatment effects in two covariate strata are equal and
the effect of a covariate is equal in both treatment and control groups. It is
also assumed that the treatment and covariate effects are additive on the logit
scale. Figure 7.1 shows that the bias in the treatment effect increases as the
absolute covariate effect size increases. The size of the bias is more dramatic
as the treatment effect size in each stratum increases. Therefore, the bias will
increase for larger covariate effects and larger within-stratum treatment effects,
suggesting that it may be important to account for the effect of covariates when
performing meta-analyses, particularly when both treatment effects and covariate
effects are strong. However, while this can be easily done when treatment effects
are reported within covariate categories, it raises questions about trials where
treatment effects are pooled over covariate levels.
The objective of this Chapter is to develop and illustrate methods for control-
ling of ecological bias where trials fail to report treatment effects within covariate
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Figure 7.1: Scatterplot showing the effect of covariate odds ratio and within
strata treatment odds ratio on the pooled treatment odds ratio
for within stratum odds ratios of 2, 4 and 6. Note that for this
plot the proportion of survivors in the treatment group of stratum
one was chosen as 0.8.
categories, but instead “collapse” over categories. Treatment effects will be es-
timated controlling for ecological bias by using the data available within the
trials to impute the distribution of covariates in trials where this is not reported.
These methods are applied in a mixed treatment comparison evidence synthesis
(Lu and Ades, 2006; Higgins and Whitehead, 1996). Indirect treatment compar-
isons emerge when treatments of interest are not directly compared to each other,
but are compared with some other common treatment. For example, suppose tri-
als TAB compare treatment A versus B, while trials TBC compare treatments B
versus C. It may be of interest to compare treatments A and C, but due to ethical
issues this may not be directly possible. However, the comparison of A versus B
and B versus C can provide information indirectly on the comparison of A versus
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C. Where more than 3 treatments are being compared, these data structures have
been termed mixed treatment comparisons (MTC) (Lu and Ades, 2006).
The model controlling for ecological bias is compared to two simpler ap-
proaches: in the first the analysis is stratified as finely as the available data
allows, treating each stratum as a separate trial; in the second only fully aggre-
gated data are used, ignoring all covariate information. In Section 7.2 a mixed
treatment comparison model is described that includes two covariate effects, as
it would be if the treatment effect data were available within each covariate cat-
egory. Also, described are variant models for random covariate effects and inter-
actions between covariates, and methods for model choice. Section 7.3 describes
the extensions required for the model in Section 7.2.1 to obtain the collapsed
categories models (stratified and aggregated), while Section 7.4 gives an example
of these models applied to trials comparing various systems of acute stroke care.
Section 7.5 concludes with a discussion of the potential impact of the proposed
models.
In common with many of the recent developments in evidence synthesis for
complex data structures (Ades and Sutton, 2006), a Bayesian Markov chain
Monte Carlo framework with vague priors was adopted, and computed using
WinBUGS (Lunn et al., 2000).
CHAPTER 7. COLLAPSED AND OVERLAPPING COVARIATES 108
7.2 Mixed treatment comparisons model with
covariate effects
7.2.1 Model description
Covariate information is most likely to be available in categorical form. For
clarity in the following notation, two covariates, each having up to three levels,
are allowed. This is likely to be sufficient in most contexts, but the model may
easily be extended to allow a greater number of levels per covariate.
In the basic covariate model, fixed covariate effects and random treatment
effects are assumed. The fixed effect assumes the covariate effect from each study
included in the analysis estimates the same quantity with any deviations due
to random sampling variability, whereas the random effect allows the treatment
effects to differ across studies but assumes they are drawn from a common dis-
tribution of effect sizes.
The probability of an event in cell k of Table 7.1 for the treatment in arm j
Table 7.1: Summary of format of covariate data
Covariate 2 Covariate 1
1 2 3 marginal
1 [1] [2] [3] [A]
Covariate 1 2 [4] [5] [6] [B]
3 [7] [8] [9] [C]
Covariate 2
[T] [U] [V] [Z]
marginal
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(j = 2, ..., J) of trial i is given by Λijk, such that
logit(Λijk) = λik + δij, (7.1)
where δij are the estimated treatment effects in arm J , described in more detail
below, and
λi1 = µi,
λi2 = µi + α1, (7.2)
λi3 = µi + α2, (7.3)
λi4 = µi + β1, (7.4)
λi5 = µi + α1 + β1, (7.5)
λi6 = µi + α2 + β1, (7.6)
λi7 = µi + β2, (7.7)
λi8 = µi + α1 + β2, (7.8)
λi9 = µi + α2 + β2. (7.9)
The α1 and α2 are the additional effects of levels 2 and 3, respectively, of covariate
1 compared to the baseline category of level 1, while β1 and β2 are the equivalent
for covariate 2. All covariate effects are given vague priors,
α1, α2, β1, β2 ∼ Normal(0, 103). (7.10)
The µi ∼ Normal(0, 103) are the baseline event rates. This refers to observations
in level 1 of both covariates for treatment 1. This formulation only allows the
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modelling of the relative effect of the covariates on the baseline, not the absolute
effects.
Therefore, given a trial with full information of both covariates (that is, those
trials with information on cells [1] to [9] of Table 7.1), the numbers of events are
rijk ∼ Binomial(Λijk, nijk).
In the mixed treatment effect model it is easiest to begin by considering a
situation where every trial might include all 6 treatments. Then the true effects
of treatments 2 to 6 relative to treatment 1 are distributed as

δi2(1)
δi3(1)
δi4(1)
δi5(1)
δi6(1)

∼ Normal


d2
d3
d4
d5
d6

,

τ 2 0.5τ 2 0.5τ 2 0.5τ 2 0.5τ 2
0.5τ 2 τ 2 0.5τ 2 0.5τ 2 0.5τ 2
0.5τ 2 0.5τ 2 τ 2 0.5τ 2 0.5τ 2
0.5τ 2 0.5τ 2 0.5τ 2 τ 2 0.5τ 2
0.5τ 2 0.5τ 2 0.5τ 2 0.5τ 2 τ 2


,
(7.11)
The priors for the means of the individual treatment effects, dt, are given by
d1 = 0,
d2, ..., dT ∼ Normal(0, 103),
where T is the total number of treatments and the prior for the variance parameter
is given as
1
τ 2
∼ Gamma(0.01, 0.01).
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It is then assumed that the selection of which treatments are actually included
in each trial is independent of the results.
7.2.2 Random covariates and covariate interactions
The need for fixed or random effects on the covariate, as well as the possibility of
an interaction existing between the covariates, may be investigated. The following
four models were compared:
1. fixed covariate effects (as described in Section 7.2.1),
2. random covariate effects,
3. fixed covariate effects, with additional interaction term between covariates,
4. random covariate effects, with additional interaction term between covari-
ates.
For the random covariate model (model 2), equations (7.2)-(7.9) of the fixed
covariate model described in Section 7.2.1 are changed to give
λi2 = µi + αi1,
λi3 = µi + αi2,
λi4 = µi + βi1,
λi5 = µi + αi1 + βi1,
λi6 = µi + αi2 + βi1,
λi7 = µi + βi2,
λi8 = µi + αi1 + βi2,
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λi9 = µi + αi2 + βi2,
with priors for the covariate effects given in equation (7.10) becoming
αi1 ∼ Normal(α1, σ2),
αi2 ∼ Normal(α2, σ2),
βi1 ∼ Normal(β1, σ2),
βi2 ∼ Normal(β2, σ2),
with vague priors on the hyper-parameters
α1, α2, β1, β2 ∼ Normal(0, 103),
and
1
σ2
∼ Gamma(0.01, 0.01).
The interaction effects (model 3) were included by adjusting equations (7.5),
(7.6), (7.8) and (7.9) to include the additional interaction terms
λi5 = µi + α1 + β1 + γ1,
λi6 = µi + α2 + β1 + γ2,
λi8 = µi + α1 + β2 + γ3,
λi9 = µi + α2 + β2 + γ4,
where
γ1, γ2, γ3, γ4 ∼ Normal(0, 103).
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Finally, model 4 includes the random effects of the covariates as in model 2
and also random interaction effects where equations (7.5), (7.6), (7.8) and (7.9)
are now
λi5 = µi + αi1 + βi1 + γi1,
λi6 = µi + αi2 + βi1 + γi2,
λi8 = µi + αi1 + βi2 + γi3,
λi9 = µi + αi2 + βi2 + γi4,
with interaction priors given as
γi1 ∼ Normal(γ1, σ2),
γi2 ∼ Normal(γ2, σ2),
γi3 ∼ Normal(γ3, σ2),
γi4 ∼ Normal(γ4, σ2),
where
γ1, γ2, γ3, γ4 ∼ Normal(0, 103).
Model choice was determined by the Deviance Information Criterion (DIC)
(Spiegelhalter et al., 1998) and whether the posterior credible interval for inter-
action effects contained 0. The DIC is the sum of the ‘fit’ (that is, the posterior
expectation of the deviance denoted by D¯) and the complexity (the effective
number of parameters, pD) of a model. The terms making up the DIC therefore
represent a goodness-of-fit term and a term representing a penalty for increasing
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model complexity.
7.3 Collapsed categories model
Up to this point, treatment effects and covariate effects were modelled in a stan-
dard logistic regression framework, in which numerators and denominators for
treatment and control were available for each set of covariate values. However,
some trials may only have marginal data for one or both of the covariates and
often trials have no covariate breakdown at all. Those trials with collapsed and
overlapping categories can also be included into the covariate model and their
structure can be expressed in terms of the parameters introduced thus far.
The approach estimates the proportions of the trial population, piik, for trial
i in each cell k of Table 7.1. These proportions are assumed to be samples from
a common Dirichlet distribution,
pii,1, ..., pii,9 ∼ Dirichlet(κ1, ..., κ9),
and the hyper-parameters, κ1, ..., κ9, are given vague priors and estimated from
the data. To ensure positive values greater than one, which would represent a
uniform prior, the log(κ1, ..., κ9) were assigned Half Normal priors truncated at
zero:
log(κj) ∼ Normal(0, 102) for log(κj) > 0.
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7.3.1 Incorporating data on collapsed and overlapping cat-
egories
7.3.1.1 Full covariate data
The full covariate model is described in Sections 7.2.1 and 7.2.2. The cell sizes
when full data are available are represented by
nij(1:9) ∼ Multinomial(pii(1:9), Nij),
where Nij =
∑9
k=1 nijk, is the total number of patients in all k cells in treatment
arm j of trial i.
7.3.1.2 Data collapsed over either covariate
Cells [A] to [C] of Table 7.1 correspond to those trials with marginal data for
covariate 1 and these give the following probabilities of event
θijA =
(pii1Λij1 + pii2Λij2 + pii3Λij3)
pii(α0)
,
θijB =
(pii4Λij4 + pii5Λij5 + pii6Λij6)
pii(α1)
,
θijC =
(pii7Λij7 + pii8Λij8 + pii9Λij9)
pii(α2)
,
where
pii(α0) = pii1 + pii2 + pii3,
pii(α1) = pii4 + pii5 + pii6,
pii(α2) = pii7 + pii8 + pii9.
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The number of events in each level of the covariate are therefore
rijk ∼ Binomial(θijk, nijk),
where k = A,B,C and the number of patients in each cell has a multinomial
distribution
(nijA, nijB, nijC) ∼ Multinomial((pii(α0), pii(α1), pii(α2)), Nij),
Similarly, cells [T] to [V] of Table 7.1 correspond to those trials with marginal
data for covariate 2 with the following probabilities of event
θijT =
(pii1Λij1 + pii4Λij4 + pii7Λij7)
pii(β0)
,
θijU =
(pii2Λij2 + pii5Λij5 + pii8Λij8)
pii(β1)
,
θijV =
(pii3Λij3 + pii6Λij6 + pii9Λij9)
pii(β2)
,
where
pii(β0) = pii1 + pii4 + pii7,
pii(β1) = pii2 + pii5 + pii8,
pii(β2) = pii3 + pii6 + pii9.
such that the number of events in each level are given as
rijk ∼ Binomial(θijk, nijk),
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where k = T, U, V and the number of patients in each cell has a multinomial
distribution
(nijT , nijU , nijV ) ∼ Multinomial((pii(β0), pii(β1), pii(β2)), Nij).
7.3.1.3 Collapsed and overlapping data for covariates 1 and 2
Some trials may have the marginal data for covariate 1 and the marginal data for
covariate 2. In considering the information on treatment effects it is important
to avoid using information more than once. For example, if binomial information
on treatment effects was available for covariate 1 (marginals [A], [B], and [C] in
Table 7.1) as well as covariate 2 (marginals [U] and [V]), then this is enough
information to determine the marginal numerator and denominator for cell [T].
Thus, conditional on the information in the other marginals, [T] provides no
further information on treatment effects. The likelihood is therefore specified as
rijk ∼ Binomial(θijk, nijk),
in each cell where k = A,B,C, U, V .
The likelihood for the cell frequency information is, however, the product of
the likelihoods for the two marginal multinomials given in Section 7.3.1.2. This
is because the distribution of the marginal totals for covariate 1 ([A], [B] and [C]
in Table 7.1) does not put any constraints on the distribution of the marginals
totals of covariate 2 ([T], [U] and [V]).
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7.3.1.4 Collapse of data over both covariates
In Table 7.1, cell [Z] represents those trials where there were no data available
for either covariate. In this case the number of events are given as
rijZ ∼ Binomial(θijZ , Nij),
where the probability of event is given as
θijZ =
9∑
k=1
piikΛijk.
7.3.1.5 Trials on subsets of the patient population
In some trials there may be an absence of data in one or more levels of a covariate.
It is assumed here that these zeros in the marginal totals are structural. That is,
instead of there simply being no cases within a covariate level, the zeros are due
to the inclusion criteria of trials where data on one or more levels of a covariate
were not collected. In the case where a trial has structural zeros for a covariate,
this trial is not allowed to inform the distribution of the covariate where data
has not been collected (that is the piik) but it can inform the distribution for the
other covariate.
7.3.2 Stratified and fully aggregated models
The results from the model described in Sections 7.2 and 7.3.1, which makes max-
imal use of covariate information, is contrasted with two alternative approaches.
The stratified model (where each stratum can be considered a ‘separate’ trial) and
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aggregated model (where no covariate data is used) are technically the same, with
the difference between these models lying in the data format used. In the strati-
fied model, any data available for cells [1] to [9] (in Table 7.1) are marginalised,
giving data in the cells [A] to [C], [T] to [V], or [Z] if no covariate breakdown were
available. Where a trial has marginal data for both covariates, only one set of
marginal data is chosen. The choice is determined by the amount of information
available for both covariates. The covariate with the least data available across
all trials is chosen in order to increase the amount of information for this covari-
ate. This subgroup data is then incorporated by treating each subgroup stratum
as if it were a different trial.
For the aggregated model it is assumed there are no subgroup data, and all
data are aggregated into one level for each treatment in each trial, equivalent to
cell [Z].
In order to analyse these collapsed data structures, equation (7.1) is changed.
The numbers of events are assumed to be Binomially distributed with probability
pij such that
logit(pij) = µi + δij,
where µi ∼ Normal(0, 103) and δij is described in equation (7.11).
7.3.3 Parameter estimation
All analyses were carried out in WinBUGS 1.4.1 (Lunn et al., 2000). The mul-
tivariate normal distribution for the δit(1) was realised as a series of conditional
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univariate distributions. The common Dirichlet distribution for the piik was re-
alised as a series of conditional beta distributions (Gelman et al., 2004). Con-
vergence was assessed using the Brooks-Gelman-Rubin diagnostic tool (Brooks
and Gelman, 1998) and considered adequate after 20,000 iterations in all models.
For each model, a further sample of 50,000 iterations was then run on which the
results are based.
7.4 Example: organised inpatient (stroke unit)
care
7.4.1 Data
Data from a collaborative systematic review carried out by the Stroke Unit Tri-
alists Collaboration (Stroke Unit Trialists’ Collaboration, 2007) are used. This
database is described in Chapter 4. In summary, the review examined whether
improving the organisation of inpatient stroke services can bring about improve-
ments in important patient outcomes. A very broad definition of stroke unit care
was used and the review included any trial which compared organised (stroke
unit) care (defined as a multi-disciplinary team specialising in stroke care) ver-
sus the contemporary conventional care such as a general medical ward or less
organised form of stroke care. Stroke unit care could include services based in a
discrete ward or provided by a mobile stroke team. Outcome data on the number
of deaths within each treatment group of each trial was recorded. In addition
to this, the number of deaths within subgroups of age and severity were sought.
Age was categorised into those less than or equal to 75 versus those greater than
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Table 7.2: Number of trials providing subgroup data.
Trials providing data on distribution of severity and age
Joint age and severity 2
Marginal age and severity 9
Marginal severity only 15
Marginal age only 1
No breakdown 2
Trials providing data on a subset of severity and age
No age recorded Old only All ages
No severity recorded 2 - 1
Moderate only 4 - -
Mild and moderate 1 - -
Moderate and severe 1 - -
All severities 9 1 10
75 years of age, while baseline severity was categorised into mild, moderate and
severe using the Barthel Index (BI) of activities of daily living (Mahoney and
Barthel, 1965), where mild is equivalent to BI 10-20, moderate BI 3-9 and severe
BI 0-2.
Altogether, the SUTC provided data for 31 trials. Service comparisons within
these 31 trials are summarised in Figure 4.1. The commonest comparison was
between comprehensive stroke ward (service 2) and general medical ward (service
6) with eleven trials looking at this comparison. Davis et al. (2000) also provided
their data comparing an acute stroke ward system of care with a comprehensive
stroke ward system of care. Therefore, data were available from a total of 32
trials. Three trials were excluded as the number of deaths recorded was zero.
Table 7.2 summarises the remaining 29 trials. Note there were only 2 trials that
provided individual patient data, therefore providing data on the combination of
age and severity. Table 7.2 also summarises the number of trials that provided
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Table 7.3: Summary of format of data available
Age Severity
Young Old marginal
Mild [1] [2] [A]
Severity Moderate [3] [4] [B]
Severe [5] [6] [C]
Age marginal [T] [U] [Z]
data from a subset of the six severity and age cells as shown in Table 7.3. Table 7.3
shows the combination of the covariates where cells [1] to [6] correspond to data
for both age and severity, cells [A] to [C] represent severity marginal data only,
cells [T] and [U] represent age marginal data and finally cell [Z] represents no
breakdown data available for age or severity.
7.4.2 Covariate model choice
Firstly, the covariate models were fitted to the data. The DIC, summarised
in Table 7.4, and the presence of substantial interaction effects determined the
model choice. The Dbar and pD results for the cell frequency data was very much
the same for all models and is not shown in Table 7.4. The DIC in the random
covariate model (model 2) is lower than those for the fixed covariate model and
the fixed interaction model, indicating that random covariate effects are needed.
The posterior credible intervals for the interaction terms in model 4 were not
substantial (old*moderate: OR 0.27, 95% CrI 0.002 to 9.09; old*severe: 0.40,
0.003 to 8.17). Therefore, the random covariate model was chosen for further
investigation of the effect of collapsing covariate categories. The WinBUGS code
for this model is given in Appendix D.
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Table 7.4: DIC for the four covariate models
Model Dbar Dhat pD DIC
1. Fixed covariate effect r 698.4 639.7 58.7 757.2
Total 1386.5 1279.7 106.8 1493.3
2. Random covariate effect r 669.8 600.3 69.5 739.4
Total 1357.0 1240.6 116.4 1473.5
3. Fixed covariate effect r 698.1 638.5 59.6 757.7
with interaction Total 1386.5 1278.4 108.0 1494.5
4. Random covariate effect r 669.3 599.9 69.4 738.6
with interaction Total 1356.6 1240.7 115.9 1472.4
7.4.3 Collapsed categories results
The estimated treatment effects obtained from the three modelling strategies
(aggregated, stratified and random covariate) are summarised in Figure 7.2. The
estimates of treatment effect appear to be consistent in the three models, with the
estimates in the aggregated model slightly closer to 1. Although the treatment
effect estimates for the covariate model are slightly more variable than the other
models, this model also provides additional estimates for the effects of severity and
age on outcome. As expected, the odds of death increases for older patients (OR
7.69, 95% CrI 3.41 to 20.03) and also increases as severity increases (moderate vs.
mild: 6.83, 3.47 to 14.63; severe vs. mild: 52.04, 26.92 to 128.90). However, there
is large variability in these estimates. Note for those trials where there existed
marginal covariate information for both age and severity, the age covariate data
in these trials was chosen to be included as this covariate had fewer data points
available across all trials.
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Figure 7.2: Posterior credible intervals for the odds ratios of treatment ef-
fect compared to general medical ward for each of the covariate,
stratified and aggregate models. Treatments are (a) acute stroke
ward; (b) comprehensive stroke ward; (c) rehabilitation stroke
ward; (d) mixed rehabilitation ward; and (e) mobile stroke team.
7.5 Discussion
Described here is a mixed treatment comparisons model with covariate effects
which incorporates data on collapsed and overlapping categories. The model
allows the inclusion of studies with the joint distribution of covariates, those
with marginal data for one or two covariates as well as those with no covariate
information and provides an estimate of the covariate effects. The estimates of
treatment effects are obtained using direct and indirect comparisons giving a
more powerful comparison between treatment types.
The covariate model chosen to analyse the SUTC data was the random co-
variate model without interaction (model 2). Although the random covariate
model with interaction (model 4) had a smaller DIC value, the interaction effect
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magnitudes were not substantial in this model. Also, since the treatment effect
estimates were small and unaffected by the difference in models, the simpler of
the two models were chosen.
The treatment effect estimates obtained from the model were compared with
those of the stratified covariate model (where each stratum can be considered a
‘separate’ trial) and a fully aggregated model (where no covariate data are used).
Simple calculations show that bias may exist in the treatment effect if covariate
effects are not taken into account. Therefore, the aggregate data analysis is
expected to be most biased. The stratified model should perform better than
the aggregated model but it should also be biased since there is still a high level
of aggregation. This means that the estimated treatment odds ratios in the
aggregate and stratified models should be closer to one than the covariate model.
In the example using the SUTC data, there appears to be no substantial bias
in the estimation of treatment effect between aggregated, stratified and covariate
models, although the odds ratios of the treatment effect from the aggregated
model compared to the other models, shown in Figure 7.2, are slightly closer to
1. Figure 7.1 showed that a large covariate effect increased the size of the bias in
the treatment effect. However, although the size of the covariate effect is fairly
large in the example, it may be that there does not appear to be substantial bias
because the size of the treatment effect is relatively small. This is also shown in
Figure 7.1: when the within stratum treatment effect size is small (the bottom
line), the bias is less than when the treatment effect is large.
Several authors have previously investigated the use of collapsed categories
models when analysing data. For example Dominici (2000) introduced a multi-
nomial logistic normal hierarchical model that combines contingency tables with
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different dimensions in order to investigate the association between air pollution
and mortality. This model combines all studies reporting the categorical vari-
ables, even when some included studies do not report all variables. However,
Dominici assumes a logistic normal family to model the cell probabilities instead
of a Dirichlet prior as the environmental data may have had positive correlations
between cells.
Salanti et al. (2006) consider synthesising evidence from multiple epidemi-
ological studies. They have also addressed the question of combining data on
categorical variables where only one trial recorded the joint effect of all categori-
cal variables and most only recorded one or two covariates of interest. However,
unlike the collapsed categories model presented here, their model makes use of
external data sources to inform the unobserved variables and they extend their
model to include methods for case-control designs.
Rothman and Greenland (1998) also observed that ecological bias does not
exclusively occur in meta-analysis of randomised clinical trials. They provide
examples of ecological bias occurring in several observational studies with aggre-
gated data.
Finally, the mixed treatment comparisons model can be easily adapted to
include additional covariates, or covariates with greater than three levels. The
model may also be adapted to include treatment-covariate interactions in addition
to interactions between covariates.
Chapter 8
Mixed treatment comparison of
different systems of organised
inpatient (stroke unit) care
Chapter 4 conducted several comparisons of “more” organised inpatient services
with “less” organised services. However, this analysis did not include information
on indirect comparisons or the possible effects of age and severity on outcome.
Using the model introduced in Chapter 7, a network meta-analysis is performed
to explore whether any one system of care is most effective at improving patient
outcomes, while also accounting for possible associations of age and severity with
patient outcome. Given the results from Chapter 3, this Chapter assumes that the
categorisation of severity from different measures of stroke severity are equivalent
and that most of the prognostic information from the full scales is retained.
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8.1 Background
It has been well established that organised inpatient (stroke unit) care reduces
the risk of death, dependency and the need for institutional care following stroke
(Stroke Unit Trialists’ Collaboration, 2007). However, it has not been established
which system of organised care is most effective. Stroke Unit Trialists’ Collab-
oration (2007) show that “more” organised is better than “less” organised care,
but generally the analyses cannot differentiate between the different systems of
organised care.
However, in these analyses not all of the information available has been used.
One of the obvious sources of information often not incorporated into analyses
are patient subgroup information. Another source of information not utilised are
indirect comparisons of treatment. In most organised inpatient care analyses,
the most common comparison (organised care versus general medical ward) uses
only trials where an organised service are compared to a general medical ward.
However, data may be available from other trials that compare different systems
of organised care. These trials hold indirect information about the comparisons
between each organised care system and general medical ward; data from all trials
can therefore be included in a network meta-analysis where direct and indirect
information are used to obtain treatment effect estimates based on the maximum
quantity of information.
A mixed treatment comparisons (MTC) meta-analysis including patient sub-
group data was used to explore whether any one system of care is most effective
in improving patient outcomes while also taking account of associations of age
and severity with patient outcome.
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8.2 Methods
8.2.1 Data
Data from the updated Stroke Unit Trialists Collaboration systematic review was
used to conduct this analysis. In summary, the SUTC database currently con-
tains 31 clinical trials (6936 subjects) and six care systems were identified: semi-
intensive acute stroke ward; comprehensive stroke ward; rehabilitation stroke
ward; mixed-rehabilitation ward; mobile stroke team; and general medical ward.
The network of trials is given in Figure 4.1. Davis et al. (2000) also provided data.
This trial compared an acute stroke ward system of care with a comprehensive
stroke ward system of care.
The outcomes considered were death, death or dependency, and death or need
for institutional care; subgroup data for age and severity were extracted. Age
was classified as those under 75 versus those over 75 and severity was classified
as moderate versus mild and severe versus mild, where mild, moderate and se-
vere are defined by the Barthel Index in Table 3.1 or an equivalent measure of
severity. Trials included in this analysis may have measured severity in a number
of different ways. However, Chapter 3 shows the equivalence of several methods
of categorising severity. Therefore, it assumed the severity categorisations used
in each trial of this analysis are also equivalent.
8.2.2 Statistical methods
Using data from direct and indirect comparisons and Bayesian hierarchical mod-
els, odds ratios and 95% credible intervals (CrI) were calculated for outcomes in
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each alternative system of care versus general medical wards. Systems of care
were also ranked in order of most effective at reducing poor patient outcomes,
giving the probability of each ward being the most effective at improving out-
comes. The random covariate model without interactions (model 2 as described in
Section 7.2) was used. In this model, the treatment and covariate effects are con-
sidered random and no interaction exists between the covariates. In this analysis
there is one 2-level covariate (age) and one 3-level covariate (severity) as shown
in Table 7.3. Residual deviance, as described in Section 5.2.2, was calculated to
check model fit.
8.3 Results
Table 8.1 shows the number of trials that provided subgroup data for each of
the main outcomes. For the outcome of death or dependency there were only
Table 8.1: Number of trials providing subgroup data for each of the main
outcomes.
Subgroup Death
Death or Death or
institutional care dependency
Joint∗ age and severity 2 2 2
Marginal† age and severity 9 9 1
Marginal severity only 15 11 21
Marginal age only 1 0 0
No breakdown‡ 2 9 4
Total 29 31 28
∗Joint distribution of covariates is equivalent to data in cells [1] to [6] of Table 7.3.
†Marginal distribution of covariates is equivalent to data in cells [A] to [C] for
severity and [T] to [U] for age in Table 7.3.
‡No breakdown by covariate is equivalent to data in cell [Z] of Table 7.3.
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Table 8.2: Number of data points and residual deviance for each outcome.
Outcome Data points Residual deviance
Death 364 326
Death or institutional care 348 325
Death or dependency 229 298
three trials that provided information on age. Therefore, due to lack of data,
an estimate for the effect of age could not be obtained for this outcome. For
all outcomes the fit of the model was adequate as given by residual deviance.
Table 8.2 shows that the residual deviance is less than the number of data points.
Figure 8.1 shows that, compared to general medical ward, there were signif-
icant reductions in odds of death in rehabilitation stroke ward (OR 0.58; 95%
CrI 0.35 to 0.93) and significant reductions in odds of death or institutional care
in comprehensive stroke ward (0.72; 0.56 to 0.93). There appeared to be reduc-
tions in odds of death in comprehensive stroke ward (0.83; 0.66 to 1.05) and in
odds of death or institutional care in rehabilitation stroke ward (0.67; 0.43 to
1.01), however these were not significant. For death or dependency there was a
significant reduction of poor outcome in acute stroke ward compared to general
medical ward (0.43; 0.21 to 0.84).
Table 8.3 gives the probabilities of each service type being the most effective in
reducing the odds of poor outcome. For all three outcomes, general medical ward,
mobile stroke team and mixed rehabilitation ward can be considered ineffective
systems of care due to the loww probabilities associated with them.
The odds ratios for poor outcome of patient subgroups are given in Table 8.4.
Notice that older patients tend to have an increased odds of death and death
or institutional care. Also, as the severity of stroke increases, the odds of poor
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Figure 8.1: Comparing organised stroke unit care with general medical wards
for the outcomes of death, death or institutional care and death
or dependency. Comparisons are: (a) semi-intensive acute ward;
(b) comprehensive stroke ward; (c) rehabilitation stroke ward;
(d) mixed-rehabilitation ward; and (e) mobile stroke team. Re-
sults are presented as median odds ratios (shaded diamond) of
organised stroke unit care versus general medical ward, with cor-
responding 95% credible intervals represented by the line. Odds
ratios are plotted on the natural log-scale.
outcome also tend to increase for all outcomes. However, the credible intervals
are wide so care must be taken when interpreting these results.
As in Chapter 4, sensitivity analysis was performed excluding the seven trials
with an informal method of randomisation that is prone to bias (Ronning and
Guldvog, 1998; Patel, 2000; Yagura et al., 2005; Cavallini et al., 2003; von Arbin
et al., 1980; Strand et al., 1985; Hamrin, 1982). The conclusions for death and
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Table 8.3: Probabilities of each service type being the most effective in re-
ducing odds of poor outcome.
Service Death
Death or Death or
institutional care dependency
General medical ward <0.01 <0.01 <0.01
Mobile stroke team <0.01 <0.01 0.02
Mixed rehabilitation ward 0.02 0.01 0.01
Rehabilitation stroke ward 0.76 0.47 0.17
Comprehensive stroke ward 0.04 0.20 0.01
Acute stroke ward 0.17 0.31 0.80
Due to rounding, probabilities do not sum to 1 in every outcome.
death or institutional care remain unchanged when trials with such informal
randomisation procedures were excluded. However, this is not true for death
or dependency. The results of the sensitivity analysis for death or dependency
are given in Table 8.5. The reduction in odds of poor outcome in acute stroke
wards is no longer significant, but rehabilitation stroke wards and comprehensive
stroke wards have a possible reduction in the odds of death or dependency, but
these were not significant. Again, general medical ward, mobile stroke team and
mixed rehabilitation ward can be considered ineffective systems of care due to the
low probabilities associated with them. There was no change in the conclusions
Table 8.4: Covariate odds ratios and 95% credible intervals.
Covariate/
Death
Death or Death or
Comparison institutional care dependency
Age
Old vs young 6.82 (3.41, 20.03) 3.99 (1.79, 8.74) NA
Severity
Moderate vs mild 6.83 (3.47, 14.62) 6.51 (3.88, 11.12) 9.16 (5.33, 16.79)
Severe vs mild 52.04 (26.92, 100>) 44.61 (26.95, 86.49) 69.27 (36.63, 100>)
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Table 8.5: Odds ratios and probabilities each treatment is most effective for
death or dependency sensitivity analysis.
Comparison
Odds ratios (95% CrI) New probability
All data Sensitivity most effective
Treatment
General medical ward - - <0.01
Mobile stroke team 0.92 (0.51, 1.65) 0.88 (0.48, 1.53) 0.11
Mixed rehabilitation ward 0.81 (0.53, 1.25) 0.89 (0.62, 1.28) 0.03
Rehabilitation stroke ward 0.62 (0.35, 1.08) 0.67 (0.41, 1.05) 0.52
Comprehensive stroke ward 0.80 (0.54, 1.17) 0.76 (0.54, 1.06) 0.15
Acute stroke ward 0.42 (0.21, 0.84) 0.82 (0.42, 1.48) 0.19
Severity
Moderate vs mild 9.16 (5.33, 16.79) 8.55 (4.55, 17.11) -
Severe vs mild 69.27 (36.63, 100>) 60.70 (28.50, 100>) -
regarding the associations of covariates with outcome. The sensitivity analysis
results are similar to the results given in Figure 8.1 for the outcomes of death
and death or institutional care.
8.4 Discussion
This analysis examined the effect of the five types of organised inpatient (stroke
unit) care compared to general medical ward using more of the available informa-
tion than previous analyses. The results show that patients treated in a dedicated
stroke setting perform better than those in general medical wards. Rehabilitation
stroke wards and comprehensive stroke wards have greatest reduction in odds of
death, dependency and requirement for institutional care. General medical ward,
mobile stroke team and mixed rehabilitation ward can be considered ineffective
systems of care. Finally, the analysis shows that as age and stroke severity in-
crease then so does the odds of poor outcome.
The model used to analyse the data has a number of strengths. It allows
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a more powerful comparison between different types of organised care by using
direct and indirect comparison data. For example, the most common direct com-
parison was between comprehensive stroke ward and general medical ward. The
information provided by these direct comparisons along with the direct compar-
isons between comprehensive stroke ward and, say, acute stroke ward can be used
to obtain indirectly an estimate of the comparison between acute stroke ward and
general medical ward. This network meta-analysis uses more information than
previous analyses, therefore giving more precise treatment effect estimates. It
also allows each type of organised service to be compared to a common reference
service so it can be seen more easily which type of organised service performs bet-
ter. The model also includes the patient subgroups of age and severity, adjusting
for these effects and providing an estimate of their magnitude. The model used
can also be adapted to test for any interactions between covariates. The inter-
action term was not included here as no substantial interaction existed between
age and severity.
In the sensitivity analysis, where trials of lower methodological quality were
excluded, the conclusions for the death or dependency outcome were qualitatively
different. A potential reason may have been that the trials excluded did not use
a formal randomisation procedure, therefore, treatment effects could possibly
have been exaggerated in these trials. Another potential reason could be due
to less data being analysed in the sensitivity analysis. However, the results of
the sensitivity analyses for death or dependency are consistent with the results
achieved for death and death or institutional care.
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Other limitations in the analysis are the wide credible intervals for the sub-
groups effects and the inability to estimate the effect of age on death or depen-
dency. Individual patient data could not be obtained for all trials, therefore, lack
of data prevented the precise estimation of subgroup effects. If individual patient
data were available for all trials then this would allow more precise estimation of
the effects of age and severity on all outcomes as the information available would
be greater than that in the categorised age and severity used here.
Even with its limitations, this analysis provides further evidence that organ-
ised stroke unit care reduces the odds of death, death or institutional care and
death or dependency compared to general medical wards. Dedicated wards such
as the rehabilitation stroke wards, comprehensive stroke wards and acute stroke
wards appear to perform better than mobile stroke teams and mixed rehabil-
itation wards, and such findings are robust to adjustment for case mix in the
form of age and stroke severity. Future research should focus on evaluating the
benefits of an acute system of care and rehabilitation stroke care to improve pa-
tient outcomes. Attempts should be made to obtain individual patient data and
future studies should make individual patient data available for the purposes of
meta-analysis to allow more accurate estimation of the effects of age and severity.
Chapter 9
Cost-utility analysis of different
systems of organised inpatient
(stroke unit) care
Chapter 4 shows that organised inpatient (stroke unit) care reduces deaths, de-
pendency and requirement for institutional care and Chapter 8 shows that dedi-
cated stroke unit services perform better than systems which are not restricted to
stroke patients. However, the additional cost of stroke unit care may outweigh the
benefits achieved. This Chapter implements a cost-utility analysis to determine
which system of organised inpatient (stroke unit) care is most cost-effective.
9.1 Background
Stroke is the leading cause of long-term neurological disability in adults (Wolfe,
2000) meaning that stroke-related costs are one of the largest components in
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health care expenditure in Scotland (Isard and Forbes, 1992). Given that the
number of patients with first ever stroke is predicted to increase over the next
15 years (Malmgren et al., 1989), it is important to understand the relative cost-
effectiveness of different models of inpatient care.
It has been shown that stroke units reduce deaths, requirement for institu-
tionalisation and dependency in stroke patients (Chapter 4) and that stroke units
with acute care, comprehensive care and rehabilitation perform better than care
systems which are not restricted to patients with acute stroke (Chapter 8). How-
ever, it is unclear how the models of inpatient care compare in terms of costs
and benefits. Therefore a cost-utility analysis (described in more detail in Sec-
tion 9.2) is employed to evaluate the additional costs per quality-adjusted life
year (QALY) gained by each of the different inpatient service models.
9.2 Economic evaluation
In an ideal world, improvements to service organisation would be accepted pro-
vided they improved patient outcomes. However, service improvements often
come at a higher cost, and since this is not an ideal world, these costs must be
taken into account when deciding which service improvements should be accepted.
Evers et al. (2000) describe four main types of economic evaluation: cost-
minimisation analysis; cost-effectiveness analysis; cost-utility analysis; and cost-
benefit analysis. A cost-minimisation analysis examines equally effective health
care programs so that only costs need to be compared further. The outcome in
a cost-effectiveness analysis can be assessed in a variety of ways (for example life
years gained, decreased length of stay, cases prevented, pain free days), limiting
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comparison between studies as the outcomes can be measured in different ways
across different studies. However, a cost-utility analysis expresses health out-
comes in a uniform way, the quality-adjusted life-year (QALY). A QALY takes
into account both the quantity and the quality of life. The quantity of life (life
years) is adjusted using utility values (where 1 corresponds to perfect health and
0 to death) to give a measure of the quality of the life-years. Finally, a cost-
benefit analysis allows the analyst to see immediately whether benefits outweigh
costs by expressing the outcome of the study in monetary terms so that costs
and benefits are measured in the same unit.
A cost-minimisation analysis would not be appropriate as Chapter 8 shows
that not all systems of care are equivalent. Additionally, it is difficult to assign
monetary values to clinical outcomes, therefore a cost-benefit analysis was not
performed. Finally, utility values were readily available, therefore, a cost-utility
analysis was preferred over a cost-effectiveness analysis.
The cost-utility analysis considered National Health Service (NHS) costs and
health benefits to individuals; it therefore used the same perspective as the Na-
tional Institutes for Health and Clinical Excellence (NICE) in evaluating health
technologies. Costs and benefits were estimated for a period of one year after
the patient had the stroke; this was selected due to the lack of long term RCT
follow-up.
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9.3 Methods
9.3.1 Data
Data from the Stroke Unit Trialists Collaboration systematic review, described
in Section 1.5.4 and Chapter 4, were used. In summary, this database includes 31
prospective trials using some form of random allocation of stroke patients to an
organised system of inpatient (stroke unit) care or an alternative form of inpatient
care. Six systems of care were identified: semi-intensive acute stroke ward; com-
prehensive stroke ward; rehabilitation stroke ward; mixed-rehabilitation ward;
mobile stroke team; and general medical ward (GMW). In addition to the main
outcomes (death, death or dependency and death or need for institutional care),
data were also gathered on average length of stay and the timings of deaths.
In total 25 trials (Ronning and Guldvog, 1998; Vemmos et al., 2001; Ma et
al., 2004; Patel, 2000; Stevens et al., 1984; Garraway et al., 1980; Svensson et al.,
1993; Fagerberg et al., 2000; Sulter et al., 2003; Kaste et al., 1995; Cabral et al.,
2003; Sivenius et al., 1985; Aitken et al., 1993; Juby et al., 1996; Kalra et al., 1993,
2000; Yagura et al., 2005; Cavallini et al., 2003; Hankey et al., 1997; von Arbin
et al., 1980; Laursen et al., 1995; Ilmavirta, 1994; Indredavik et al., 1991; Strand
et al., 1985; Hamrin, 1982) recorded length of stay, while 22 trials (Ronning and
Guldvog, 1998; Vemmos et al., 2001; Stevens et al., 1984; Garraway et al., 1980;
Fagerberg et al., 2000; Sulter et al., 2003; Kaste et al., 1995; Gordon and Kohn,
1966; Cabral et al., 2003; Sivenius et al., 1985; Dey et al., 2005; Wood-Dauphinee
et al., 1984; Feldman et al., 1962; Aitken et al., 1993; Juby et al., 1996; Kalra et al.,
2000; Hankey et al., 1997; Laursen et al., 1995; Ilmavirta, 1994; Indredavik et al.,
1991; Strand et al., 1985; Hamrin, 1982) provided information on the total number
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of deaths at varying time points. Unfortunately, data on the timings of those who
were dependent or required institutional care (where requirement for institutional
care is considered a surrogate measure of dependency) were not available in the
Stroke Unit Trialists’ Collaboration database. However, previous analysis by the
SUTC (Stroke Unit Trialists’ Collaboration, 1997b) provided information on the
proportions of patients who were alive and living at home at several time points,
including weeks 1, 2, 3, 4, 12, 26 and 52.
9.3.2 Costs
The variables that are assumed to affect NHS costs between types of inpatient
stroke care were NHS staff time and length of stay. It was assumed that the
use of medicines, tests, and other interventions would be similar in all types of
unit. These aspects of care are less expensive than staff time and so it is believed
they would not affect overall cost estimates. Additionally, Chapter 5 shows that
the benefits of stroke unit care can be attributed to interventions to prevent
complications, therefore, the hypothesis that observed differences in outcome are
attributable to staff time and skills seems appropriate.
Kalra et al. (2000), Langhorne and Pollock (2002) and Rodgers et al. (2003)
provide information on staffing levels for acute stroke ward, comprehensive stroke
ward, rehabilitation stroke ward and mobile stroke team. No information on
staffing levels for mixed rehabilitation was identified in the literature search.
Staff inputs of interest were allied health professionals including physiothera-
pists, occupational therapists and speech and language therapists; medical staff
(junior and senior); and nursing staff (sister, staff nurse and untrained assistant).
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It was assumed that the medical and nursing staff levels in a mobile stroke team
would be the same as those in a general medical ward. All staff type and level
information was converted to the form number of hours per patient per day. In
order to convert the values it was assumed that a working week consists of 37.5
hours; that there were 3 shifts per day; and that the proportion of staff in each
grade was the same for all systems of care. For example, it was assumed that
the proportion of senior doctors and junior doctors is the same for all systems of
care.
Costs for allied health professionals, medical and nursing staff in organised
inpatient stroke unit care were obtained from Curtis (2007), while general medical
ward costs were obtained from the Information Services Division, NHS Scotland
(2007). Total costs per patient per day were calculated for each system of care.
Total cost per patient per stay was calculated using the average length of stay
in each system of organised inpatient care (Kalra et al., 2000; Langhorne and
Pollock, 2002; Rodgers et al., 2003), while the average length of stay in general
medical ward was estimated from the SUTC database. Of the 25 trials in the
SUTC database where average length of stay was recorded, 18 compared some
model of care with a general medical ward (Ronning and Guldvog, 1998; Vemmos
et al., 2001; Ma et al., 2004; Patel, 2000; Garraway et al., 1980; Svensson et al.,
1993; Fagerberg et al., 2000; Kaste et al., 1995; Cabral et al., 2003; Sivenius et al.,
1985; Aitken et al., 1993; Juby et al., 1996; Hankey et al., 1997; von Arbin et al.,
1980; Laursen et al., 1995; Indredavik et al., 1991; Strand et al., 1985; Hamrin,
1982). However, Stroke Unit Trialists’ Collaboration (2007) also shows that there
were minimal differences in length of stay between systems of care, so estimates
of length of stay in each system will be examined in a sensitivity analysis.
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9.3.3 Benefits
The proportion of deaths among patients treated in a general medical ward at
each time point was calculated using those trials in the SUTC database where
general medical ward was the comparator. Of the 22 trials where timing of deaths
were recorded, 18 compared some model of organised inpatient (stroke unit) care
to general medical wards (Ronning and Guldvog, 1998; Vemmos et al., 2001;
Garraway et al., 1980; Fagerberg et al., 2000; Kaste et al., 1995; Gordon and
Kohn, 1966; Cabral et al., 2003; Sivenius et al., 1985; Dey et al., 2005; Wood-
Dauphinee et al., 1984; Feldman et al., 1962; Aitken et al., 1993; Juby et al.,
1996; Hankey et al., 1997; Laursen et al., 1995; Indredavik et al., 1991; Strand et
al., 1985; Hamrin, 1982). The proportion of deaths were calculated at weeks 1,
2, 3, 4, 12, 26 and 52.
Using data from Stroke Unit Trialists’ Collaboration (1997b) (Figure 9.1), the
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Figure 9.1: Proportion of patients living at home after the index stroke and
cumulative difference between stroke unit and control subjects.
Taken from Stroke Unit Trialists’ Collaboration (1997b).
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Figure 9.2: Probability of death over a 52 week period in each system of
care: (a) acute stroke ward; (b) comprehensive stroke ward; (c)
rehabilitation stroke ward; (d) mixed rehabilitation ward; (e)
mobile stroke team; and (f) general medical ward.
proportions of patients who were alive and living at home in weeks 1, 2, 3, 4,
12, 26 and 52 were obtained. Together with the proportion of patients who were
dead at each of these time points, as calculated from the SUTC database, the
proportions of patients in general medical ward in each of the dead, dependent
and independent categories at weeks 1, 2, 3, 4, 12, 26 and 52 were able to be
calculated.
The Stroke Unit Trialists’ Collaboration (2007) showed that benefits of stroke
unit care remained up to five years post-stroke. It is therefore reasonable to
assume that each treatment effect odds ratio for death and death or dependency
obtained in Chapter 8 remains constant over the 52 week period for each system
of care. The proportions of patients who were independent, dependent and dead
could then be calculated at each time point in the remaining five systems of
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Figure 9.3: Probability of dependence over a 52 week period in each system
of care: (a) acute stroke ward; (b) comprehensive stroke ward;
(c) rehabilitation stroke ward; (d) mixed rehabilitation ward; (e)
mobile stroke team; and (f) general medical ward.
organised inpatient (stroke unit) care (Figures 9.2, 9.3 and 9.4). The number
of person-years saved can then be calculated for independent and dependent
patients.
Dorman et al. (2000) give utility values for dependent (EuroQoL EQ-5D mean
0.38; 95% CI 0.29 to 0.47), independent (0.74; 0.69 to 0.79) and recovered (0.80;
0.80 to 0.96) stroke patients. For the purposes of this analysis, the recovered
utility values were not used as the data available did not distinguish between
independent and recovered.
An estimate of the QALY can then be obtained by summing the saved life-
years adjusted using the utility values.
For the base-case, it is assumed that the odds ratios are equal to the medians
given in Chapter 8. Note that the sensitivity analysis results were used for the
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Figure 9.4: Probability of independence over a 52 week period in each system
of care: (a) acute stroke ward; (b) comprehensive stroke ward;
(c) rehabilitation stroke ward; (d) mixed rehabilitation ward; (e)
mobile stroke team; and (f) general medical ward.
outcome of death or dependency as given in Table 8.5. Additionally, it is assumed
that the utility values are the mean values reported.
9.3.4 Analysis
The incremental cost-effectiveness ratio (ICER) gives a measure of the additional
cost per additional QALY gained. The ICER is calculated as
ICER =
CB − CA
QB −QA
,
where CA and CB are the costs in treatments A and B, respectively, and QA and
QB are the QALYs in treatments A and B, respectively. This gives the additional
cost of treatment B compared to treatment A per additional QALY gained.
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Incremental cost-effectiveness ratios can be calculated in two different ways
to determine the most cost-effective treatment. Firstly, in a marginal analysis
the treatments are ranked by their QALY estimates. The treatment with the
lowest QALY estimate is compared to the treatment with the second lowest. The
treatments are compared sequentially to the treatment next in rank to deter-
mine if the added cost is worth the additional gain in QALY. The second type
of ICER calculated uses a comparative approach where all treatments are com-
pared to general medical ward to determine which has the smallest extra cost per
additional QALY gained.
9.3.5 Sensitivity analysis
A summary list of all assumptions are given in Table 9.1. In the sensitivity
analysis, seven of the assumptions in Table 9.1 are varied and the effect on the
results are examined.
In assumption 4., the staffing levels obtained from Kalra et al. (2000), Langhorne
and Pollock (2002) and Rodgers et al. (2003) are assumed accurate. However, the
level of medical staffing in acute stroke may be greater than that stated, there-
fore, the level of medical staffing in an acute stroke ward is increased to match
that of general medical ward.
In assumption 5., it is assumed a working week is 37.5 hours long. However, it
is possible that greater or less than 37.5 hours are worked per week. In assumption
6., it is assumed that there are 3 nursing shifts per day on average but it is also
possible that there could be more or fewer shifts per day. For assumption 7., the
unit costs for allied health professionals, medical and nursing staff in organised
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Table 9.1: Summary of assumptions in the base-case model.
Description
1. Requirement for institutional care is a surrogate measurement for
dependency.
2. Costs of medicines, tests and additional interventions were assumed
to be similar for all systems of care.
3. Information on staffing levels for acute stroke ward, comprehensive
stroke ward, rehabilitation stroke ward and mobile stroke team ob-
tained from Kalra et al. (2000), Langhorne and Pollock (2002) and
Rodgers et al. (2003).
4. Staff levels in mobile stroke team care are similar to general medical
ward.
5. There are 37.5 hours in a working week.
6. There are 3 nursing shifts per day.
7. Average unit costs for allied health professionals, medical and nurs-
ing staff in organised inpatient stroke unit care taken from Infor-
mation Services Division, NHS Scotland (2007).
8. Proportions of staff in each grade are equal for all systems of care.
9. Length of stay in each system of care are estimated from Kalra et
al. (2000), Langhorne and Pollock (2002) and Rodgers et al. (2003).
10. Relative treatment effects are constant over a 52 week period.
11. Odds ratios are equal to the median values for treatment effect, as
given in Figure 8.1 and Table 8.5.
12. Utilities are equal to the mean of the utility values reported.
inpatient stroke unit care are varied by 25%.
Stroke Unit Trialists’ Collaboration (2007) have shown that there was not
any substantial difference in length of stay across the different systems of care.
Therefore, if it were to be assumed that length of stay was equal in all systems
of care, how would this affect the conclusions of the cost-effectiveness analysis
(assumption 9.)? It should also be noted here, however, that the length of stay is
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recorded as total length of stay in hospital and not in any one component of care.
For example, those entered into acute stay do not spend their entire hospital stay
in acute care. Similarly, those entered into rehabilitation stroke care were first
treated in an alternative form of care prior to entrance into rehabilitation. This
will be discussed further in Sections 9.6 and 9.7.
In assumption 11., the odds ratio estimates used are the median values. How-
ever, for each system of care versus general medical ward, all odds ratios have
credible intervals associated with them. In the cost-utility analysis the death,
death or dependency and death or institutional care odds ratios for each treat-
ment are varied to the upper and lower limits of the credible intervals and the
effect on the cost-effectiveness results examined. If any odds ratio values are
found to change the conclusions of the base-case analysis then these are varied
in tandem to determine their combined effects.
As with the odds ratio values, the utility values each have an associated con-
fidence interval (assumption 12.). The values for dependence and independence
are varied individually and the results of the cost-effectiveness analysis examined.
9.4 Base-case results
Table 9.2 shows the average costs of health workers and total costs per patient
per day in each system of care. Notice that rehabilitation stroke ward appears
to be the least costly per patient per day, followed by general medical ward and
mobile stroke team. Comprehensive and acute stroke wards appear to be most
costly since these systems of care have a higher amount of medical and nursing
staff, respectively.
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Results can be expressed as ICERs and cost versus QALY figures. Drawing
conclusions from cost versus QALY figures can be more difficult to interpret than
ICER results due to their informal nature, however, figures can also provide more
information than ICERs. Possible treatments that have a high QALY estimate
but low cost may be overlooked in a marginal ICER analysis due to the sequential
nature of the comparisons. For example, a treatment may be more cost-effective
than the next treatment in rank, but less cost-effective than a higher ranked
treatment.
Table 9.3 and Figure 9.5 summarise the total cost per stay and mean QALY
over one year post stroke for each system of care. Mobile stroke team has the
smallest QALY while rehabilitation stroke ward has the largest QALY. However,
also notice that of the systems of organised (stroke unit) care, rehabilitation
stroke ward has the largest cost per patient per stay.
For the marginal ICER analysis, although the system of care with the lowest
QALY is mobile stroke team, general medical ward is chosen as the initial system
of care. The reason being that general medical ward can be considered a control
Table 9.3: Estimates of QALY and total costs per patient for each system of
care
System of care QALY
Cost per patient Average length Cost per
per day (£) of stay (days)∗ stay (£)
General medical ward 0.443 173.33 39 6760
Mobile stroke team 0.395 177.15 16 2834
Mixed rehabilitation ward 0.454 - - -
Rehabilitation stroke ward 0.507 127.10 52 6609
Comprehensive stroke ward 0.482 205.29 24 4927
Acute stroke ward 0.485 207.89 9 1871
∗Average length of stay in general medical ward estimated from SUTC database. Length of stay
for other systems taken from Kalra et al. (2000), Langhorne and Pollock (2002) and Rodgers et al.
(2003).
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Figure 9.5: Cost and quality adjusted life-years in each system of care: (a)
acute stroke ward; (b) comprehensive stroke ward; (c) rehabili-
tation stroke ward; (d) mobile stroke team; (e) general medical
ward.
treatment as it contains none of the aspects of care associated with organised
inpatient (stroke unit) care. General medical ward is compared to the next most
effective treatment, comprehensive stroke ward. The ICER is then calculated as
ICER =
CComprehensive − CGMW
QComprehensive −QGMW
=
£4927−£6760
0.482− 0.443
= −£46, 878.
Therefore, one would expect to save £46,878 per additional QALY gained if com-
prehensive stroke ward was chosen over general medical ward, so it is worthwhile
accepting a comprehensive stroke ward as a new treatment compared to a gen-
eral medical ward. Table 9.4 shows the ICER results for the marginal analysis
(ICER1). Comprehensive stroke ward is compared to the next most effective
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Table 9.4: Incremental cost-effectiveness ratios for the base-case.
System of care ICER1 (£)
∗ ICER2 (£)†
General medical ward - -
Comprehensive stroke ward -46,878 -46,878
Acute stroke ward -1,099,926 -116,738
Rehabilitation stroke ward 215,040 -2,356
∗Marginal analysis, where treatments are compared sequentially.
†Comparitive analysis where all treatments are compared to gen-
eral medical ward.
treatment, acute stroke ward. Finally, acute stroke ward is compared to rehabili-
tation stroke ward where one would expect to pay £215,040 per additional QALY
gained. Typically a maximum of £20,000 per additional QALY is taken as the
threshold for accepting new treatments and £30,000 or more can be acceptable
under some circumstances (National Institutes for Health and Clinical Excel-
lence, June 2008), meaning that rehabilitation stroke ward is not cost-effective
compared with acute stroke ward.
For the comparative ICER approach, mobile stroke team is again not consid-
ered here since its QALY is lower than the QALY for general medical ward. In
Table 9.4, ICER2 compares comprehensive stroke ward, acute stroke ward and
rehabilitation stroke ward to general medical ward. Again acute stroke ward ap-
pears to be the most cost-effective system of care since it has the highest saving.
9.5 Sensitivity results
For the sensitivity analysis the changes in ICER1, the ICER results for the
marginal analysis, were examined. As with the base-case, general medical ward
is taken as the initial treatment for all ICER calculations.
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9.5.1 Assumption 4.: medical costs in acute stroke unit
and general medical ward
Table 9.5 gives the results of the sensitivity analysis when it is assumed the cost
of medical staff in an acute stroke ward is equal to that of a general medical ward.
Varying these assumptions does not affect the QALY estimates given in Table 9.3.
Table 9.5 shows that the conclusions obtained from the base-case do not change:
acute stroke unit care still appears to be the most cost-effective system of care.
Table 9.5: Incremental cost-effectiveness ratios for the sensitivity analysis on
assumption 4.: equal cost of medical staff in an acute stroke ward
and general medical ward.
System of care QALY Cost ICER (£)
General medical ward 0.443 6760 -
Comprehensive stroke ward 0.482 4927 -46878
Acute stroke ward 0.485 2100 -1,017,338
Rehabilitation stroke ward 0.507 6609 204,627
QALY values remain unchanged from base-case. Costs are calcu-
lated per stay and ICER calculated using marginal analysis, where
treatments are compared sequentially.
9.5.2 Assumptions 5., 6. and 7.: hours per week, shifts
per day and unit costs
Table 9.6 gives the results of the sensitivity analysis when assumptions 5., 6. and
7. are varied independently: assumption 5. varies the number of hours in a work-
ing week between 30 hours per week and 45 hours per week; for assumption 6.,
the number of nursing shifts per day are varied between 2 and 4 shifts per day;
and for assumption 7. the unit costs for allied health professionals, doctors and
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Table 9.6: Incremental cost-effectiveness ratios for the sensitivity analysis on
assumptions: 5. hours per week; 6. shifts per day; and 7. unit costs
for staff.
System of care
Lower value (£) Upper value (£)
Cost ICER Cost ICER
Hours per week∗
General medical ward 6760 - 6760 -
Comprehensive stroke ward 3942 -72,079 5912 -21,677
Acute stroke ward 1736 -794,007 2006 -1,405,845
Rehabilitation stroke ward 5288 161,197 7931 268,883
Shifts per day†
General medical ward 6760 - 6760 -
Comprehensive stroke ward 4927 -46,878 4927 -47,000
Acute stroke ward 1473 -1,243,149 2269 -956,704
Rehabilitation stroke ward 6609 233,099 6609 196,982
Medical staff‡
General medical ward 6760 - 6760 -
Comprehensive stroke ward 4477 -58,387 5377 -35,370
Acute stroke ward 1823 -955,104 1919 -1,244,749
Rehabilitation stroke ward 6265 201,589 6953 228,492
Nursing staff‡
General medical ward 6760 - 6760 -
Comprehensive stroke ward 4540 -56,783 5314 -37,077
Acute stroke ward 1572 -1,068,003 2169 -1,131,871
Rehabilitation stroke ward 6140 207,309 7078 222,770
Allied health professionals‡
General medical ward 6760 - 6760 -
Comprehensive stroke ward 4546 -56,611 5322 -36,788
Acute stroke ward 1754 -1,005,182 1993 -1,198,141
Rehabilitation stroke ward 5801 183,687 7449 247,619
QALY values remain unchanged from base-case. Costs are calculated per stay and
ICER calculated using marginal analysis, where treatments are compared sequentially.
∗Hours per week: lower value = 30; upper value = 45.
†Shifts per day: lower value = 2; upper value = 4.
‡Staff costs: lower value = unit cost − 25%; upper value = unit cost + 25%
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Figure 9.6: Cost and quality adjusted life-years in each system of care when
length of stay is assumed to be 39 days in each system of care: (a)
acute stroke ward; (b) comprehensive stroke ward; (c) rehabili-
tation stroke ward; (d) mobile stroke team; (e) general medical
ward. QALY values remain unchanged from base-case and costs
are calculated per stay.
nursing staff are varied by 25% in either direction. Varying these assumptions
do not affect the QALY estimates given in Table 9.3, but affect the cost of each
system of care. However, Table 9.6 shows that the conclusions obtained from
the base-case do not change: acute stroke unit care still appears to be the most
cost-effective system of care.
9.5.3 Assumption 9.: length of stay
Previously, it was assumed that the average length of stay in each system of care
was the average obtained from Kalra et al. (2000), Langhorne and Pollock (2002)
or Rodgers et al. (2003). It is now assumed that the length of stay is equal to
the general medical ward length of stay of 39 days, as obtained from Stroke Unit
Trialists’ Collaboration (2007).
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Figure 9.6 shows that rehabilitation stroke ward system of care is the most
cost-effective when the length of stay is assumed to be equal in all systems of
care. However, as will be discussed in more detail in Section 9.7, the assumption
regarding length of stay is complicated by the patient pathway through hospital.
9.5.4 Assumption 11.: odds ratios
In the base-case, the odds ratios for death, death or dependency and death or
institutional care are assumed to be the median odds ratio values for each treat-
ment. For the sensitivity analysis, the odds ratios for death, death or dependency
and death or institutional care are varied simultaneously but independently for
each treatment using the values given by the credible intervals. Varying the odds
ratios does not alter the cost per stay in each system of care, but it does affect
the QALY estimate gained for each care system.
Figure 9.7 shows that as the odds ratios in mobile stroke team, rehabilitation
stroke ward and comprehensive stroke ward are varied, the conclusions are again
unaffected: acute stroke ward appears to be most cost-effective. This is also
true when the acute stroke ward odds ratio is assumed to be the lower value of
its credible interval. However, when the upper value of the odds ratio credible
interval is chosen, the most cost-effective treatment appears to be comprehensive
stroke ward.
9.5.5 Assumption 12.: utility values
As with the odds ratios, the utility values obtained from Dorman et al. (2000) also
have confidence intervals associated with them. The utility values for dependence
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Figure 9.7: Cost and quality adjusted life-years in each system of care when
each odds ratio is varied by its credible interval: (a) acute stroke
ward; (b) comprehensive stroke ward; (c) rehabilitation stroke
ward; (d) mobile stroke team; (e) general medical ward.
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Figure 9.8: Cost and quality adjusted life-years in each system of care when
utility values for dependent and independent stroke survivors are
varied by their confidence intervals: (a) acute stroke ward; (b)
comprehensive stroke ward; (c) rehabilitation stroke ward; (d)
mobile stroke team; (e) general medical ward.
and independence are independently varied using these confidence intervals. The
results are shown in Figure 9.8.
As with previous sensitivity analysis, the conclusions are not changed after
varying the utility values. Acute stroke ward still appears to be the most cost-
effective.
9.6 Patient pathway analysis
As mentioned in Section 9.5.3 and discussed in Section 9.7, the total costs per
stay in each system of care are not strictly comparable. Patients admitted to
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hospital following stroke may be treated in more than one system of care. For
example, patients admitted to an acute stroke ward may then be transferred to
an alternative system of care if the patient requires further inpatient care. This
section attempts to estimate the cost of patient pathways through hospital in
order to compare directly the total cost per stay for each system of care.
After acute care a patient may either die, return home or require further care.
Langhorne (2003-2007) estimates that 30% (25% - 35%) of patients will require
further treatment in hospital following initial treatment. The pathways of care
considered in this section are: acute stroke ward followed by rehabilitation stroke
ward; comprehensive ward only; mobile stroke team only; and general medical
ward only.
Table 9.3 summarises the QALY, average length of stay and cost per patient
per day in each system of care. First, consider the pathway of acute stroke ward
followed by rehabilitation stroke ward. The average length of stay in an acute
stroke ward is 9 days (Rodgers et al., 2003) and the average length of stay in
a rehabilitation ward is 52 days (Langhorne and Pollock, 2002). However, only
30% of patients are admitted to a rehabilitation stroke ward. Therefore, the total
cost per stay is calculated as the acute stroke ward cost per stay plus 30% of the
rehabilitation stroke ward cost per stay.
In order to calculate a comparable total cost per stay for the other systems
of care, the average total lengths of stay must be estimated. This is given as the
average length of stay in acute ward (9 days) added to 30% of the average length
of stay in a rehabilitation ward (52 days). This gives the total average length
of stay as 24.6 days. Assuming the total average length of stay to be similar
in all systems of care (Stroke Unit Trialists’ Collaboration (2007) have shown
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Figure 9.9: Cost and quality adjusted life-years in each pathway of care:
(a) acute stroke ward and rehabilitation stroke ward (acute
stroke ward QALY); (b) acute stroke ward and rehabilitation
stroke ward (rehabilitation stroke ward QALY); (c) comprehen-
sive stroke ward; (d) mobile stroke team; (e) general medical
ward.
that there was not any substantial difference in length of stay across the different
systems of care), the total cost per stay can be estimated.
Figure 9.9 shows that acute stroke ward followed by rehabilitation stroke ward
is the most cost-effective pathway of care. Although an estimate of the QALY
for this pathway was not obtained, it is reasonable to assume that it will lie
somewhere between that of the acute stroke ward care and the rehabilitation
stroke ward care QALYs. The conclusions do not change when both QALY
estimates for acute and rehabilitation stroke ward are examined.
There is uncertainty around the estimate of the proportion of patients who
require further hospital care. Therefore, Figure 9.10 shows how the estimate
of total cost changes when this proportion is varied. Acute care followed by
rehabilitation care remains the most cost-effective pathway of care.
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Figure 9.10: Cost and quality adjusted life-years in each pathway of care
when the proportion requiring care is varied around its range:
lower value 25%, upper value 35%. Pathways are: (a) acute
stroke ward and rehabilitation stroke ward (acute stroke ward
QALY); (b) acute stroke ward and rehabilitation stroke ward
(rehabilitation stroke ward QALY); (c) comprehensive stroke
ward; (d) mobile stroke team; (e) general medical ward.
9.7 Discussion
The Stroke Unit Trialists’ Collaboration (2007) has shown that organised inpa-
tient (stroke unit) care reduces deaths, dependency and requirement for insti-
tutional care, with more organised care proving better than less organised care.
Chapter 8 shows that rehabilitation stroke wards are most effective at improving
outcomes followed by acute stroke wards and comprehensive stroke wards. How-
ever, the higher level of organisation also incurs greater expense due to higher
staffing levels. Despite this, acute stroke unit care appears to be the most cost-
effective system of care.
Social work costs were not considered in this analysis. However, social work
costs may be correlated to NHS costs, therefore, it should not affect the conclu-
sions gained.
Several assumptions are made during this analysis. Firstly, the costs of
medicines, tests and additional interventions are assumed to be similar for all
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systems of care. This seems reasonable since patients with complications related
to stroke will be treated with the same medicines regardless of which system of
care they receive. Secondly, it seems reasonable to assume that those who require
institutional care are also dependent, therefore requirement for institutional care
can be considered a surrogate measurement for dependency. Thirdly, since mo-
bile stroke teams are usually operated within a general medical ward, staffing
levels within these two systems of care will be similar. Fourthly, the proportions
of staff within each grade are assumed to be equal in all systems of care. This
means, for example, that the ratio of senior and junior doctors is equal in all
systems of care. This allowed the estimation of costs within some systems of
care where medical staffing was given but not staffing levels of each grade. This
was also assumed for nursing staffing levels. Finally, the Stroke Unit Trialists’
Collaboration (2007) show that the benefits of organised stroke unit care appear
to remain for up to 5 years post stroke, therefore, it seems reasonable to assume
that the relative benefits of stroke unit care will remain constant over a 52 week
period.
Sensitivity analysis was performed based on the remaining assumptions. The
results appear to be robust when the assumptions affecting staffing levels and
costs are varied. In the base-case, the estimate of cost of medical staff in an
acute stroke ward appears to be smaller than that of a general medical ward. A
sensitivity analysis assuming the medical staff costs are the same in these systems
of care revealed no change in the conclusions obtained in the base-case. The
results are also robust when assumptions affecting estimation of benefits (that is,
the odds ratios and utility values) are varied. Acute stroke unit care appears to
be most effective in these circumstances. However, one major limitation becomes
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apparent for the length of stay sensitivity analysis.
The length of stay estimates for the base-case results are collected from dif-
ferent sources (Kalra et al., 2000; Langhorne and Pollock, 2002; Rodgers et al.,
2003). The studies are relatively old and estimates of length of stay may have
changed since publication. The length of stay estimates from these studies are
the average lengths of stay within that particular component of care. However,
the studies do not give an indication of where the patient was either before enter-
ing care (in the case of rehabilitation stroke ward patients could have originally
been admitted to a general medical ward or acute stroke ward care and then
transferred to a rehabilitation stroke ward) or after leaving care (in case of acute
stroke ward patients could have gone on to rehabilitation stroke ward, general
medical ward, died or been discharged home or with relatives). This means that
the costs per stay calculated for each system of care (particularly acute stroke
wards and rehabilitation stroke wards) are not strictly comparable as they do
not take into account all the components of inpatient care a patient may have
received.
On the other hand, the estimates of length of stay obtained from the Stroke
Unit Trialists’ Collaboration (2007) are the average total length of stays, not just
the length of stay for a particular component. However, as previously stated,
a patient may not spend their entire inpatient stay in one component of care.
Therefore, if the total length of stay is assumed to be equal in all systems of
care then the cost of acute care will be over-estimated, as shown in Figure 9.6.
Additionally, the cost of rehabilitation stroke care may be incorrectly estimated
since patients will be transferred to rehabilitation care after receiving treatment
in another system of care. Again, this means that the costs of each system of
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care are not strictly comparable.
Identification of where the benefit of organised inpatient care is achieved is
also limited for similar reasons. For those studies randomising to acute care, the
differences achieved can be attributed to that care system since this is the only
systematic difference between groups. However, for other systems of care the
conclusion cannot be so easily determined. Therefore, given the available data,
it is not possible to determine if the benefit of inpatient care is gained in the first
few weeks of care (that is, in an acute care setting), or if the benefit is achieved
by rehabilitation.
Section 9.6 calculates the total cost per stay for different pathways of care in
order to compare the cost-effectiveness. It was shown that acute stroke ward care
followed by rehabilitation stroke ward care was the most cost-effective pathway of
care compared to comprehensive stroke ward care, mobile stroke team care and
general medical ward care alone. Although an estimate of the QALY was not
available for the acute plus rehabilitation pathway of care, by analysing QALY
estimates from both components it was shown that this pathway is still most
cost effective. The conclusion also holds when the proportion of those requiring
further care is varied.
Several other pathways of care are possible. However, there are several reasons
why these were not analysed. In some cases, such as comprehensive stroke ward
care, it would not be relevant to analyse this in addition to another component,
since this system of care includes acute care and rehabilitation if required. Lack of
data prevented the estimation of total cost per stay of patients transferred to and
from general medical ward care. The proportions of patients requiring further
care may be different for these pathways than those for acute stroke wards. Also,
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if patients were entered into a general medical ward for their acute care it may be
reasonable to speculate that the hospital may have limited resources and further
stroke care, such as rehabilitation, may not be available.
Although the costs of each system of care in this analysis are not strictly
comparable, there is a clear conclusion that organised inpatient (stroke unit)
care is cost-effective. Rehabilitation stroke ward care appears to be the most
effective system of care, but acute stroke ward care appears to be most cost-
effective for patients with shorter lengths of stay. Finally, acute stroke ward care
followed by rehabilitation stroke ward care, if required, appears to be the most
cost-effective pathway of care compared to the other pathways analysed. Stroke
Unit Trialists’ Collaboration (2007) found that the benefit of organised stroke
unit care may remain for up to 5 or even 10 years post stroke, suggesting that
the results of the economic analysis may also be stable for this period of time.
Future trials could randomise the pathway of care a patient receives while in
hospital instead of randomising to a particular component of care to determine
where the benefit of inpatient stroke unit care is achieved and to estimate accu-
rately the total cost of stay for a patient suffering from stroke. Length of stay in
each component of care should be recorded to aid the costing of inpatient stay.
Acute stroke ward, comprehensive stroke ward and rehabilitation stroke ward
care should be examined in particular to determine the benefits of each system
of care, while cost estimates should be obtained for the entire patient journey
through care, and not just for a particular component of care. Individual patient
data should be made available wherever possible to determine costs of patient
care and also to allow the inclusion of the data into a meta-analysis to give a
more precise estimate of cost-effectiveness.
Chapter 10
Conclusions
10.1 Summary of clinical results
In Chapter 2, a novel stroke severity scale, the IMAGES Stroke Scale (ISS) was
introduced and its ability to predict outcome was compared to that of current
stroke severity scales. It was found that the IMAGES Stroke Scale is easily de-
rived from routinely available data and requires no specific training for its use.
This offers an alternative to the commonly used National Institutes of Health
stroke scale (NIHSS), where language barriers or limited access to training ma-
terial may prevent it being implemented. The modest correlation between ISS
and NIHSS is possibly explained by the fact that ISS measures a range of aspects
of stroke severity. Despite this, however, the wide familiarity and standardised
video training make the NIHSS the preferred acute stroke scale.
Chapter 3 investigates the amount of prognostic information retained when
stroke severity is categorised into 3 groups: mild, moderate and severe. This
study showed that the categorisation of four currently used stroke scales did not
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substantially reduce the predictive ability of the scales. Furthermore, the four
stroke scales stratified in this way appear to be equivalent to each other, and
although the prognostic accuracy for longer follow-up is lower, it is not further
reduced by categorisation of the stroke scales.
Chapter 4 shows that the addition of new trials to the Stroke Unit Trial-
ists’ Collaboration (2006) systematic review does not alter the conclusions found
in this previous version. The updated review illustrates that patients receiving
organised (stroke unit) care are more likely to survive, return home and regain
independence than those receiving a less organised service, with a suggestion that
the benefit may last for five or even ten years post stroke. However, Chapter 4
does not explain why stroke unit care improves patient outcomes: possible ex-
planations include the prevention of complications or more intense monitoring of
acute patients, as explored in Chapters 5 and 6, respectively.
Chapter 5 examines how organised inpatient care improves patient outcomes
by exploring the use of interventions to prevent complications. The results in-
dicate that stroke unit care appears to reduce complications of immobility (in
particular, infections), although there were also reductions in stroke recurrence
or progression. The findings suggest that some of these reductions could be
explained by a more comprehensive implementation of measures to prevent com-
plications.
Chapter 6 compares a conventional stroke unit approach with conventional
stroke unit care plus continuous monitoring in the acute phase and addresses
whether routine automated monitoring for, and treatment of physiological ab-
normalities reduce adverse outcomes in stroke patients. Routine monitoring may
reduce the risk of stroke progression with the reduction in the monitoring group
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being greater in mild stroke patients than in moderate or severe patients. The
reduction in death or dependency in the monitoring group was greatest in those
patients classed as low risk and the reduction in death was greatest in those who
did not suffer heart failure. However, caution is needed when interpreting these
conclusions since they are based on relatively small data sets.
Chapters 4 to 6 showed that organised inpatient care improves patient out-
comes and provides possible explanations for how this is achieved, but there are
several different systems of organised inpatient care. Using the mixed treatment
comparisons model presented in Chapter 7, Chapter 8 explores whether any one
system of care is more effective in improving patient outcomes while also tak-
ing account of associations of age and severity with patient outcome. It was
found that dedicated wards such as the rehabilitation stroke wards, comprehen-
sive stroke wards and acute stroke wards appear to perform better than mobile
stroke teams and mixed rehabilitation wards, and such findings are robust to
adjustment for case mix in the form of age and stroke severity.
Finally, given which systems of care are most effective, Chapter 9 implements
a cost-utility analysis to determine which system of inpatient care is most cost-
effective. Although the costs of each system of care in this analysis were not
strictly comparable, there is substantial evidence that organised inpatient (stroke
unit) care is cost-effective. Rehabilitation stroke ward care appears to be the most
effective system of care, but acute stroke ward care appears to be most cost-
effective for patients with shorter lengths of hospital stay. An attempt was made
to estimate the cost of different pathways of care and found that care in an acute
stroke ward followed by rehabilitation stroke ward was the most cost-effective of
the pathways analysed.
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10.2 Summary of meta-analysis techniques
In Chapters 4 through 8, various meta-analysis techniques are used; the complex-
ity of the techniques increases with every successive Chapter. Initially, a basic
frequentist approach to meta-analysis was employed in Chapter 4 to analyse ag-
gregated data and incorporated fixed and random effect estimates as required.
Chapter 5 also analyses aggregated data but introduces a Bayesian random-effects
meta-analysis model to calculate odds ratios and absolute risk differences of treat-
ment effect. This model was developed further in Chapter 6 to include covariates
in a meta-regression while also expanding the data into an individual patient data
format.
Finally, a novel Bayesian meta-analysis model was presented in Chapter 7
that incorporates direct and indirect treatment comparisons along with covariate
effects in a network meta-analysis. The inclusion of indirect comparison data
increases the ability of the model to estimate precisely the effect of each sys-
tem of care by utilising the information provided by the combinations of direct
comparisons.
This Chapter also shows that not adjusting for covariate effects in a meta-
analysis may lead to bias in the estimate of the treatment effect. The data for
two covariates were therefore incorporated into the analysis. The model may be
expanded to account for more than two covariates. Not all trials included in a
meta-analysis provide information on the joint distribution of covariates. How-
ever, the model allows for the possibility of some trials only providing marginal
data for one or more covariates or no data on the breakdown of covariates. This
makes use of all the available data (individual patient data and aggregated data)
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for analysis by including trials that do not provide covariate information.
The model describes the estimation of treatment effects using random effects.
Covariate effects may be estimated using either fixed or random effects and in-
teractions between the covariates may also be introduced.
10.3 Alternative methodological techniques
The novel Bayesian meta-analysis model presented in Chapter 7 can be developed
further. The model can be adapted to examine relative risks and absolute risk
differences as well as odds ratios. Additionally, the model could also be adapted
to include treatment-covariate interaction terms. As shown in Chapter 6, patients
with mild stroke appear to improve more than patients with moderate or severe
strokes. Therefore, including treatment-covariate interaction terms may show
that certain patient types improve more depending on the type of inpatient care
they receive.
Access to individual patient data not only increases the ability to predict pre-
cisely the effect of each system of care and the relationship of covariates with
outcome, but also allows the use of other meta-analysis techniques. For exam-
ple, dependency is categorised using the equivalent of the Barthel Index < 19,
but individual patient data could allow the use of continuous outcomes meta-
analysis (Higgins et al., 2001). Care must be taken here though as this type of
analysis assumes equal spacing of the categories, which may not be reasonable in
dependency data.
Whitehead and Jones (1994) describe a meta-analysis model for an ordinal
response and the model is extended by Whitehead et al. (2001) for the use of
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individual patient data. They consider a simple categorical response and a small
number of categories with a clear ordering to the categories. With appropriate
data, the combined outcomes described in this thesis could be analysed using
this approach. Instead of death or dependence, the outcome could be death,
dependence and independence. Similarly, death or institutional care could be
analysed as death, institutional care and home. With individual patient data,
the full dependency scale could even be used, though Whitehead et al. (2001)
warn that there is little to gain in efficiency by using more than five categories.
Berkey et al. (1998) present a random effects approach to meta-regression of
multiple outcomes compared to fixed effects meta-analysis and meta-regression
with separate and multiple outcomes. They find that the random-effect multiple
outcomes models provide a more realistic estimate of effects compared to fixed-
effect models and the multiple outcomes models provide a more efficient test.
Their model may be extended to incorporate several treatments and outcomes.
This type of model may also be implemented given the appropriate data, and
could possibly be combined with the ordinal outcomes technique.
The sensitivity analysis for the cost-utility analysis in Chapter 9 was per-
formed by varying the values of some of the assumptions given in Table 9.1.
This is a straightforward method of sensitivity analysis and as a result there
are a number of potential problems, particularly regarding the robustness of the
results. Varying one parameter at a time in a series of one-way sensitivity anal-
yses may underestimate the uncertainty, leading to false claims of robustness,
whereas multi-way sensitivity analysis (where two or more parameters are var-
ied simultaneously) is difficult to present and interpret (Claxton, 2008). The
uncertainty may be better characterised using probabilistic sensitivity analysis.
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Instead of point estimates, the input parameters in the model are given specified
probability distributions so that the uncertainty surrounding their values can be
reflected. The choice of distribution is determined by the form of the data, the
type of parameter, and how the parameter is estimated (Claxton et al., 2005).
10.4 Future research
Although the stroke severity scales tested in Chapter 3 appear to be equivalent,
they are only four of the currently used measurements. Others scales used in
practice, such as the Glasgow Coma Scale (Jennett and Teasdale, 1977), the
Canadian Neurological Scale (Coˆte´ et al., 1989) or the Edinburgh Stroke Predictor
(Weir et al., 2003), should also be examined. Also, the follow-up times of the
scales examined in Chapter 3 are fairly short: 1 and 3 months. Follow-up lengths
of time in meta-analyses are often longer, for example six or twelve months.
Therefore, it would be of interest to perform comparisons of stroke severity scales
at later follow-up times to assess if the equivalence of full and categorised scales
is maintained.
The findings in Chapter 5 emphasise the potential importance of complica-
tions as a treatable factor in stroke outcome. Future research should explore the
best ways of preventing and managing specific complications, particularly those
that seem to carry a high risk of causing harm. Chapter 6 shows that routine
automated monitoring may reduce the risk of stroke in progression and reduce
the length of hospital stay. However, the magnitude of benefits may be small,
therefore, a large multi-centred trial is required to clarify the uncertainties found
in this meta-analysis and to identify if the added costs and efforts of such a policy
CHAPTER 10. CONCLUSIONS 174
are justified by better patient recovery. The trial should be sufficiently large to
examine which subgroups of patients and subgroups by co-morbidity may benefit
most from routine automated monitoring.
Chapter 8 showed that dedicated wards such as the rehabilitation stroke
wards, comprehensive stroke wards and acute stroke wards appear to perform
better than mobile stroke teams and mixed rehabilitation wards, and such find-
ings are robust to adjustment for case mix in the form of age and stroke severity.
Future research should incorporate covariate-treatment interaction terms to ex-
amine if any subgroups of patients respond better to any one treatment. Trials
should focus on evaluating the benefits of an acute system of care and rehabili-
tation, independently and in combination, to improve patient outcomes.
Finally, future trials should randomise patients to pathways of care instead of
particular components to determine how the benefit of inpatient stroke unit care
is achieved and accurately estimate the total cost of stay for a patient suffering
from stroke. Length of stay in each component of care should be recorded to aid in
the costing of inpatient stay. Acute stroke ward, comprehensive stroke ward and
rehabilitation stroke ward care should be examined in particular to determine
the benefits of each system of care, while cost estimates should be obtained
for the entire patient journey, and not just for a particular component of that
pathway of care. Early supported discharge services should also be considered
as part of the patient pathway. Although not considered here, Early Supported
Discharge Trialists (2008) show that stroke patients who receive input from an
early supported discharge service not only return home earlier than those who
received conventional care, but are also more likely to be alive, independent and
still living at home 6 months post stroke.
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Attempts should be made to obtain individual patient data and future studies
should make individual patient data available for the purposes of meta-analysis to
allow more accurate estimates of the effects of age and severity and to determine
costs of organised inpatient (stroke unit) care.
10.5 Summary
Overall, the novel mixed treatment comparison model presented here compares
several systems of organised inpatient (stroke unit) care, but also allows the es-
timation of covariates. It was found that patients treated in organised inpatient
(stroke unit) care have reduced odds of death, dependence and requirement for
institutional care. Rehabilitation stroke ward care appears to be the most effec-
tive system of care, but acute stroke ward care appears to be most cost-effective
for patients with shorter lengths of hospital stay. Finally, acute stroke ward care
followed by rehabilitation stroke ward care, if required, appears to be the most
cost-effective pathway of care compared to the other pathways analysed.
Appendices
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Appendix A
Complications and interventions
odds ratio WinBUGS code
WinBUGS 1.4 code for the odds ratio model used in Chapter 5 is given below. Notice that the
treatment effect variance has been given the Inverse-Gamma prior.
model{
for(i in 1:m){
# model events as Binomial
rC[i] ~ dbin(pC[i],nC[i])
rT[i] ~ dbin(pT[i],nT[i])
# log odds ratio model
logit(pC[i]) <- mu[i]
logit(pT[i]) <- mu[i] + delta[i]
# priors for mu and delta
mu[i] ~ dnorm(0,1.0E-6)
delta[i] ~ dnorm(d,prec)
}
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# priors for delta parameters
d ~ dnorm(0,1.0E-6)
# Inverse-Gamma treatment variance
prec ~ dgamma(0.001,0.001)
tau.sq <- 1/prec
tau <- sqrt(tau.sq)
# residual deviance for C group
for(i in 1:m){
rChat[i] <- pC[i] * nC[i]
devC[i] <- 2* (rC[i]*(log(rC[i]/rChat[i]))
+ (nC[i]-rC[i])*(log((nC[i]-rC[i])/(nC[i]-rChat[i]))))
}
resdevC <- sum(devC[])
# residual deviance for T group
for(i in 1:m){
rThat[i] <- pT[i] * nT[i]
devT[i] <- 2* (rT[i]*(log(rT[i]/rThat[i]))
+ (nT[i]-rT[i])*(log((nT[i]-rT[i])/(nT[i]-rThat[i]))))
}
resdevT <- sum(devT[])
# total residual deviance
resdev <- resdevC + resdevT
}
Appendix B
Complications and interventions
absolute risk difference
WinBUGS code
WinBUGS 1.4 code for the absolute risk difference model used in Chapter 5 is given below.
Notice that the treatment effect variance has been given the Inverse-Gamma prior.
model{
for(i in 1:m){
# model events as Binomial
rC[i] ~ dbin(pC[i],nC[i])
rT[i] ~ dbin(pT[i],nT[i])
# absolute risk difference model
pC[i] <- mu[i]
pT[i] <- mu[i] + min(max(delta[i],-pC[i]),(1-pC[i]))
# priors for mu and delta
mu[i] ~ dunif(0,100)
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delta[i] ~ dnorm(d,prec)
}
# priors for delta parameters
d ~ dnorm(0,1.0E-6)
# Inverse-Gamma treatment variance
prec ~ dgamma(0.001,0.001)
tau.sq <- 1/prec
tau <- sqrt(tau.sq)
# residual deviance for C group
for(i in 1:m){
rChat[i] <- pC[i] * nC[i]
devC[i] <- 2* (rC[i]*(log(rC[i]/rChat[i]))
+ (nC[i]-rC[i])*(log((nC[i]-rC[i])/(nC[i]-rChat[i]))))
}
resdevC <- sum(devC[])
# residual deviance for T group
for(i in 1:m){
rThat[i] <- pT[i] * nT[i]
devT[i] <- 2* (rT[i]*(log(rT[i]/rThat[i]))
+ (nT[i]-rT[i])*(log((nT[i]-rT[i])/(nT[i]-rThat[i]))))
}
resdevT <- sum(devT[])
# total residual deviance
resdev <- resdevC + resdevT
}
Appendix C
Physiological monitoring
covariate WinBUGS code
WinBUGS 1.4 code for the covariate odds ratio model used in Chapter 6 is given below. Notice
that the treatment effect variance has been given the Inverse-Gamma prior.
model{
# IPD model
for (i in 1:m) {
for (j in 1:Nsubj[i]) {
# model events as Bernoulli
Y[i,j] ~ dbern(pi[i,j])
# log-odds ratio model with covariate main effect and interaction
logit(pi[i,j]) <- mu[i] + delta[i]*t[i,j]
+ beta0[i]*x[i,j] + beta*x[i,j]*t[i,j]
}
# priors for mu, beta0 and delta
mu[i] ~ dnorm(0,1.0E-6)
beta0[i] ~ dnorm(b,bprec)
delta[i] ~ dnorm(d,prec)
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}
# priors for delta parameters
d ~ dnorm(0,1.0E-6)
# Inverse-Gamma treatment variance
prec ~ dgamma(0.001,0.001)
tau.sq <- 1/prec
tau <- sqrt(tau.sq)
# prior for beta
beta ~ dnorm(0,1.0E-6)
# priors for beta0 parameters
b ~ dnorm(0,1.0E-6)
# Inverse-Gamma covariate variance
bprec ~ dgamma(0.001,0.001)
btau.sq <- 1/bprec
btau <- sqrt(btau.sq)
# storing pooled treatment and covariate effects
# treatment effect only
delta[(m+3)] <- d
# covariate effect only
beta0[(m+3)] <- b
# treatment effect and covariate effect
delta[(m+4)] <- d + b
# treatment effect and covariate effect with interaction
delta[(m+5)] <- d + b + beta
}
Appendix D
MTC random covariate
WinBUGS code
WinBUGS 1.4 code for the random covariate odds ratio model without interaction terms (model
2) used in Chapter 6 is given below. Notice that the treatment effect variance has been given
the Inverse-Gamma prior.
model{
# i = study, j = treatment arm, k = cell of Sev*Age table
# pi ~ dirichlet
for (k in 1:6){
lkappa[k] ~ dnorm(0,0.1)I(0,)
log(kappa[k]) <- lkappa[k]
sumfrom[k] <- sum(kappa[k:6])
}
for (i in 1:ns){
pi[i,1] ~ dbeta(kappa[1],sumfrom[2])
for (k in 2:5){
phi[i,k] ~ dbeta(kappa[k],sumfrom[k+1])
pi[i,k] <- (1 - sum(pi[i,1:(k-1)])) * phi[i,k]
}
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pi[i,6] <- 1 - sum(pi[i,1:5])
}
# true successes modelled logistically
for (i in 1:ns) {
lam[i,1] <- mu[i]
lam[i,2] <- mu[i] + ddA[i]
lam[i,3] <- mu[i] + ddS2[i]
lam[i,4] <- mu[i] + ddS2[i] + ddA[i]
lam[i,5] <- mu[i] + ddS3[i]
lam[i,6] <- mu[i] + ddS3[i] + ddA[i]
for (j in nf[i]:na[i]){
for (k in 1:6) {
# log-odds ratio model
logit(LAM[i,j,k]) <- lam[i,k] + delta[i,t[i,j]]*(1-equals(j,1))
}
# equations for marginal event probabilities
XAM[i,j,1] <- (pi[i,1]*LAM[i,j,1] + pi[i,2]*LAM[i,j,2]) / XP[i,1]
XAM[i,j,2] <- (pi[i,3]*LAM[i,j,3] + pi[i,4]*LAM[i,j,4]) / XP[i,2]
XAM[i,j,3] <- (pi[i,5]*LAM[i,j,5] + pi[i,6]*LAM[i,j,6]) / XP[i,3]
XAM[i,j,4] <- (pi[i,1]*LAM[i,j,1] + pi[i,3]*LAM[i,j,3]
+ pi[i,5]*LAM[i,j,5]) / XP[i,4]
XAM[i,j,5] <- (pi[i,2]*LAM[i,j,2] + pi[i,4]*LAM[i,j,4]
+ pi[i,6]*LAM[i,j,6]) / XP[i,5]
XAM[i,j,6] <- pi[i,1]*LAM[i,j,1] + pi[i,2]*LAM[i,j,2]
+ pi[i,3]*LAM[i,j,3] + pi[i,4]*LAM[i,j,4]
+ pi[i,5]*LAM[i,j,5] + pi[i,6]*LAM[i,j,6]
}
# probabilities of being in each marginal cell
XP[i,1] <- pi[i,1] + pi[i,2]
XP[i,2] <- pi[i,3] + pi[i,4]
XP[i,3] <- pi[i,5] + pi[i,6]
XP[i,4] <- pi[i,1] + pi[i,3] + pi[i,5]
XP[i,5] <- pi[i,2] + pi[i,4] + pi[i,6]
}
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# read in and model data
#######################
# age * severity (N6) #
#######################
for (i in 1:N6){
for (j in nf[i]:na[i]){
for (k in 1:6){
# model events as Binomial
r[i,j,k] ~ dbin(LAM[i,j,k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- LAM[i,j,k] * n[i,j,k]
dev.r.N6[(i-lowN6+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n as multinomial
n[i,j,1:6] ~ dmulti(pi[i,1:6],ntot[i,j])
for (k in 1:6){
# n deviance contribution
nhat[i,j,k] <- pi[i,k]*ntot[i,j]
dev.n.N6[(i-lowN6+1),(j-nf[i]+1),k]
<- 2* n[i,j,k]*log(n[i,j,k]/nhat[i,j,k])
}
}
}
# residual deviance for N6 r and n
sumdev.r.N6 <- sum(dev.r.N6[,,])
sumdev.n.N6 <- sum(dev.n.N6[,,])
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#######################
# age + severity (N4) #
#######################
for (i in (N6+1):(N6+N4)){
for (j in nf[i]:na[i]){
for (k in 1:4){
# model events as Binomial
r[i,j,k] ~ dbin(XAM[i,j,k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- XAM[i,j,k] * n[i,j,k]
dev.r.N4[(i-lowN4+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n as multinomial
# severity breakdown
n[i,j,1:3] ~ dmulti(XP[i,1:3],ntot[i,j])
# age breakdown
n[i,j,4] ~ dbin(XP[i,4],ntot[i,j])
for (k in 1:3){
# n deviance contribution - severity
nhat[i,j,k] <- XP[i,k] * ntot[i,j]
dev.n.N4s[(i-lowN4+1),(j-nf[i]+1),k]
<- 2* n[i,j,k]*log(n[i,j,k]/nhat[i,j,k])
}
# n deviance contribution - age
nhat[i,j,4] <- XP[i,4] * ntot[i,j]
dev.n.N4a[(i-lowN4+1),(j-nf[i]+1),1]
<- 2* (n[i,j,4]*(log(n[i,j,4])-log(nhat[i,j,4]))
+ (ntot[i,j]-n[i,j,4])*(log(ntot[i,j]-n[i,j,4])
- log(ntot[i,j]-nhat[i,j,4])))
}
}
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# residual deviance for N4 r and n (age and severity)
sumdev.r.N4 <- sum(dev.r.N4[,,])
sumdev.n.N4s <- sum(dev.n.N4s[,,])
sumdev.n.N4a <- sum(dev.n.N4a[,,])
###################################
# old age only + severity (N4old) #
###################################
for (i in (N6+N4+1):(N6+N4+N4old)){
# probabilities in each severity marginal
for (k in 1:3){
XP3[i,k] <- pi[i,k*2] / XP[i,5]
}
for (j in nf[i]:na[i]){
for (k in 1:3){
# model events as Binomial
r[i,j,k] ~ dbin(LAM[i,j,k*2],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- LAM[i,j,k*2] * n[i,j,k]
dev.r.N4old[(i-lowN4old+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n as multinomial
n[i,j,1:3] ~ dmulti(XP3[i,1:3],ntot[i,j])
for (k in 1:3){
# n deviance contribution
nhat[i,j,k] <- XP3[i,k] * ntot[i,j]
dev.n.N4old[(i-lowN4old+1),(j-nf[i]+1),k]
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<- 2* n[i,j,k]*log(n[i,j,k]/nhat[i,j,k])
}
}
}
# residual deviance for N4old r and n
sumdev.r.N4old <- sum(dev.r.N4old[,,])
sumdev.n.N4old <- sum(dev.n.N4old[,,])
######################
# severity only (N3) #
######################
for (i in (N6+N4+N4old+1):(N6+N4+N4old+N3)){
for (j in nf[i]:na[i]){
for (k in 1:3){
# model events as Binomial
r[i,j,k] ~ dbin(XAM[i,j,k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- XAM[i,j,k] * n[i,j,k]
dev.r.N3[(i-lowN3+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n as multinomial
n[i,j,1:3] ~ dmulti(XP[i,1:3],ntot[i,j])
for (k in 1:3){
# n deviance contribution
nhat1[i,j,k] <- XP[i,k]*ntot[i,j]
dev.n.N3[(i-lowN3+1),(j-nf[i]+1),k]
<- 2* n[i,j,k]*log(n[i,j,k]/nhat[i,j,k])
}
}
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}
# residual deviance for N3 r and n
sumdev.r.N3 <- sum(dev.r.N3[,,])
sumdev.n.N3 <- sum(dev.n.N3[,,])
#################################
# mild and moderate only (N3mm) #
#################################
for (i in (N6+N4+N4old+N3+1):(N6+N4+N4old+N3+N3mm)){
# probability in mild
XPmm[i] <- XP[i,1]/(XP[i,1] + XP[i,2])
for (j in nf[i]:na[i]){
for (k in 1:2){
# model events as Binomial
r[i,j,k] ~ dbin(XAM[i,j,k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- XAM[i,j,k] * n[i,j,k]
dev.r.N3mm[(i-lowN3mm+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n (mild) as binomial
n[i,j,1] ~ dbin(XPmm[i],ntot[i, j])
# n deviance contribution
nhat[i,j,1] <- XPmm[i]*ntot[i,j]
dev.n.N3mm[(i-lowN3mm+1),(j-nf[i]+1),1]
<- 2* (n[i,j,1]*(log(n[i,j,1])-log(nhat[i,j,1]))
+ (ntot[i,j]-n[i,j,1])*(log(ntot[i,j]-n[i,j,1])
- log(ntot[i,j]-nhat[i,j,1])))
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}
}
# residual deviance for N3mm r and n
sumdev.r.N3mm <- sum(dev.r.N3mm[,,])
sumdev.n.N3mm <- sum(dev.n.N3mm[,,])
#########################
# moderate only (N3mod) #
#########################
for (i in (N6+N4+N4old+N3+N3mm+1):(N6+N4+N4old+N3+N3mm+N3mod)){
for (j in nf[i]:na[i]){
# model events as Binomial
r[i,j,2] ~ dbin(XAM[i,j,2],n[i,j,2])
# r deviance contribution
rhat[i,j,2] <- XAM[i,j,2] * n[i,j,2]
dev.r.N3mod[(i-lowN3mod+1),(j-nf[i]+1),1]
<- 2* (r[i,j,2]*(log(r[i,j,2])-log(rhat[i,j,2]))
+ (n[i,j,2]-r[i,j,2])*(log(n[i,j,2]-r[i,j,2])
- log(n[i,j,2]-rhat[i,j,2])))
}
}
# residual deviance for N3mod r
sumdev.r.N3mod <- sum(dev.r.N3mod[,,])
###################################
# moderate and severe only (N3ms) #
###################################
for (i in (N6+N4+N4old+N3+N3mm+N3mod+1):(N6+N4+N4old+N3+N3mm+N3mod+N3ms)){
# probability in moderate
XPms[i] <- XP[i,2]/(XP[i,2] + XP[i,3])
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for (j in nf[i]:na[i]){
for (k in 2:3){
# model events as Binomial
r[i,j,k] ~ dbin(XAM[i,j,k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- XAM[i,j,k] * n[i,j,k]
dev.r.N3ms[(i-lowN3ms+1),(j-nf[i]+1),k-1]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n (moderate) as binomial
n[i,j,2] ~ dbin(XPms[i],ntot[i,j])
# n deviance contribution
nhat[i,j,2] <- XPms[i] * ntot[i,j]
dev.n.N3ms[(i-lowN3ms+1),(j-nf[i]+1),1]
<- 2* (n[i,j,2]*(log(n[i,j,2])-log(nhat[i,j,2]))
+ (ntot[i,j]-n[i,j,2])*(log(ntot[i,j]-n[i,j,2])
- log(ntot[i,j]-nhat[i,j,2])))
}
}
# residual deviance for N3mm r and n
sumdev.r.N3ms <- sum(dev.r.N3ms[,,])
sumdev.n.N3ms <- sum(dev.n.N3ms[,,])
#################
# age only (N2) #
#################
for (i in (N6+N4+N4old+N3+N3mm+N3mod+N3ms+1):
(N6+N4+N4old+N3+N3mm+N3mod+N3ms+N2)) {
for (j in nf[i]:na[i]){
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for (k in 1:2){
# model events as Binomial
r[i,j,k] ~ dbin(XAM[i,j,3+k],n[i,j,k])
# r deviance contribution
rhat[i,j,k] <- XAM[i,j,3+k] * n[i,j,k]
dev.r.N2[(i-lowN2+1),(j-nf[i]+1),k]
<- 2* (r[i,j,k]*(log(r[i,j,k])-log(rhat[i,j,k]))
+ (n[i,j,k]-r[i,j,k])*(log(n[i,j,k]-r[i,j,k])
- log(n[i,j,k]-rhat[i,j,k])))
}
# model n (young) as binomial
n[i,j,1] ~ dbin(XP[i,4],ntot[i,j])
# n deviance contribution
nhat[i,j,1] <- XP[i,4] * ntot[i,j]
dev.n.N2[(i-lowN2+1),(j-nf[i]+1),1]
<- 2* (n[i,j,1]*(log(n[i,j,1])-log(nhat[i,j,1]))
+ (ntot[i,j]-n[i,j,1])*(log(ntot[i,j]-n[i,j,1])
- log(ntot[i,j]-nhat[i,j,1])))
}
}
# residual deviance for N2 r and n
sumdev.r.N2 <- sum(dev.r.N2[,,])
sumdev.n.N2 <- sum(dev.n.N2[,,])
#####################
# no breakdown (N1) #
#####################
for (i in (N6+N4+N4old+N3+N3mm+N3mod+N3ms+N2+1):
(N6+N4+N4old+N3+N3mm+N3mod+N3ms+N2+N1)){
for (j in nf[i]:na[i]){
# model events as Binomial
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r[i,j,1] ~ dbin(XAM[i,j,6],n[i,j,1])
# r deviance contribution
rhat[i,j,1] <- XAM[i,j,6] * n[i,j,1]
dev.r.N1[(i-lowN1+1),(j-nf[i]+1),1]
<- 2* (r[i,j,1]*(log(r[i,j,1])-log(rhat[i,j,1]))
+ (n[i,j,1]-r[i,j,1])*(log(n[i,j,1]-r[i,j,1])
- log(n[i,j,1]-rhat[i,j,1])))
}
}
# residual deviance for N1 r
sumdev.r.N1 <- sum(dev.r.N1[,,])
# model treatment effect
for (i in 1:ns){
w[i, 1] <- 0
delta[i,t[i,1]] <- 0
mu[i] ~ dnorm(0,0.0001)
# delta prior, mixed effect comparison and multi-arm adjustment
for (j in 2:na[i]){
# trial-specific LOR distributions
delta[i,t[i,j]] ~ dnorm(md[i,t[i,j]], dprec[i,t[i,j]])
# mean of LOR distributions
md[i,t[i,j]] <- d[t[i,j]] - d[t[i,1]] + sw[i,j]
# cumulative adjustment for multi-arm trials
sw[i,j] <- sum(w[i,1:j-1])/(j-1)
# adjustment, multi-arm trials
w[i,j] <- (delta[i,t[i,j]] - d[t[i,j]] + d[t[i,1]])
# precision of LOR distributions
dprec[i,t[i,j]] <- prec*2*(j-1)/j
}
}
# vague priors for delta parameters
d[1]<-0
for (j in 2:nt){
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d[j] ~ dnorm(0,0.0001)
}
prec ~ dgamma(0.01,0.01)
tau.sq <- 1/prec
tau <- sqrt(tau.sq)
# vague priors for age and severity parameters
for (i in 1:ns){
ddA[i] ~ dnorm(dA,cprec)
ddS2[i] ~ dnorm(dS2,cprec)
ddS3[i] ~ dnorm(dS3,cprec)
}
dA ~ dnorm(0,0.001)
dS2 ~ dnorm(0,0.001)
dS3 ~ dnorm(0,0.001)
cprec ~ dgamma(0.01,0.01)
ctau.sq <- 1/cprec
ctau <- sqrt(ctau.sq)
# ranking treatment means to find best intervention
for (j in 1:6){
pbest[j]<- equals(rank(d[],j),1)
}
# residual deviance for all r
resdev.r <- sumdev.r.N6 + sumdev.r.N4 + sumdev.r.N4old + sumdev.r.N3
+ sumdev.r.N3mm + sumdev.r.N3mod + sumdev.r.N3ms
+ sumdev.r.N2 + sumdev.r.N1
# residual deviance for all n
resdev.n <- sumdev.n.N6 + sumdev.n.N4s + sumdev.n.N4a + sumdev.n.N4old
+ sumdev.n.N3 + sumdev.n.N3mm + sumdev.n.N3ms + sumdev.n.N2
# total residual deviance
resdev <- resdev.r + resdev.n
}
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